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Abstract 
Adverse drug reactions are responsible for 6.5% of all hospital admissions. They also affect 10 to 20% of 
hospitalized patients. Drug-induced hypersensitivity reactions constitute an important major subtype of type B 
adverse drug reactions. Low molecular weight (i.e. penicillins, sulfamethoxazole and abacavir) and high 
molecular weight (biologics) drugs are both associated with the inadvertent activation of the adaptive immune 
system, which manifests as hypersensitivity in certain individuals. 
 
Pharmacogenomic research revealed that several forms of immunological drug reactions are strongly associated 
with specific human leukocyte antigens (HLA) alleles. The underlying mechanisms of HLA associated 
immunological drug reactions are still under exploration, however abacavir hypersensitivity represent a prototype 
model that exclusively occurs in individuals carrying the risk allele HLA- B*57:01. One hundred and ten CD8
+
 T-
cell clones out of 1304 clones generated  from 3 HLA-B*57:01 healthy volunteers displayed proliferative 
responses and/or secreted interferon gamma in the presence of abacavir which have been used for further 
mechanistic studies to evaluate mechanisms of drug antigen presentation. Approximately half of the clones were 
activated with abacavir in the absence of antigen presenting cells. Of the remaining clones, interestingly about 
half were activated with abacavir pulsed APC. The APC pulse negative clones are likely activated via a PI 
mechanism involving the direct binding of abacavir to surface HLA-B*57:01. In contrast, the pulse positive 
clones seem to be activated via the altered peptide repertoire mechanism involving abacavir binding to 
endogenous HLA-B*57:01. Some clones were also activated with APC from certain allogeneic donors expressing 
different HLA-B alleles. APC-dependent abacavir-specific clones were activated by the drug in the presence of 
APC from at least 3 allogenic different donors. 
 
Sixteen 6-amino substituted abacavir analogues were synthesized. Computational docking studies were completed 
to predict capacity for analogue binding within HLA-B*57:01. Abacavir-specific CD8
+
 clones were generated to 
study the association between HLA-B*57:01 analogue binding and T-cell activation. Antiviral activity and the 
direct inhibitory effect of analogues on proliferation were assessed. MHC class I-restricted CD8
+
 clones 
proliferated and secreted interferon gamma following abacavir binding to surface and endogenous HLA-B*57:01. 
Several analogues retained antiviral activity and showed no overt inhibitory effect on T-cell proliferation, but 
displayed highly divergent antigen-specific T-cell responses. Abacavir and N-propyl abacavir were equally potent 
at activating clones, while the closely-related analogues N-isopropyl and N-methyl isopropyl abacavir were 
devoid of T-cell activity. Docking abacavir analogues to HLA-B*57:01 revealed a quantitative relationship 
between drug-protein binding and the T-cell response. These studies demonstrate that the unwanted T-cell activity 
of abacavir can be eliminated whilst maintaining the favourable antiviral profile. 
 
A relatively large panel of abacavir-dependent HLA-B*57:01 binding self peptides were utilised to understand 
the mechanism of T-cell activation. Our data provides experimental evidence that a 9mer peptide (Peptide 15; 
NTVELRVKI) is responsible for the polyclonal CD8+ T-cell activation seen in abacavir hypersensitive patients. 
Furthermore, the discovery that most discovered unique altered self peptides are unable to induce CD8+ T-cell 
activation indicated that the immune response is highly peptide specific. 
 
Collectively the data generated enhances our understanding of how a single drug abacavir interacts with 
immunological receptors to initiate an unwanted and often pathogenic immune response. Even for this most 
highly HLA-restricted immunological drug reaction the nature of the drug receptor interaction is much more 
complex than initially anticipated. Thus, further studies are needed to determine how the results presented herein 
relate to other forms of immunological drug reaction.                              
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1.1  Preface 
Adverse drug reactions are responsible for 6.5% of all hospital admissions (Davies et 
al, 2009). They also affect 10 to 20% of hospitalized patients (Pirmohamed et al, 
2004). Morbidity and mortality associated with drugs in the United States has been 
estimated to cost more than diabetic and cardiovascular care with an annual budget of 
$136 billion (Bharadwaj et al, 2012). Adverse drug reactions associated with drugs 
are classified into two broad types. Type A reactions are predictable and dose 
dependent adverse drug reactions. Type B reactions are off target usually 
immunological reactions that are unpredictable, dose independent and often life–
threatening, which makes them a major human health concern and an impediment to 
the drug development process. Drug hypersensitivity is the term normally applied to 
describe type B reactions that are believed to involve drug antigen-specific T-
lymphocytes. Abacavir hypersensitivity is a form of delayed-type hypersensitivity 
reaction, which develops within the first 3 weeks of starting treatment. Reactions are 
observed in approximately 8% of exposed patients.  
 
The discovery of a strong association between the presence of HLA-B*57:01, HLA-
DR7 and HLA-DQ3 and hypersensitivity to abacavir in 2002 by Hetherington et al 
(2002) and Mallal et al (2002) resulted in a renewed interest in the mechanisms of 
delayed-type drug hypersensitivity reactions. Maybe reactions should no longer be 
defined as unpredictable. A double-blind prospective, randomized study involving 
1956 patients was designed to establish the effectiveness of prospective HLA-
B*57:01 screening to prevent hypersensitivity reactions to abacavir. Patients were 
assigned to undergo screening, with exclusion to HLA-B*57:01 positive patients from 
abacavir therapy, or undergo standard approach to treatment with no screening 
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(Mallal et al, 2008). Abacavir patch testing was conducted to confirm immune-
mediated hypersensitivity reactions. Screening effectively eliminated abacavir 
hypersensitivity; patch test confirmed reactions were not detected in the HLA-
B*57:01 negative group. These data resulted in widespread use of cost-effective 
screening for this HLA-allele in clinical practice at HIV clinics to prevent reactions to 
abacavir (Hughes et al, 2004). If HLA-B*57:01 is intrinsically linked to the 
mechanism of hypersensitivity, the drug antigen must in some way interact with the 
protein encoded by the HLA allele to activate the adaptive immune system.  
 
Since discovery of the HLA-B*57:01 abacavir hypersensitivity association, 
pharmacogenetic studies have identified strong associations between hypersensitivity 
reactions to several drugs targeting skin and liver and specific human leukocyte 
antigens in single or multiple ethnic populations. Table 1.1 shows 4 drug examples of 
strong HLA associations with 100% negative predictive values for abacavir, 
carbamazepine and allopurinol and 99.99% for flucloxacillin. The table includes 
abacavir hypersensitivity/flucloxacillin-induced liver injury and HLA-B*57:01
+
, 
carbamazepine-induced Stevens–Johnson Syndrome (SJS) and toxic epidermal 
necrolysis (TEN) in Asian populations and HLA-B*15:02
+
 and allopurinol-induced 
hypersensitivity syndrome and SJS/TEN and HLA-B*58:01
+
 (Phillips and Mallal, 
2010, Pompeu et al, 2012, Pavlos et al, 2015). Notably, these drugs vary in chemical 
structure, molecular weight and lipophillicity which may partly explain why they bind 
to different HLA molecules to induce hypersensitivity. Notably, many other HLA 
allele-restricted drug hypersensitivity associations have been identified, but the 
negative predictive values and calculated odds ratio tend to be lower. Carbamazepine- 
and allopurinol-specific T-cells have been isolated from patients with hypersensitivity 
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reactions (Naisbitt et al, 2003; Wei et al, 2012; Wu et al, 2007; Wu et al, 2006; Yun et 
al, 2013; Chung et al, 2015) and drug-naïve human volunteers carrying the known 
risk alleles (Yun et al, 2014; Lichtenfels et al, 2014; Ko et al, 2011).  Carbamazepine 
and certain carbamazepine metabolites activate T-cells through a direct interaction 
with the HLA risk alleles expressed on the surface of antigen presenting cells. The 
binding interaction is readily reversible and T-cell responses can be blocked by 
washing antigen presenting cells prior to addition of the T-cells. Similarly, T-cells 
from allopurinol hypersensitive patients are activated via the drug antigen interacting 
directly with the HLA risk allele. However, in this case the response is driven by the 
stable metabolite oxypurinol (Yun et al, 2014). It is important to note, with both of 
these examples, the location of the drug HLA binding interaction has not been 
defined. Furthermore, it is not known whether the drugs interact with the HLA 
molecule itself or a specific HLA binding peptide. Finally, these data do not exclude a 
role for reactive metabolites in the pathogenesis of the reactions. Reactive metabolites 
might induce stress signaling pathways that (1) direct T-cells into the tissue and/or (2) 
polarize the T-cell response resulting in a more pathogenic outcome. Furthermore, it 
is possible that the irreversible binding of reactive metabolites to protein might lead to 
the liberation of haptenic antigenic peptides as has been shown for sulfonamides 
(Schnyder et al, 2000; Castrejon et al, 2010) and β-lactam antibiotics (Jenkins et al, 
2013; Brander et al, 1995). However, to date it has not been possible to develop cell 
culture systems incorporating viable lymphocytes and the reactive metabolites.   
 
Why is abacavir hypersensitivity and flucloxacillin-induced liver injury associated 
with expression of the same HLA allele B*57:01? Interestingly, for both forms of 
reaction, drug exposure and carriage of the HLA allele are necessary, but alone not 
Chapter 1     
 
5 
sufficient to explain tissue specificity and the clinical syndrome. Approximately half 
of HLA-B*57:01 positive individuals exposed to abacavir develop hypersensitivity, 
whereas with flucloxacillin only 1 in a 1000 drug exposed B*57:01 positive 
individuals develop liver injury (Mallal et al, 2002, 2008; Daly et al, 2009).  Hence, 
other, yet to be defined, genetic or environmental factors must be present.  
 
Despite this, flucloxacillin and abacavir represent the most appropriate drugs to use to 
explore the different pathways by which drugs activate T-cells. Flucloxacillin is a β-
lactam antibiotic that binds covalently to lysine residues on proteins in vitro and in 
drug-exposed patients (Jenkins et al, 2009). Drug-specific T-cells isolated from 
PBMC of patients with liver injury are for the most part CD8+ and activated via a 
hapten mechanism involving protein processing by antigen presenting cells (Monshi 
et al, 2013). The drug antigen (presumably a flucloxacillin-modified peptide) activates 
the CD8+ T-cells in a highly HLA allele-restricted fashion. Clones are stimulated to 
proliferate and secrete effector molecules in the presence of flucloxacillin and antigen 
presenting cells expressing HLA-B*57:01, but not antigen presenting cells expressing 
other HLA-B alleles (Yaseen et al, 2015). Flucloxacillin-responsive T-cells can also 
be expanded from drug-naïve volunteers expressing the risk allele by culturing the 
cells with mM concentrations of soluble drug (Yaseen et al, 2015; Wuillemin et al, 
2014). T-cells from these individuals are activated by the parent drug binding directly 
to the HLA molecule which presumably occurs as a consequence of the high levels of 
drug exposure that would not be seen in patient plasma. Nevertheless, the data 
indicates that saturation of HLA-B*57:01 peptide binding groove with soluble 
flucloxacillin might mimic the action of the drug hapten in patients.   
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Drug  Molecular 
weight 
Lipophillicity Type of 
hypersensitivity 
Risk 
HLA 
allele 
Odds 
ratio 
NPV PPV 
Abacavir 
 
286.3 0.9 Systemic 
hypersensitivity 
HLA-
B*57:01 
960 100% for 
confirmed 
patch test 
55% 
Carbamazepine 
 
236.2 2.5 SJS/TEN HLA-
B*15:02 
> 1000 100% in 
Han 
Chinese 
3% 
Allopurinol 
 
136.1 -0.5 Severe 
cutaneous 
adverse 
reactions 
HLA-
B*58:01 
> 800 100% in 
Han 
Chinese 
3% 
Flucloxacillin 
 
453.9 2.6 Drug-induced 
liver injury 
HLA-
B*57:01 
81 99.99% 0.12% 
Table 1.1 HLA-associated drug hypersensitivity. NPV and PPV stand for negative and positive predictive 
value respectively. Stevens Johnson Syndrome described as SJS and toxic epidermal necrolysis as TEN. 
 
The smaller size of abacavir may permit a sterically less hindered fit within HLA-
B*57:01. The PI concept proposes that abacavir would bind non-covalently to the 
surface of HLA-B*57:01 molecule (Pichler et al, 2011). This drug-HLA complex 
once bound with sufficient affinity to specific T-cell receptors would then drive the 
immune reaction and pathogenic response in patients. In support of this argument, 
Adam et al. (2012) found that cloned T-cells expanded from drug-naïve HLA-
B*57:01 positive volunteers were activated rapidly with the parent drug via a pathway 
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that was independent of antigen processing. These data, however, are in stark contrast 
to the elegant studies of Chessman et al. (2008) who (1) found that abacavir-specific 
CD8+ T-cell responses were HLA-B*57:01-restricted, (2) characterized the single 
amino acid within the B*57:01 binding groove (serine 116) that abacavir interacts 
with to activate T-cells and (3) demonstrated that responses were blocked by 
inhibitors of proteosomal processing. At this point in time, the mechanism of 
abacavir-specific T-cell activation and in particular the role of abacavirs aldehyde 
metabolite (Walsh et al, 2002) in the T-cell response was ill-defined.  
 
Prior to commencement of my studies, Bell et al. (2013) generated an extensive panel 
of abacavir-responsive CD8+ T-cell clones from HLA-B*57:01 positive donors. The 
authors proposed that T-cells are activated with abacavir via 2 pathways: the first 
pathway involving a direct drug MHC T-cell receptor binding interaction as proposed 
by Pichler; the second involving protein processing and the liberation of antigenic 
HLA-B*57:01 binding peptides. Three independent research teams published related 
structural, computer modelling and immunological studies that seemed to define the 
mechanism of the latter pathway (Illing et al, 2012; Ostrov et al, 2012; Norcross et al, 
2012). Abacavir was shown to bind non-covalently deep in the cleft of the HLA-
B*57:01 peptide binding groove prior to transport of the MHC molecule to the cell 
surface. Abacavir binding altered the molecular space within the binding cleft in a 
manner that allowed the display of a novel repertoire of self-peptides (Figure 1.1). As 
one would expect this pathway is dependent on protein processing within antigen 
presenting cells. Abacavir must be cultured with antigen presenting cells for the 
duration of the experiment (i.e., 16 hours) otherwise the peptide repertoire is not 
altered and T-cells are not activated. It was proposed that these novel amino acid 
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sequences are what activate certain “abacavir-responsive” CD8+ T-cells in 
hypersensitive patients; however, definitive evidence for the peptide-specific 
activation of T-cells and indeed the amino acid sequence of the antigenic peptides was 
lacking. Interestingly, Norcross et al. (2012) used fluorescent B*57:01 binding probes 
to compare the effect of abacavir and flucloxacillin and found that only abacavir alters 
self-peptide loading, which agrees with the above discussion stating that 
flucloxacillin-hapten peptides are the major antigenic determinants in patients and that 
when antigen presenting cells are exposed to high concentrations of soluble drug it 
likely binds to HLA-B*57:01 above the embedded peptide, not underneath as is the 
case for abacavir. The aldehyde metabolite of abacavir was synthesized in the MRC 
Centre for Drug Safety Science. Covalent bonds between abacavir aldehyde and 
amino acid residues on human serum albumin at positions Lys159 and Lys90, His146, 
and Cys34 have been reported (Meng et al, 2014). Furthermore, abacavir metabolites 
have been found to form covalently adducts with protein in vivo (Charneira et al, 2011 
and 2012). Despite this, preliminary studies have shown that the aldehyde metabolite 
does not activate T-cells (unpublished data).   
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Figure 1.1 Crystal structure of abacavir (orange spheres) bound to HLA-B*57:01 molecule 
proposed to alter self-peptide (cyan spheres) recognized by T-cell receptor (Pompeu et al, 
2012). 
  
Drug-induced hypersensitivity reactions constitute a major subtype of type B reaction. 
This chapter sheds some light on drug-induced hypersensitivity reactions, their 
different phenotypes, the three possible concepts explaining the underlying 
mechanisms of such reactions, and the available techniques for investigating drug 
hypersensitivity, paying particular attention to weaknesses. Low molecular weight 
(i.e. penicillins, sulfamethoxazole and abacavir) and high molecular weight 
(biologics) drugs are described in detail, since they are both associated with the 
inadvertent activation of the adaptive immune system, which manifests as 
hypersensitivity in certain individuals.  
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1.2 Immune system 
The immune system is comprised of both innate and adaptive immune response. The 
innate immune response is often a generalised and non-specific response attributable 
to cell damage, trauma or infection. In contrast, the adaptive immune response is a 
specific and acquired response attributable to antigen recognition. Immune cells 
involved in both types originate from pluripotent stem cells found in the bone 
marrow. Phenotypically different cell types can be generated in response to stimuli. 
20% of the circulating white blood cells are lymphocytes. T and B lymphocytes are 
derived from lymphoid progenitor cells; however, each has unique functions and 
developmental lineages. B lymphocytes develop in the foetal liver and represent the 
source for antibody production and secretion. They express immunoglobulins which 
recognize antigen and stimulate B lymphocytes to proliferate and differentiate to 
memory and plasma cells. Plasma cells secrete antibodies to specific antigen to enable 
neutralisation of viral components, complement fixation and/or antigen coating to aid 
phagocytosis. Memory cells express high affinity IgA and IgG molecules compared to 
lower affinity IgD and IgM molecules on naïve cells. Memory cells circulate in the 
resting state but respond rapidly when the antigen is encountered again. CD19 
molecule is a cell surface marker for B lymphocytes. T lymphocytes develop in the 
thymus. They express T-cell receptors (TCR) that recognize specific antigen and each 
T lymphocyte expresses only one TCR, therefore, a small number of antigens are 
recognized by individual cells. TCR recognises part of the antigen; i.e. few amino 
acids. Antigen-specific T-cells expressing the corresponding TCR will proliferate and 
differentiate to effector T-cells when the antigen is encountered again. The effector 
function of CD8
+
 T-cells is cytotoxicity, CD4
+
 T-cells were originally referred to as 
helper cells but they have recently been shown to have cytotoxic functions (Marshall 
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and Swain, 2011). Naïve cells are known as type 0 (Th0) cells but in the presence of 
interleukin-2 and interlukin-4 activated Th0 cells will become Th1 cells and Th2 cells 
will be produced, respectively. Th1 cells subsequently secrete interleukin-2 and 
interferon gamma whereas Th2 cells secrete interleukin-4, 5, 9 and 13 (Mosmann and 
Coffman, 1989). Secretion of these polarized cytokines influences the type of immune 
response since Th1 cytokines promote T-cell mediated immunity whereas Th2 
cytokines promote B-cell humoral response. 
- 1.2.1 Major histocompatibility complex (MHC) 
The MHC region at the short arm of chromosome 6 comprises a cluster of genes. 
Genes in this region play an important role in both adaptive and innate immunity.  
The MHC region is the most polymorphic region in the human genome. MHC genes 
encode a diverse array of cell surface glycoproteins that involved in the presentation 
of antigens to T-cell receptor. In humans, MHC class I and II genes are named as 
human leukocyte antigen (HLA) class I and II. First, MHC class I molecules are 
expressed by most of the nucleated cells. They include the HLA-A, HLA-B and HLA-
C loci in which they consist of one gene encoding a polymorphic light chain (α) and 
share a common β-chain (β2m). β2m is not membrane bound but plays a key role in 
transporting newly synthesised MHC molecules to the cell surface. The peptide-
binding groove accommodates 9mer-11mer peptides. Hydrogen bonds and Van der 
Waals forces secure the peptide binding. Second, MHC class II molecules are only 
expressed by specific antigen-presenting cells such as dendritic cells, macrophages 
and B-cells. They included the HLA-DR, HLA-DQ and HLA-DP loci in which the 
genes for (α and β) chains are located within the MHC region. Longer peptides can be 
accommodated in the peptide-binding groove. 
 
Chapter 1     
 
12 
- 1.2.2 Antigen processing and presentation 
T-cells express TCRs that are specific to bind MHC-peptide complexes, therefore, 
antigens to be recognised they must be presented via MHC molecule. Antigen 
presenting cells (APCs) process the antigens by two distinct pathways. First, the 
intracellular antigens that are often formed as a result of viral infection in which viral 
peptides are released into the host cell cytosol. Peptides are transferred to the 
endoplasmic reticulum via a transporter called TAP molecule. In the endoplasmic 
reticulum, MHC molecule is formed together with the peptide repertoire required for 
stability (Neefjes et al, 2011). MHC-peptide complex is then released and migrate to 
the cell membrane. MHC class I molecules present intracellular derived peptides to 
CD8
+
 T-cells whereas MHC class II molecules present extracellular peptides to CD4
+
 
T-cells. Second, the extracellular antigens that are formed as a result of pathogen 
exposure whereby pathogens are processed by APCs such as dendritic cells and 
macrophages in which they are phagocytosed within the cell and subsequently 
enzymes degrade pathogen into peptide fragments. 
- 1.2.3 Danger signalling 
Matzinger proposed that immune activation is not just a case of self versus non-self; 
however, it is the antigen presentation that determines whether an immune response is 
initiated (Matzinger, 1994). At least two signals are involved in immune activation. 
The engagement of the TCR with an MHC-peptide complex represents the first 
signal; however, this is not sufficient to activate immune system. Signal two is the 
interaction of various co-stimulatory molecules expressed on the T-cell and APC. 
Thus, in the absence of signal two, signal one leads to immune tolerance. Exogenous 
pathogen associated molecular pattern (PAMPs) such as viral RNA and LPS and 
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endogenous damage associated molecular pattern (DAMPs) such as heat shock 
proteins, HMGB1 which are released from damaged cells can contribute to danger 
signalling. Drugs that are found to induce danger signalling include abacavir, 
sulfamethoxazole metabolites and amoxicillin. Abacavir induces heat shock protein 
redistribution in APCs (Martin et al, 2007), sulfamethoxazole metabolites increase 
dendritic cell expression of CD40 (Sanderson et al, 2007) and amoxicillin drives 
dendritic cells towards maturation (Rodriguez-Pena et al, 2006). 
 
1.3 Definitions 
Low molecular weight compounds such as penicillins, sulfamethoxazole and abacavir 
and high molecular weight compounds such as biologics (e.g monoclonal antibodies 
and interferons) are able to exert immunological reactions when they act as antigens, 
immunogens, and/or co-stimulatory molecules. For certain drugs to act as antigens 
they must form a haptenic determinant. The following descriptions have been 
designed particularly to help understanding drug-induced hypersensitivity reactions 
(Uetrecht, 2001; Bigby et al, 1986). 
o Hapten is a low-molecular-weight compound with tendency to bind to protein 
irreversibly. This binding might or might not stimulate the immune response. 
o Antigen is a substance that interacts with high affinity to immune receptors. 
o Immunogen is a substance that stimulates the immune response. An 
immunogen has the potential to stimulate the innate and adaptive immune 
system. 
o Co-stimulatory agent is a substance that binds to dendritic cells, stimulating 
maturation and possibly polarization of the immune response. Drugs can act as 
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co-stimulatory agents and provide maturation signals to dendritic cells, 
however, dendritic cells might also receive maturation signals from other 
sources of drug or non-drug induced cell such as trauma, stress, and disease 
(Naisbitt et al, 2007).  
 
1.4 Drug-induced hypersensitivity reactions 
Drug therapy is often a balance between harm and beneﬁt. Puzzling effects are often 
caused by the immune system whereby immune responses that develop into tissue 
injury are known as hypersensitivity reactions or type B (bizarre or idiosyncratic) 
reactions (Naisbitt et al, 2007). Some scientists prefer to call them off-target reactions 
since they are unpredictable drug effects. Interestingly, some of these reactions are 
now quite predictable because they are highly associated with particular HLA alleles 
(Alfirevic and Pirmohamed, 2010). Hypersensitivity per se implicates some form of 
immune involvement. It is a general term used to describe immunological adverse 
reactions and, also, defined as ''a heightened response in a body tissue toward an 
otherwise non-toxic agent'' (Naisbitt et al, 2007). These reactions are unpredictable 
from the known primary pharmacology of the drug, unrelated to drug overdose, and 
affect only minority of the population. Other than the HLA association discussed in 
detail, it is largely unknown why only certain people are susceptible to 
hypersensitivity. Many drugs associated with higher incidence of hypersensitivity, 
have been administered at higher doses (Uetrecht, 2001). This dose threshold might 
be responsible for the development of tissue pathology since sufficient quantity of the 
parent drug or reactive metabolite possibly delivered to the immunological synapse 
(Naisbitt et al, 2007). However, dose is not the only susceptibility factor as many 
patients receiving the same drug do not develop hypersensitivity.  
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- 1.4.1 Importance of the clinical problem of drug hypersensitivity  
Drug hypersensitivity accounts for approximately one-sixth of all adverse drug 
reactions (Pichler, 2008). Some of these hypersensitivity reactions are quite severe 
and even fatal (Lazarou et al, 1998; Roujeau and Stern 1994). Hypersensitivity can 
present in many different ways, however, it has been reported to present most 
frequently in the skin (Hunziker et al, 1997). Drug cutaneous reactions affect 2 – 3% 
of hospitalised patients (Naisbitt et al, 2007). Skin rashes are also seen in 0.1 – 1% of 
patients exposed to drugs during premarketing trials (Roujeau, 2005). However, the 
incidence of hypersensitivity differs according to the pharmacology of the drug and 
patient susceptibility factors; such as age, sex, ethnicity and disease state. Table 1.2 
listed common drugs associated with higher incidence of hypersensitivity including 
penicillins, sulfonamides, antiepileptics and antiretroviral drugs (Naisbitt et al, 2007). 
 
Drug classes associated with hypersensitivity 
 
NSAIDs                                   (e.g diclofenac) 
Penicillins                                (e.g amoxicillin) 
Sulfonamides                           (e.g sulfamethoxazole) 
Anticonvulsants                       (e.g carbamazepine) 
Antivirals                                 (e.g abacavir, nevirapine) 
Table1.2 Common drugs associated with hypersensitivity 
 
- 1.4.2 Chemical basis of drug hypersensitivity 
a) Hapten concept 
The recognition of drugs such as penicillin by T lymphocytes or B lymphocytes is 
usually explained by the hapten theory (Naisbitt et al, 2000; Pichler, 2003). Haptens 
are chemically reactive small molecules; normally less than 1 kilo dalton molecular 
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weight, that have the propensity to bind covalently to a larger protein or peptide in a 
stable and irreversible manner (Pichler, 2008). The subsequent modification of that 
protein or peptide allows the small molecule drug to act as antigen. Drugs can bind to 
the peptide embedded in the major histocompatibility complex (MHC) molecule, cell-
bound proteins (e.g., integrins), or soluble autologous proteins (e.g., albumin). As a 
result, many different antigens are formed, which induce different types of immune 
reaction and lead to great heterogeneity of clinical pictures (Figure 1.2 A). A typical 
example of haptenic drug is penicillin G, which binds irreversibly to ε-amino groups 
of lysine residues located on soluble and cell-bound proteins, thus, modifying these 
proteins and eliciting T-cell and B-cell reactions (Pichler, 2008). Additionally, 
penicillin G may bind directly to the immunogenic peptide within the binding groove 
of MHC-molecules, so, no processing is required. Evidence from animal models 
suggests that modification of the MHC molecule itself is possible but occurs less 
frequently (Martin and Weltzien, 1994).
  
b) Prohapten concept 
Many drugs are not chemically reactive, although, they are still able to elicit an 
immune-mediated response. The prohapten concept tries to explain this phenomenon 
and reconcile it with hapten concept by stating that a parent drug may become 
chemically reactive when it undergoes metabolism (Naisbitt et al, 2000; Pichler, 
2003; Griem et al, 1998). A typical example of a prohapten drug is sulfamethoxazole, 
which is not chemically reactive itself but becomes immunogenic after intracellular 
cytochrome p450 and peroxidise catalysed metabolism that leads to 
sulfamethoxazole-hydroxylamine (Pichler, 2008; Figure 1.2 B). This metabolite can 
be found in the urine and can easily transformed to the highly reactive metabolite 
sulfamethoxazole-nitroso by auto-oxidation.
 
The nitroso metabolite is a chemically 
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reactive compound that binds covalently to cysteine residues on peptides and proteins, 
thereby, forming neoantigens capable of inducing different types of immune response. 
The resulting clinical picture can have great heterogeneity as with hapten drugs. 
Sulfamethoxazole causes many different forms of cutaneous hypersensitivity reaction 
as well as reactions that target internal organs (Pichler, 2008). These adverse reactions 
are mainly mediated by antibodies developed against the drug antigen and/or antigen-
specific T lymphocytes.  
c) P-I concept 
The third possible mechanism, namely the pharmacological interaction of drugs with 
immune receptors (p-i) has been revealed recently. According to p-i concept, 
chemically unreactive drugs that are incapable of binding covalently to proteins or 
peptides can directly stimulate T cells if they fit into any of numerous MHC 
molecules and cross-link T-cell receptors (Zanni et al, 1998; Pichler, 2002). This 
binding might result in highly selective T-cell stimulation, similar to the stimulation 
occurs by MHC associated peptides. By this process, the drug does not require 
transformation or metabolism, additionally, the generation of neoantigens by the drug 
interaction with a carrier protein and subsequent processing by antigen presenting 
cells (APCs) is also not required. When the drug binds to T-cell receptors, according 
to the p-i concept, an additional MHC binding with T-cell receptor is also required for 
full activation (Figure 1.2 C). Presumably, the drug stimulates previously primed 
memory T cells with lower threshold of reactivity than naïve T cells (Pichler, 2008). 
This threshold might be further lowered in patients with human immunodeficiency 
virus infection, autoimmune diseases, and generalized herpes infections, because of 
the massive immune stimulation of T cells under these conditions (Pichler, 2008).
 
Interestingly, this can explain the high incidence of drug hypersensitivity reported for 
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these patients.
 
The p-i concept has changed significantly our understanding of 
hypersensitivity reactions that are induced by medications, by explaining some 
unusual features of hypersensitivity that are not covered by hapten concept. 
According to the p-i concept, the symptoms of hypersensitivity result from the 
pharmacological interaction between the drug and the immunologically competent 
cells, and not due to neoantigen formation. Analysis of T-cell responses to drugs such 
as carbamazepine, phenytoin, and sulfamethoxazole, suggests that both p-i and hapten 
concepts often occur together in the same hypersensitive patient (Pichler, 2008).
 
 
 
Figure 1.2 Hapten, prohapten and p-i concept (Pichler, 2003 and 2008). (A) Haptens: drugs are considered haptens 
(e.g. penicillin G) if they are capable of binding covalently to either soluble or cell-bound proteins. They can also bind 
directly to the embedded peptide of the MHC molecule on APC, or to the MHC molecule itself. Accordingly, the 
chemical reactivity of haptens leads to the formation of numerous distinct antigenic epitopes that can generate cellular 
immune responses once bound to TCR. (B) Prohaptens: drugs are considered prohaptens (e.g. sulfamethoxazole) if they 
require biotransformation to generate chemically reactive haptens. This reactive metabolite may lead to modification of 
cell-bound or soluble proteins similar to a true hapten molecule. (C) The p-i-concept: drugs often contain structures that 
bind selectively to specific proteins or enzymes to stimulate or block a function of interest. Some drugs may also happen 
to fit into some of the available T-cell receptors which may lead to an immune response. When the drug bound to T-cell 
receptors as mentioned by p-i concept, an additional MHC binding with T-cell receptor is also required for full activation. 
This type of immune stimulation leads to an exclusive T-cell activation. 
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- 1.4.3 Types of drug-induced hypersensitivity reactions 
Drug-induced hypersensitivity reactions can cause several types of disease. To 
categorize this great heterogeneity of clinical picture, Coombs and Gell successfully 
classified drug-induced hypersensitivity reactions as well as other immune responses. 
Four categories, namely type I, II, III, and IV reactions were developed (Coombs and 
Gell, 1976). Recently, this classification has been modified to take into account T-
lymphocyte function as well as the interdependence of these reactions because, for 
example, the maturation of B lymphocytes to IgG-producing plasma cells depends 
mainly on T-lymphocytes (Pichler, 2003). Notably, type II and even type III reactions 
often occur together with type IVa reactions, similarly, type I and type IVb reactions 
often occur together. However, the ultimate clinical picture seen in the patient is 
probably dependant on the most prevalent immune reaction (Pichler, 2008). 
- 1.4.3.1 Antibody-mediated drug reactions      
The hapten-like features of a chemically reactive drug allow the modification of 
proteins and formation of neoantigens. The natural reaction of the immune system 
toward these antigens leads to the development of a humoral immune response 
(Pichler, 2008). Therefore, when a humoral immune response develops, the drug 
should have hapten-like features forming hapten–carrier complexes, or itself be 
protein containing foreign determinants. Indeed, the majority of available drugs able 
to elicit IgE-mediated reactions are either hapten drugs, or even protein therapies 
containing foreign antigenic determinants (Table 1.3). 
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Drugs involved in IgE-mediated allergies 
 
Foreign proteins  
(chimeric antibodies) 
 
Immunoglobulin preparations  
(IgE anti-IgA) 
 
Β-lactam antibiotics  
(penicillin, cephalosporin, pyrazolones, quinolones, muscle relaxants) 
 
Table 1.3 Drugs causing IgE-mediated reactions 
 
i. IgE-mediated reactions (Type I, allergic mechanism)            
The IgE-system is a highly sensitive system and geared to interact with small amounts 
of antigens. This extraordinary sensitivity of IgE-system originated from the 
ubiquitous presence of mast cells that are equipped with high-affinity Fcε receptors 
(Fcε-RI) bound with IgE molecules (Pichler, 2008). Apparently, very little amounts of 
the drug-specific IgE antigen is sufficient to bind to these receptors bound IgE 
molecules and stimulate them. Upon cross-linking with Fcε-RI, several mediators are 
released; such as histamine, tumour necrosis factor-α (TNF-α), prostaglandins, and 
leukotrienes, which lead to different manifestations. It is assumed that IgE-mediated 
reactions against drugs are usually dependent on a prior development of an immune 
response toward a hapten–carrier complex, because B lymphocytes require maturation 
into IgE-secreting plasma cells, and T lymphocytes help in this process by interacting 
with B lymphocytes (for example, interaction of CD40 with CD40L) and by releasing 
cytokines (for example, interleukin-4 and interleukin-13) that are key elements for 
IgE synthesis (Pichler, 2008). The sensitization phase is asymptomatic and might 
occur during a previous course of the drug, but upon next exposure with the same 
drug, a hapten–carrier complex is formed again that crosslinks with the already 
preformed IgE specific drug molecules on mast cells. The resulting IgE-mediated 
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reactions develop in the presence of very small amounts of drug and can cause severe 
reactions. However, further diminishing the dose – as seen in desensitization 
procedures – shows these reactions are clearly dose-dependent (Pichler, 2008). IgE-
mediated reaction (e.g. anaphylaxis, angioedema, and atopy) usually occur within 
seconds among sensitized individuals, especially, if drug is administered parenterally 
and within minutes if administered orally. Anaphylactic reactions have been reported 
to occur within 15 minutes, while asphyxia reaction can occur any time during the 
first hour (Pichler, 2008). Early alarm signs of severe anaphylactic reaction include 
itching in genital, axillary and palm area, which is often followed by diffuse erythema 
that affects the trunk first, and then the whole body becomes red in colour. Also, 
urticaria may appear simultaneously with swelling of the genital, periorbital, and 
perioral areas (Figure 1.3). 
 
Figure 1.3 Urticaria with itching wheals (Pichler, 2008) 
 
Patients may experience hoarse voice due to laryngeal edema, and speaking difficulty 
due to tongue swelling. These are symptoms for asphyxia reaction that account for 
60% of anaphylaxis-related deaths (Pichler, 2008). Also, some patients may suffer 
chest tightness, dyspnea, and hypotension. All these symptoms are recognized as 
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anaphylactic shock which is fatal in 1% of patients and survivors may have 
intellectual or cognitive impairment. The majority of IgE-mediated reactions against 
drugs are self-limiting urticaria, angioedema, and localised wheal. However, every 
IgE-mediated drug reaction can be potentially life threatening, as every drug course is 
thought to boost the IgG response. 
 
ii. IgG-mediated reactions (Type II, cytotoxic mechanism)           
IgG-mediated reactions (Type II and III) depend on the formation of complement 
fixing IgG antibodies (IgG1, IgG3), nevertheless, IgM is involved occasionally. Type 
II and type III reactions are quite similar, because both depend on immune complex 
formation and both rely on an interaction with complement and Fcγ receptor on 
natural killer cells and macrophages, but,  the physiological consequences for each 
type reaction are quite diverse. In type II reactions, either the immune complex is 
activated on the cell surface, or the antibody is directed toward cell membrane 
components which causes cell destruction. Affected target cells include white blood 
cells, red blood cells, platelets, and hematopoietic precursor cells in the bone marrow.  
The mechanism of type II reactions is still not fully defined, since the hapten-specific 
immune reaction requires more investigation, however, two potential patterns have 
been revealed recently (Aster, 1999; Arndt and Garratty, 2005). First, development of 
type II immune reaction toward the hapten–carrier complex mainly occurs after 
extended period of high dose therapy. This immune reaction is best documented for 
high dose penicillin and cephalosporin drugs, due to complement-fixing antibodies 
that are mainly seen in the form of IgG1 and IgG3 isotypes. However, IgM 
immunoglobulins have been also detected in some rare cases. Surprisingly, some 
antibody reactivity such as autoantibodies may be directed specifically to the carrier 
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molecule but not the hapten in which the resulting immune reaction lasts for several 
weeks instead of days (Pichler, 2008). Second, non-selective adherence of 
autoantibodies may occur when the drug or the metabolite is bound to cell 
membranes, creating a new antigenic complex in combination with cell membrane 
proteins or enzymes. For instance, quinine-induced immune thrombocytopenia is 
driven by IgG and IgM immunoglobulins that react with selected epitopes on platelet 
membrane glycoproteins; usually GPIb/IX receptor (i.e. von Willebrand factor 
receptor) or GPIIb/IIIa receptor (i.e. fibrinogen receptor), only when the quinine drug 
is available in soluble form (Aster, 1999). Moreover, clinical cases of IgG type II 
reactions have been reported for this mechanism with quinidine and sulphonamide 
drugs. Although, the antibodies seem to be hapten non-specific, it remains unknown 
how a soluble drug like the quinine can influence binding of innocuous antibody to a 
membrane glycoprotein and cause cell destruction. 
 
iii. IgG-mediated reactions (Type III, immune complex deposition)     
Type III immune reactions depend mainly on immune complex formation which is a 
common consequence for a normal immune response and usually not associated with 
any clinical manifestation. Immune complexes can be formed after drug therapy, 
especially if the drug is a partly foreign protein that causes immune reaction itself 
(e.g., murine-antibodies or even if the drug forms a hapten–carrier complex) (Pichler, 
2008). These immune complexes will be rapidly cleared when bound to complement 
receptor (CR1) on reticuloendothelial cells or Fcγ-RI on natural killer cells and 
macrophages. The clearance of immune complexes decreases the efficiency of the 
therapy, although no symptoms arise. High levels of immune complex indicate 
aberrant Fcγ-R function or deficiency of some complement components, and therefore 
lower capacity to clear immune complexes. Furthermore, a low number of Fcγ-RIII 
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was found to be associated with immune complex disease called glomerulonephritis 
(Aitman et al, 2006). Examples of symptoms found in immune complex diseases 
include vasculitis, myalgia, arthralgia, and fever. Signs of immune complex may 
appear also in the skin of adults as purple and red spots (i.e. palpable purpura) and 
also in children as Henoch–Schönlein purpura often associated with arthritis. In 
addition, internal organs such as joints, kidneys and gastrointestinal tract can be 
affected by lesions that occasionally ulcerate (Pichler, 2008). Type III reactions may 
present as serum sickness and small-vessel vasculitis. Currently, the most common 
cause of serum sickness is non-protein compounds, while hypersensitivity vasculitis 
has been reported from protein and non-protein compounds such as amoxicillin, 
cephalexin, cefaclor, trimethoprim-sulfamethoxazole, diuretics, and nonsteroidal anti-
inflammatory drugs (Pichler, 2008). Serum sickness was first seen during 
heterologous serum treatment used for passive immunization. Antibodies develop 
within 4 to 10 days which then interact with the non-self antigen and form soluble 
circulating immune complexes. Complement immune complexes are deposited in the 
postcapillary venules, thus attracting white blood cells and bind to Fcγ-RIII which 
causes tissue damage due to the release of proteolytic enzymes (Stokol et al, 2004). 
 
- 1.4.3.2 Cytokine-mediated drug reactions (Type IV, T-cell-mediated 
reactions, delayed drug hypersensitivity)      
The original classification of drug hypersensitivity reactions was established four 
decades ago before different T-cell functions and subsets had been defined. Recent 
research has revealed that T-cells support various forms of inflammation and 
antibody-dependent reactions. Thus, type IV reactions have been further categorized 
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to type IVa, IVb, IVc, and IVd reactions (Figure 1.4; Elzagallaai et al, 2011; Pichler, 
2004). The new classification considers several factors including cytokine release by 
T lymphocytes, distinct forms of Th1 and Th2 cells, cytotoxic activity of CD4 and 
CD8 T lymphocytes, and contribution of effector cells such as neutrophils, 
eosinophils and monocytes which cause tissue damage and inflammation. 
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Figure 1.4 Updated classification of drug-induced hypersensitivity reactions. All immune reactions are T-cell regulated, however, the effector functions 
may either rely on antibody-release (type I, II, and III) or cytokine-release (type IVa, IVb, IVc, and IVd) (Pichler, 2004). 
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a. Type IVa reactions       
 
Type IVa immune reactions involove Th1-type CD4
+
 T-cells; the Th1-type T-cells 
stimulate macrophages through secreting high levels of interferon gamma (Pichler, 
2008). Th1-type T-cells also drive the production of complement-fixing antibody 
isotypes IgG1 and IgG3 involved in type II and III reactions, respectively. 
Furthermore, they serve as co-stimulatory factors for CD8 T-cell responses and 
proinflammatory reactions. T-cells mediate these reactions by secreting of interferon 
gamma and other cytokines such as interleukin-18 and TNF-α. Furthermore, in vivo 
models show monocyte activation; for example, granuloma formation rich with 
monocytes occurs after tuberculin exposure. Th1 cells are also known to stimulate 
CD8 T lymphocytes, which may explain the relationship between type IVa and type 
IVc reactions seen in contact dermatitis. 
 
b. Type IVb Reactions       
 
Type IVb immune reactions involve Th2-type T-cells; the Th2- type T-cells secrete 
the cytokines interleukin-4, 5 and 13 which subsequently support B-cell production of 
IgG4 and IgE, which causes macrophage deactivation and induction of mast cell 
responses. High levels of interleukin-5 can cause eosinophilic inflammation; a distinct 
inflammation for many drug hypersensitivity reactions (Pichler, 2003). Th2-type T- 
cells influence IgE production through cytokine secretion which indicates a link to 
type I reactions. Furthermore, in vivo models show similar results of eosinophil 
activation; for example, maculopapular exanthema are rich with eosinophils and the 
inflammation of the bronchi and the nasal mucosa occurs which leads to asthma and 
rhinitis. 
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c. Type IVc Reactions       
 
T lymphocytes can behave as effector cells; since they can migrate to tissue sites and 
kill tissue cells; for example, keratinocytes and hepatocytes, through secretion of 
perforin and granzyme B (Figure 1.5; Nassif et al, 2002; Schnyder et al, 1998). Type 
IVc reactions occur in most drug-induced delayed hypersensitivity reactions in 
combination with other type IV reactions. Therefore, cytotoxic T lymphocytes play 
critical role in maculopapular skin diseases, contact dermatitis and neutrophilic 
inflammation, such as acute generalized exanthemtous pustulosis (AGEP). Type IVc 
reactions are postulated to be responsible for Stevens–Johnson syndrome (SJS) and 
toxic epidermal necrolysis (TEN) in which activated CD8 T-cells kill keratinocytes 
(Pichler, 2003; Nassif et al, 2002; Schnyder et al, 1998). These type IVc reactions 
may also be responsible for drug-induced nephritis and hepatitis. 
 
Figure 1.5 CD4
+
 T-cell mediate killing of activated keratinocytes 
 
 
Granzyme B 
Perforin 
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 d. Type IVd Reactions       
 
T lymphocytes may coordinate sterile neutrophilic inflammation such as acute 
generalized exanthemtous pustulosis, pustular psoriasis, and Behçet's disease (Keller 
et al, 2005). T lymphocytes recruit neutrophilic leukocytes through CXCL8 release, 
and prevent apoptosis of such leukocytes by granulocyte–macrophage colony-
stimulating factor (GM-CSF) release (Britschgi et al, 2001). Importantly, advances in 
immunological research by the discovery of new T-cell populations such as Th9, 
Th17, Th22 and regulatory T-cells now makes above mentioned classification of 
adverse drug reactions somewhat obsolete. Th17 and Th22 characterized by 
interleukin-17 and interleukin-22 secretion, respectively, have been identified 
(Harrington et al, 2005; Eyerich et al, 2009). These cytokines are involved in 
immune-mediated cutaneous reactions such as atopic dermatitis, allergic contact 
dermatitis and psoriasis (Eyerich et al, 2010; Cavani et al, 2012). Interleukin-17 
shows strong pro-inflammatory activity in the presence of interferon gamma which 
leads to T-cell-keratinocyte adhesion and T-cell-mediated cytotoxicity. Interleukin-22 
plays a protective role by stimulating keratinocyte proliferation and migration 
(Eyerich et al, 2009; Eyerich et al, 2010). Regulatory T-cells, natural and inducible, 
are a heterogeneous group of Foxp3
+
CD25
+
CD4
+ 
cells that act to suppress the 
immune system upon immune activation. This immune suppression is either through 
the CTLA-4 dependent pathway or secretion of immunosuppressive cytokines; 
interleukin-10 and TGF-β, (Wing et al, 2008; Sakaguchi et al, 2009). Compared to 
effector CD4+ T-cells, regulatory T-cells represent a small population of CD4+ T-
cells and express a diverse repertoire of αβTCR (Pacholczyk and Kern 2008). More 
work is needed to explore how these T-cell subsets impact on hypersensitivity 
reactions. 
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- 1.4.4 Challenges in the evaluation of drug-induced hypersensitivity 
reactions 
There are factors that contribute to the difficulty of diagnosing drug-induced 
hypersensitivity reactions. Most importantly, the overlap with symptoms of other 
clinical diseases such as malignancy and infection, the appearance of variable clinical 
pictures of drug hypersensitivity, and the delayed temporal relationship between 
administration of the drug and the appearance of such symptoms (Elzagallaai et al, 
2009). Furthermore, systemic rechallenge is not acceptable because of the possibility 
of severe adverse reactions to the individual. Diagnosis of drug-induced 
hypersensitivity reactions is based mainly on the expertise of the clinical team, 
physical examination and history of the patient, and the results of laboratory tests for 
liver and kidney function and blood cell count (Elzagallaai et al, 2011). 
 
- 1.4.5 In vitro diagnosis of drug-induced hypersensitivity reactions  
In vitro testing methods are mainly based on either measuring the degree of activation 
of the immune system through measuring immunoglobulins and cell proliferation or 
measuring the cell susceptibility to toxic metabolites (Elzagallaai et al, 2011). The 
selection of any in vitro technique depends mainly on the underlying pathophysiology 
related to that clinical picture as well as the type of such reaction. Also, there are 
some tests that are highly recommended to use for immediate IgE-mediated reactions 
and other tests that are better for delayed hypersensitivity reactions. 
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- 1.4.5.1 In-vitro diagnostic tests for immediate drug-induced 
hypersensitivity reactions  
In vitro diagnostic testing for immediate drug-induced hypersensitivity reactions are 
mainly based on the determination of specific IgE antibodies that are key mediators of 
type I hypersensitivity reactions. Common techniques for investigating type I 
reactions include enzyme-linked immunosorbent assay (ELISA), cellular fluorescent 
assay–IgE, and radioallergosorbent assay, because they are known to offer low 
negative predictive value and high positive predictive value (Edwards et al, 1982). 
Although positive results indicate antigen-specific immune mediation of the reaction, 
negative results do not exclude the relationship (Elzagallaai et al, 2011). Skin testing 
or drug rechallenge is required to confirm the safety of the culprit drug. 
i. CAP system FEIA       
The use of CAP system FEIA; a commercially available cellular in vitro test, in the 
diagnosis of β-lactam antibiotic-specific IgE antibodies was found to have sensitivity 
ranging from 0 to 25% and specificity from 83.3 to 100% (Elzagallaai et al, 2011). 
This variation was thought to be dependent on the various clinical picture of 
immediate hypersensitivity (Fontaine, 2007).
 
Currently, determination of drug-
specific IgE antibodies is now widely used technique in the diagnosis of immediate 
hypersensitivity reactions to β-lactam antibiotics, non-steroidal anti-inflammatory 
drugs, and muscle relaxants. 
ii. Basophil activation test             
Basophil activation test is also a cellular in vitro test used for immediate reactions. 
Basophils respond to drug stimulation through release of histamine and leukotrienes 
and expression of specific surface markers such as CD63, CD45, CD11b, CD11c, 
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CD203c, and CD62L (Elzagallaai et al, 2011). Therefore, the release of mediators 
such as histamine can be measured in the media as a sign of basophil stimulation. 
However, these measurements are limited by low sensitivity (Mayorga et al, 2010). 
Sensitivity was increased by the use of flow cytometry as well as fluorescent 
antibodies for cell surface markers. The flow cytometry approach has been clinically 
validated for immediate hypersensitivity reactions that are induced by β-lactam 
antibiotics (Torres et al, 2004), non-steroidal anti-inflammatory drugs (Sanz et al, 
2005; De Weck, 2009), and muscle relaxants (Abuaf et al, 1999). The limitations of 
basophil activation test include its usefulness for limited number of drugs and the 
relative low sensitivity (Table 1.4). 
iii. Lymphocyte transformation test     
The lymphocyte transformation test is a characteristic cellular test that relies on 
measuring drug-specific proliferation of T-cells from peripheral blood of 
hypersensitive patient samples. This test is used primarily for assessment of delayed T 
cell–mediated reactions (see Table 1.4); however, positive results also occur with 
IgE-mediated reactions (Bircher, 1995).  
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Table 1.4 Comparison between in-vitro testing methods used for drug-induced hypersensitivity reactions (DHRs) 
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- 1.4.5.2 In-vitro diagnostic tests for delayed drug-induced hypersensitivity 
reactions        
i. Lymphocyte transformation test     
A characteristic sign of drug-induced hypersensitvity in an affected patient is the 
presence of drug-specific T-cell clones in the peripheral blood. These T-cell clones 
can be isolated and cloned  in vitro, because they respond when incubated with the 
culprit drug by showing T-cell proliferation and expression of specific surface 
markers (Elzagallaai et al, 2011). T-cell proliferation and surface markers can be 
detected using different methods. Interstingly, both cell proliferation and surface 
markers can implicate the magnitude of the immune response to the culprit drug. 
Lymphocyte transformation test involves isolation of peripheral blood monnuclear 
cells (PBMCs) using differential centrifugation which limits the use to advanced 
research laboratories and makes the use in the clinical practice quite difficult (Naisbitt 
et al, 2003). The sensitivity of lymphocyte test has been ranged from 56 to 78%, and 
the specificity 85% to 93% (Elzagallaai et al, 2009). The factors that can affect the 
predictive ability of this test include type of drug or drug metabolite involved, clinical 
picture of hypersensitivity, test procedure and read-out systems used, and timing of 
the running the test in relation to the initial reaction (Elzagallaai et al, 2011).  
 
ii. Lymphocyte/platelet toxicity assay  
Lymphocyte toxicity assay is performed by isolating peripheral blood cells from 
patients' samples and incubating such cells with the parent drug or the suspected drug 
metabolite in a presence of metabolic activation system such as phenobarbital-induced 
rat liver microsomes (Elzagallaai et al, 2009). After incubating with different 
concentrations of drug or drug metabolite for 2 hour at 37°C, the cells are allowed to 
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recover for 16 hours, and their viability is then measured using trypan blue or 
diphenyltetrazolium bromide. The degree of the cell death from patients samples are 
then compared with the percentages of cell death from healthy individuals who do not 
experience immune reactions with the given drug. Thus, the increase in the percentage 
of cell death of incubated patient cells versus controls is considered a sign of patient 
susceptibility to immune reactions in the future (Neuman et al, 2000). The predictive 
ability of lymphocyte toxicity assay remains difficult to say, due to lack of gold 
standard test for comparison (Elzagallaai et al, 2011). In a recent study, 147 
hypersensitive patients were treated with different drugs such as β-lactam antibiotics, 
antiepileptics, and sulfonamides to evaluate lymphocyte toxicity assay (Elzagallaai et 
al, 2010). Unfortunately, the predictive value changes between these drugs. It is 
thought that the rat liver microsomes behave differently to generate metabolites of a 
drug to different extents compared to human liver microsomes. Also, the 
pharmacokinetic and pharmacodynamic properties of a human system are not 
accounted for this in vitro system.  
 
Platelet toxicity assay is performed by isolating peripheral blood platelets that are 
small size and low density thrombocytes and by using differential centrifugation 
(McNicol, 1996). Thrombocytes have an important role in inflammation, allergy, 
hypersensitivity reactions and blood homeostasis (Tamagawa-Mineoka, 2009; 
Pitchford, 2007; Capron et al, 1987). Interestingly, thrombocytes do not proliferate 
which is an advantage in studying the percentage of cell death. Platelets from 
hypersensitive patients respond to the drug in pattern similar to peripheral blood cells, 
however, the percentage of cell death is higher and easier to detection (Elzagallaai et 
al, 2011).
 
In a comparative study, the lymphocyte toxicity assay and platelet toxicity 
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assay were used for 13 hypersensitive patients (to sulfonamide drugs) to validate the 
latter test (Elzagallaai et al, 2011). There was agreement in 11 patients (85%) who 
showed positive result in both tests. The disagreement was only in 2 cases; the results 
of platelet toxicity assay were positive while lymphocyte toxicity assay results were 
negative. This suggests greater sensitivity the platelet test has in determining patient 
susceptibility to hypersensitivity reactions. 
 
iii. Enzyme-linked immunospot (ELISpot) assay  
The ELISpot assay is a highly sensitive technique used to detect drug-specific 
cytokine-secreting T-cells (Monshi et al, 2013). Activated T-cells of Th1 can secrete 
variety of pro-inflammatory cytokines such as interferon gamma, interleukin-2, 6, 12, 
13 and TNF-α whereas Th2 cytokines are interleukin-4, 5, 10 and TGF-β; in addition 
to other effector molecules (granzyme, perforin and Fas ligand) (Lehmann and Zhang, 
2012). Interferon gamma is an important cytokine implicated in delayed-type drug 
hypersensitivity reactions, thus, the interferon gamma released from T-cells is 
quantifiable as a diagnostic measure of drug-induced hypersensitivity reactions 
(Pichler, 2003; Naisbitt et al, 2005). Elevated levels of interferon gamma serve as a 
biomarker for cytotoxic T-cells. ELISpot sensitivity of 90% has been reported using 
interferon gamma as a readout for the detection of penicillin-specific T-cells in 
patients with maculopapular exanthema (Rozieres et al, 2009). 
 
iv. Flow cytometry 
Flow cytometry is an important technique used to characterize cell surface expression 
and identify cell phenotype. Cell surface markers of activated T-cells can be used to 
detect antigen-specific T-cell populations involved in immune reactions. The up-
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regulation of CD69 on CD4
+
 T-cells upon antigenic stimulation has been used to 
detect phenytoin-specific T-cells (Lochmatter et al, 2008). Importantly, up-regulation 
of CD25, CD40L, CD71 and HLA-DR cell surface markers was also found on drug-
specific T-cells and this does not occur in non-sensitized individuals (Beeler and 
Pichler, 2006). Flow cytometry can be used to evaluate T-cell proliferative responses 
after antigenic stimulation. Drug-specific T-cells are stained with the fluorescent dye 
called carbooxyfluorescin diacetate succinimidyl ester (CFSE) that interacts with the 
amino group of intracellular proteins. The intensity of fluorescence is reduced by half 
when each cell divides as a result of drug stimulation. The dividing T-cell population 
of drug-specific T-cells can be evaluated. 
 
v. T-cell cloning 
In some individuals, it is difficult to detect drug-specific T-cells using the lymphocyte 
transformation test and ELISpot. T-cell cloning provides an important alternative 
method to diagnose delayed-type drug hypersensitivity reactions. T-cell cloning can 
be performed according to the well-established method of ‘limiting dilution’ 
(Staszewski, 1984). T-cell clones can be characterised by looking at cell surface 
markers, T-cell proliferation and cytokine secretion after drug stimulation, thus, 
evaluating the mechanisms of drug-induced hypersensitivity. 
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1.5 Drugs associated with hypersensitivity reactions 
Recently, an increased understanding to the mechanism of action of drug-induced 
hypersensitivity reactions has been reported to explain pathomechanism. A selection 
of paradigm compounds illustrating different mechanisms of T-cell activation; 
penicillin the hapten concept, sulfamethoxazole the prohapten concept, abacavir the 
altered peptide repertoire, will be discussed. In addition, biological compounds which 
have been introduced to the market recently will be covered. 
- 1.5.1 Penicillins     
The penicillins are either natural or synthetic antibacterial compounds that primarily 
derived from fungi organisms. The penicillin family is one of the most valuable 
groups of antibiotics in health care, since they are bacteriocidal and highly efficacious 
against wide range of organisms. The development of synthetic penicillins has 
enhanced the efficacy of these medications as well as broadened the spectrum of 
activity. Penicillins remain after decades of use, the first line therapy for many mild, 
localized soft tissue infections and of special importance during pregnancy (Miller, 
2002). A history of penicillin allergy does not necessarily prohibit the use of 
penicillin. 
- 1.5.1.1 Structural components       
All penicillins share three fundamental chemical components; a thiazolidine ring, β-
lactam ring, and a side chain (Figure 1.6; Fellner, 1986). Other antibiotics that share a 
similar characteristic β-lactam structure with penicillin include cephalosporins, 
monobactams, and carbapenamines. These antibiotic classes including penicillins are 
often described as β-lactams. 
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Figure 1.6 Simple penicillin molecule. The generic name is potassium benzyl-penicillin G 
(374 molecular weight).
 
 
- 1.5.1.2 Classes of penicillin        
Currently, the penicillin antibiotics have been divided into ﬁve basic categories; 
natural penicillins, penicillinase-resistant penicillins, amino-penicillins, extended 
spectrum penicillins, and amino-penicillin/β-lactamase inhibitor combinations, based 
on chemical structure and antibacterial spectrum (Table 1.5; Miller, 2002). 
Class of drug Name of drug Antibiotic spectrum 
 
Natural penicillin 
 
Penicillin G 
Penicillin V 
 
Gram –positive cocci and streptococci 
Gram-negative staphylococci 
Clostridium species 
Actinomyces 
 
 
Penicillinase-resistant 
penicillins 
 
Methicillin 
Cloxacillin/Dicloxacillin 
Nafcillin 
Oxacillin 
 
 
Methicillin-sensitive  
staphylococcus and streptococcus  
 
Aminopenicillins 
 
Ampicillin 
Bacampicillin 
Amoxicillin 
 
Similar to natural penicillin plus 
 listeria, enterococcus, proteus, borrelia 
 and escherichia coli 
 
 
Aminopenicillins with β-
lactamase inhibitor 
 
Ampicillin + sulbactam 
Amoxicillin + clavulanic acid 
 
Similar to aminopenicillins plus 
 methicillin-sensitive staphylococcus, H. 
influenza and moraxella 
 
 
Broad spectrum penicillin 
 
Carbenicillin 
Mezlocillin 
Ticaracillin 
Piperacillin 
Piperacillin + tazobactam 
 
 
Klebsiella, pseudomonas 
staphylococci aureus and pneumonia 
 
 
Table 1.5 Classes of penicillin
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- 1.5.1.3 Mode of action               
All penicillin antibiotics are bacteriocidal to actively growing and dividing microbes. 
They inhibit cell wall synthesis through binding to enzymes that produce protein 
cross-links to form the bacterial cell wall. These enzymes located just beneath cell 
walls are also called penicillin-binding proteins. The resulting weakness in structural 
cell walls is enhanced by the activation of autolytic enzymes that cause lysis of the 
susceptible bacteria (Miller, 2002). 
 
- 1.5.1.4 Formation of drug antigens      
Penicillin is a simple chemical molecule which only becomes antigenic if it rearranges 
chemically; in vivo or in vitro, to form highly reactive metabolite called penicillenic 
acid (Fellner, 1986). The penicillin molecule has a low molecular weight of 374 and is 
not antigenic by itself. Penicillenic acid couples with soluble proteins in the blood that 
ultimately produce penicilloyl-protein conjugates and other penicillin-derived protein 
conjugates formed (Fellner, 1986). These conjugates are the antigens responsible for 
the different clinical form of hypersensitivity reactions observed following treatment 
with penicillin. Cephalosporins and other antibiotics that share similar β-lactam 
structure of penicillin can produce reactions clinically identical to the penicillin 
reactions. Most of these antibiotics share the presence of a β-lactam ring but the side 
chains are different. Ampicillin differs from penicillin only in the presence of a single 
added amino group, yet acts differently against microbial organisms and in the overall 
incidence of rashes; estimated at 5-10% for ampicillin compared to 1-3% for 
penicillin (Fellner, 1980; Shapiro et al, 1969).  
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The penicillin structure has been studied in great detail to permit identification of the 
major chemical hapten responsible for clinical hypersensitivity reactions. Penicillin 
forms a penicilloyl haptenic group that binds to protein (Figure 1.7; Fellner, 1986). 
Albumin and gamma immunoglobulins are two proteins which couple to penicillenic 
acid; the reactive penicillin metabolite that binds covalently to proteins. The 
Penicilloyl hapten coupled to protein is referred to as major antigenic determinant of 
penicillin hypersensitivity, because 95% of the drug that undergoes rearrangement 
produces penicilloyl structure. The remaining 5% of penicillin that becomes antigenic 
is called the minor determinants since they represent a minor percentage of the 
haptenic species formed. Penicillins are haptens that need to bind to proteins 
covalently to elicit an immune response. They form covalent adducts with proteins 
through the nucleophilic opening of the β-lactam ring and hapten addition to lysine 
residues (Faulkner et al, 2014). Although benzylpenicillin is the most studied, 
antigenic determinants have been defined for all β-lactam antibiotics (Ariza et al, 
2015). The formation of β-lactam protein adducts is likely selective since amoxicillin 
was found to modify human serum albumin, transferrin, and immunoglobulin heavy 
and light chains (Ariza et al, 2015). The formation of β-lactam protein adducts in 
humans and animals has identified albumin the major target for β-lactam (Faulkner et 
al, 2014). 
 
Figure 1.7 Penicilloyl haptenic group as major antigenic determinant involved in penicillin 
hypersensitivity. 
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- 1.5.1.5 Immunological Reactions      
Penicillins are generally considered among the safest antibiotics prescribed in the 
clinic. There are approximately 28 types of adverse reactions reported following 
administration of penicillin or structurally related compounds (Table 1.6; Fellner, 
1986). The incidence of adverse reactions to penicillin ranges from 0.7-10% and may 
manifest in the immune, nervous, renal, gastrointestinal, and hematologic systems 
(Wright, 1999). Adverse reactions are further subdivided into side effects and allergic 
and hypersensitivity reactions. 
Generalized Skin Other systems 
 
Anaphylaxis 
Serum sickness 
Seizures 
Fever 
Death 
 
 
Maculopapular rashes 
Erythema 
Contact dermatitis 
Toxic epidermal necrolysis 
Edema 
Urticaria 
Nodules 
 
 
Local neurotoxicity 
Nephritis 
Pneumonitis 
Anemia 
Leukopenia 
Thrombocytopenia 
Angioedema 
 
 
Table 1.6 Adverse reactions caused by penicillin 
 
Hypersensitivity reactions are the most common adverse reactions associated with 
penicillin exposure, and the most misunderstood. Hypersensitivity reactions to 
penicillin have been classified according to the type of reaction, time of onset, 
immune mechanism, and clinical syndrome (Weiss and Adkinson, 1988; Levine, 
1966). Type I reactions lead to systemic anaphylactic manifestations such as urticaria, 
erythema, pruritis, angioedema, laryngeal edema, and bronchospasm. They are 
mediated by speciﬁc IgE antibodies and usually occur within one hour of drug 
exposure, although they may appear as late as 72 hours later (Miller, 2002). However, 
life-threatening reactions might occur later than one hour of drug exposure, although 
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very rarely. Late reactions are those occurring 72 hours or more after drug 
administration. These reactions have been classiﬁed as types II, III, IV, and idiopathic 
based on the underlying immune mechanism involved for each type. Notably, none of 
these are IgE mediated. The most common hypersensitivity response among these 
types are maculopapular rashes (Figure 1.8); estimated to occur in 1-4% of patients 
taking penicillin and 5.2-9.5% in those taking ampicillin (Salkind et al, 2001). These 
rashes are characterized by symmetrical, conﬂuent maculopapular eruptions of the 
extremities but avoiding soles and palms. The exact underlying immunological cause 
of these rashes remains unknown. However, incidence of ampicillin-induced rash is 
higher among patients with viral infections such as Epstein-Barr virus and 
cytomegalovirus (Sogn et al, 1992). The higher incidence of ampicillin-induced 
rashes may also be attributable to impurities of drug formulation rather than to 
ampicillin hypersensitivity. Importantly, penicillin forms stable covalent bonds with 
larger proteins or peptides. The resulting modified protein or modified peptide is 
thought to be directly involved in the immunogenicity of penicillin. Penicillin 
derivatives found to bind covalently to lysine residues of serum albumin (Yvon et al, 
1990) may lead to the generation of drug-specific humoral or cellular immune 
responses. 
 
Figure 1.8 Maculopapular rash from exposure to Ampicillin (Fellner, 1986).
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Brander et al (1995) found that penicillin G-responsive T-cell clones were HLA class 
I or class II restricted and antigen processing was not required as fixed antigen 
presenting cell could still present penicillin G. This suggests that T-cell activation 
occurs via direct antigen binding to MHC molecule on the cell surface or to the 
embedded peptide. In contrast, they also found penicillin G modified protein-
responsive T-cell clones that required antigen processing to stimulate clones as fixed 
antigen presenting cell were unable to present penicillin G-modified protein. This 
suggests that antigen binding to soluble proteins (e.g. albumin) undergoes processing 
and presentation of an immunogenic form. Similarly, an independent group found 
synthesized designer peptides containing a DRB1*0401-binding motifs and 
covalently modified them with penicillin G via a lysine ε-amino group. These 
modified peptides were found to be recognized by T-cells and induced proliferation 
and cytokine release (Padovan et al, 1997). β-lactam antibiotics (e.g., piperacillin, 
meropenem, and aztreonam) form covalent binding with human serum albumin at 
Lys190 and at least 6 additional lysine residues in a time and concentration dependent 
manner (Jenkins et al, 2013). T-cell proliferative responses and cytokine release were 
detected from peripheral blood cells of allergic patients, but not tolerant controls. 
These important studies demonstrated how haptenic structures can be formed and 
recognized by the immune system and provided a chemical basis for the drug-specific 
T-cell response. Moreover, different modes of antigen presentation may explain the 
heterogeneity of the clinical pictures seen in penicillin hypersensitivity. 
- 1.5.2 Sulfamethoxazole 
Sulfamethoxazole is a drug used in combination with trimethoprim (co-trimoxazole) 
in a ratio of 5:1 to treat Pneumocystis carinii in patients with HIV and respiratory 
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infections in cystic fibrosis patients (Elsheikh et al, 2011). The mechanism of action 
for sulfamethoxazole involves a competitive inhibition of dihydrofolate reductase that 
catalyses the formation of folic acid; an essential element for bacterial DNA synthesis 
(Hong et al, 1995; Kalkut, 1998). High doses of co-trimoxazole are associated with a 
high incidence of cutaneous reactions in patients with HIV and those suffering from 
cystic fibrosis (Elsheikh et al, 2011). Estimated incidence of adverse drug reactions in 
these patients following sulfamethoxazole administration is approximately 30% 
compared to 1-3% in the normal population. Hyper-reactivity of the immune system 
and low levels of glutathione in these patients are thought to contribute to increased 
prevalence of hypersensitivity reactions to sulfamethoxazole. Although, 
sulfamethoxazole is a chemically inert compound and unable to interact covalently 
with soluble proteins, hepatic metabolism of cytochrome P450 generates a 
hydroxylamine metabolite. This metabolite is not protein reactive and excreted 
unchanged in urine. Nevertheless, auto oxidation of sulfamethoxazole hydroxylamine 
generates nitroso-sulfamethoxazole metabolites which modify cysteine residues on 
soluble proteins to form antigenic epitopes for drug specific T-cells (Park et al, 1987; 
Naisbitt et al, 1996). T-cells are activated with sulfamethoxazole and 
sulfamethoxazole oxidative metabolites. Fourty four percent of T-cell clones isolated 
from hypersensitive patients were activated specifically by sulfamethoxazole 
metabolites, while 14% were activated with the parent drug. The remaining clones 
were cross-reactive in that they are activated by parent drug and metabolites, likely 
via different mechanisms (Castrejon et al, 2010).  Nitroso sulfamethoxazole is highly 
immunogenic; CD4+ and CD8+ responses are readily detectable in metabolite 
exposed experimental animals (Naisbitt et al, 2001; Farrell et al, 2003), while naïve 
human T-cells can be activated ex vivo when the drug antigen was presented in the 
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context of professional antigen presenting cells (Faulkner et al, 2012). Finally, 
different nitroso sulphonamide metabolites have been synthesized and studied in 
terms of antigenicity and immunogenicity. The different metabolites form distinct 
antigenic determinants on model proteins and display some degree of T-cell cross-
reactivity (Castrejon et al, 2010). This indicates that formation of haptenic structures 
in patients could be responsible for multiple hypersensitivity reactions in sulphur-
allergic patients. 
- 1.5.3 Abacavir 
Abacavir is a nucleoside reverse transcriptase inhibitor that is commonly used in 
combination therapy to treat human immunodeficiency virus (HIV). Abacavir was 
primarily developed as an analogue of carbovir in order to reduce the toxicity and 
enhance the solubility (Daluge et al, 1997). Substituting the 3’ alcohol group with a 
cyclopropylamine provided comparable antiviral potency and a better 
pharmacokinetic profile. For instance, oral bioavailability was increased in rats 
significantly (Daluge et al, 1997). Abacavir is a guanine analogue that competitively 
inhibits viral reverse transcriptase and chain termination of the growing viral RNA. 
Additionally, abacavir is a prodrug that undergoes intracellular phosphorylation 
catalysed by adenosine phosphotransferase (Faletto et al, 1997). The stereospecificity 
of the latter enzyme is thought to be responsible for the lack of pharmacological 
action of the alternative enantiomer of abacavir. Abacavir phosphorylation provides 
carbovir triphosphate; a molecule that inhibits viral reverse transcriptase (Faletto et al, 
1997). Abacavir hypersensitivity is defined as a delayed-type hypersensitivity 
reaction, which develops within the first 3 weeks after starting treatment. Reactions of 
fever, malaise and gastrointestinal symptoms are observed in approximately 8% of 
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exposed patients and a late mild-moderate rash in approximately 70% of patients 
(Cutrell et al, 2004). The incidence of these hypersensitivity reactions following 
abacavir exposure will be discussed in detail throughout this thesis. 
- 1.5.4 Biological therapies   
The use of biological therapies; including interferon, interleukin, and monoclonal 
antibodies, is becoming increasingly common in clinical practice to treat a wide range 
of diseases. These range from infectious diseases; such as treating respiratory virus, to 
coronary diseases; such as inhibition of platelet aggregation during coronary 
angioplasty with monoclonal antibody against glycoprotein IIB/IIIA. Table 1.7 
represents a partial list of some biological therapies with their respective target 
molecules and the disease condition they are used for (Kong et al, 2006). 
 
Table 1.7 Biological drugs 
 
RA=Rheumatoid Arthritis, JRA=Juvenile Rheumatoid Arthritis, PsA=Psoriatic Arthritis, AS=Ankylosing 
Spondylitis, CLL=Chronic Lymphocytic Leukemia, NH=Non-Hodgkin's, CD=Crohn's Disease, UC 
=Ulcerative Colitis, EGFR=Epidermal Growth Factor Receptor, ERBB2=receptor tyrosine kinase HER2, 
VEGFR =Vascular Endothelial Growth Factor Receptor (Adopted from Kong et al, 2006). 
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- 1.5.4.1 Structural components of monoclonal antibodies   
There has been progressive development from the first generated murine monoclonal 
antibodies, to chimeric monoclonal antibodies (with murine variable (V) regions 
grafted onto human constant (C) regions), to humanized monoclonal antibodies 
(which consist of a human Ig scaffold with only the complementarity determining 
regions (CDRs) being of murine origin), to the recently generated fully human 
monoclonal antibodies (Hansel et al, 2010). The CDRs within the Fab region of a 
monoclonal antibody bind to specific targets and cause either signaling or antagonism. 
The Fc region of a monoclonal antibody consists of the hinge and constant heavy 
chain domains (CH2 and CH3) and has important functions such as binding to Fc 
receptors and complement fixation (Figure 1.9). 
 
Figure 1.9 Structure of an Immunoglobulin-G Monoclonal Antibody (Hansel et al, 2010). 
 
- 1.5.4.2 Classes of monoclonal antibodies            
Engineered monoclonal antibodies intended for human use are all of the IgG isotype 
and categorized into the following classes. First, murine monoclonal antibodies that 
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are entirely made of murine amino acids. Second, chimeric monoclonal antibodies 
that are made of constant regions of human amino acids and variable regions from 
murine amino acids. Third, humanized monoclonal antibodies that are made of 
complementarity determining regions derived from murine source and the remaining 
constant and variable regions derived from human source. Fourth, primatized 
monoclonal antibodies that are made of variable regions derived from cynomolgus 
macaques and constant regions derived from human source. Lastly, human 
monoclonal antibodies that are entirely made of human source of amino acid 
sequences. The latter class can be derived from a human source using several 
molecular biology techniques; including immortalized human B-lymphocytes, human 
hybridomas, transgenic mice, and phage display. The B-lymphocytes technique would 
be ideal but these cell lines are often unstable and generate only little amount of 
monoclonal antibodies (Kong et al, 2006). 
  
- 1.5.4.3 Mode of action of monoclonal antibodies            
Monoclonal antibodies operate through various mechanisms (Hansel et al, 2010). The 
mechanism of antagonism occurs when the Fab portion of an antibody molecule 
bound to either a receptor or ligand and delivers an antagonistic effect which prevents 
T-cell stimulation. While, the mechanism of signaling occurs when the Fab portion of 
an antibody molecule bound to the receptor and delivers an agonist signal. These 
functions can be independent of the Fc part, although interactions of the Fc with other 
molecules can enhance this mechanism. Antagonism and signaling pathways are 
highly controlled by specific CDRs within the Fab part (Figure 1.10).  Examples of 
antagonist molecules that can specifically bind to a ligand include infliximab and 
omalizumab and those that bind to a receptor include natalizumab and daclizumab. 
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TGN1412 was found a CD28 super-agonist. Antibody molecules can also operate 
through Fc region (Figure 1.10) via antibody dependent cell-mediated cytotoxicity 
(ADCC) and complement-dependent cytotoxicity (CDC). Certain drugs can lyse T or 
B cells through complement activation, while others can bind to Fcϒ receptors and 
mediate cell lysis. Recruitment of T-cells is highly dependent on the isotype of the 
antibody and its ability to recruit effector T cells or complement. 
 
 
 
Figure 1.10 Mechanism of action of an IgG antibody (Hansel et al, 2010). 
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- 1.5.4.4 Immunological reactions       
Biological therapies are generally well tolerated in humans, although they contain 
ingredients that can be recognized as a foreign antigen and sensitize the immune 
system (Hansel et al, 2010). Immunological reactions can develop after exposure to 
biologics including immunogenicity, cytokine release syndrome (CRS), acute 
anaphylactic and anaphylactoid reactions, and serum sickness. The clinical 
manifestations range from flu-like symptoms, pyrexia, and local skin reactions at the 
injection site, to acute anaphylaxis and systemic inflammation which can be fatal. A 
major concern with murine-derived antibody therapy is the immunogenicity of the 
foreign protein, resulting in adverse reactions (as the case with natalizumab to treat 
multiple sclerosis) or loss of efficacy (e.g. interferon-β to treat multiple sclerosis) 
(Hansel et al, 2010). The development in chimeric, humanized and full-human 
antibodies, allows human anti-human antibodies to develop against each type. 
Notably, immunogenicity of a biologic is not simply a matter of the percentage 
homology with endogenous human antibody (Clark, 2000), as the modification of 
amino acids at certain locus can also influence immunogenicity (Hansel et al, 2010). 
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1.6 Aims of thesis 
The underlying mechanisms of HLA associated immunological drug reactions are still 
under exploration, however abacavir hypersensitivity represents a prototype model 
that exclusively occurs in individuals carrying the risk allele HLA- B*57:01 (Mallal et 
al, 2008). Recently, Illing et al postulated that the interaction between abacavir and 
endogenous HLA-B*57:01 molecule guides the selection of new self peptides to bind 
HLA making an altered peptide repertoire that ultimately induces polyclonal CD8
+
 T-
cell activation (Illing et al, 2012). The aim of this thesis was to further: 
- Understand the underlying mechanism of T-cell mediated hypersensitivity 
reactions. 
- Evaluate whether the abacavir-specific T-cell response is restricted exclusively 
by HLA-B*57:01. 
- Develop an experimental approach towards overcoming hypersensitivity of 
abacavir: firstly by recognizing the molecular initiating event; secondly, 
conducting formal structure activity analysis of the molecular initiating event; 
and thirdly, designing and synthesizing abacavir analogues which are devoid 
of the unwanted immunological activity but which retain the pharmacological 
properties of this otherwise highly effective antiviral agent. 
- Investigate whether the discovered unique self peptides are capable of 
inducing T-cell response in the context of HLA-B*57:01 upon abacavir 
treatment. 
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Chapter 2: Mechanism of Abacavir Hypersensitivity and 
Evaluation of Abacavir-Specific HLA-B*57:01-
Restricted CD8+ T-Cell Activation 
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2.1 Introduction 
Pharmacogenomic research revealed that several forms of immunological drug 
reaction are strongly associated with specific human leukocyte antigens (HLA) alleles 
(Daly, 2012; Phillips et al, 2011). For a limited number of reactions, for example, 
abacavir hypersensitivity (Chessman et al, 2008), flucloxacillin-induced liver injury 
(Monshi et al 2013), carbamazepine-induced Stevens Johnson syndrome (Wei et al, 
2012), the HLA-allele-restricted drug-specific T-cell response has been described, 
which has gone some way to explain the genetic association. 
 
Abacavir hypersensitivity is unique in that skin test-confirmed reactions are only seen 
in individuals carrying the risk allele HLA-B*57:01 (Mallal et al, 2008); furthermore, 
the drug is thought to interact exclusively with the B*57:01 binding pocket to activate 
CD8
+
 T-cells (Chessman et al, 2008; Illing et al, 2012; Ostrov et al, 2012; Norcross et 
al, 2012). The high level clinical data and experimental findings support widespread 
genetic screening in the clinic for the prevention of abacavir hypersensitivity. In fact, 
HLA-B*57:01 screening of patients with HIV prior to commencement of abacavir-
containing therapy represents a paradigm for the delivery of a personalized medicine. 
 
Abacavir is a guanosine related prodrug which once metabolised to carbovir acts as a 
DNA chain terminator (Chessman et al, 2008). CD8
+
 T-cells from both abacavir 
hypersensitive patients and naïve individuals expressing HLA-B*57:01 allele 
proliferate in vitro and acquire effector functions in response to abacavir (Chessman et 
al, 2008). Abacavir stimulates the secretion of pro-inflammatory cytokines, such as 
interferon gamma and tumor necrosis factor alpha from peripheral blood cells (PBMC) 
of hypersensitive patients ex vivo (Almeida et al, 2008). Also, a marked infiltration of 
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CD8
+
 T-cells is detected in biopsies from inflamed skin of hypersensitive patients, 
suggesting cytotoxic T-cell activity is causing the tissue damage (Phillips et al, 2002). 
 
The underlying mechanisms of HLA associated immunological drug reactions is still 
under exploration, however, abacavir hypersensitivity represent a prototype model that 
exclusively occurs in individuals carrying the risk allele HLA- B*57:01 (Mallal et al, 
2008). Recently, Illing et al postulated that the interaction between abacavir and 
endogenous HLA-B*57:01 molecule guides the selection of new self peptides to bind 
HLA making an altered peptide repertoire that ultimately induces polyclonal CD8
+
 T-
cell activation. Notably, the latter suggest activation of T-cells requires no drug 
metabolism or hapten protein binding. In our study, we utilized abacavir-responsive 
CD8
+
 T-cells cloned from 3 healthy volunteers expressing the risk allele HLA-
B*57:01, in an attempt to further understand the underlying mechanism of T-cell 
mediated hypersensitivity reactions. Specifically, we evaluated whether the abacavir-
specific T-cell response is restricted exclusively by HLA-B*57:01.  
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2.2 Methodology 
- 2.2.1 Materials 
Abacavir was received as a gift from GlaxoSmithKline pharmaceutical company. 
Human AB serum and fetal bovine serum (FBS) were obtained from Innovative 
Research Class A (Michigan-USA) and Invitrogen (Paisley-UK), respectively. 
Recombinant human protein interleukin-2 (IL-2) was supplied by Peprotech (London-
UK). Multisort bead separation kits were purchased from Miltenyi Biotec (Surrey-
UK). Antibodies for staining co-stimulatory molecules (CD3-APC, CD4-FITC and 
CD8-PE) were purchased from BD Biosciences (Oxford-UK). [
3
H] thymidine was 
supplied by Moravek (California-USA). Interferon gamma ELISpot kits including 
coating, detection, streptavidin antibodies and substrate solution were obtained from 
Mabtech (Stockholm-Sweden). Other reagents were purchased from Sigma-Aldrich 
(Dorset-UK) unless otherwise mentioned. 
 
- 2.2.2 HLA-typed healthy volunteer cell bank  
Cells from three HLA-B*57:01 positive individuals were selected from our cell bank 
containing peripheral blood mononuclear cells (70-150x10
6
; stored in vials of 10x10
6 
cells) from 1000 HLA-typed donors. The clinical characteristics of the first 400 study 
subjects and HLA allele frequencies have been reported previously (Alfirevic et al, 
2012). Approval for the study was acquired from the Liverpool Local Research Ethics 
Committee and informed written consent was obtained from volunteers. 
Confidentiality was maintained throughout the study. 
 
Chapter 2    
 
57 
- 2.2.3 Cell culture media 
- 2.2.3.1 T-cell medium contained RPMI 1640 supplemented with 10% human 
AB serum, 25 mM HEPES, 2 mM L-glutamine, 1000 U/ml penicillin, 0.1 mg/ml 
streptomycin, and 25 µg/ml transferrin. 
- 2.2.3.2 Antigen-presenting cell (APC) medium contained RPMI 1640 
supplemented with 10% FBS, 25 mM HEPES, 2 mM L-glutamine, 1000 U/ml 
penicillin, 0.1 mg/ml streptomycin. 
 
- 2.2.4 Isolation of peripheral blood mononuclear cells (PBMCs) 
Venous blood was collected from healthy volunteers to start either serial dilution for 
abacavir T-cell cloning or to re-stimulate existing T-cell clones. PBMCs were isolated 
by layering 25 ml blood on top of 25 ml lymphoprep. Tubes were centrifuged at 2000 
r.p.m for 25 mins (25°C) to separate plasma and immune cells. The buffy coat layer 
containing PBMCs was carefully collected using a Pasteur pipette. PBMCs were 
washed twice in Hanks balanced salt solution (HBSS) to remove any remaining 
lymphoprep. The formed pellet was resuspended in 10 ml HBSS. 10 μl suspension of 
PBMCs was then added to an equal volume of trypan blue (0.2 % w/v) and the cells 
were counted under a Leica microscope (Leica Microsystems-Milton Keynes) using a 
haemacytometer (Sigma-Aldrich). Cell viability was evaluated by trypan blue 
exclusion. 
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- 2.2.5 Generation of autologous EBV-transformed B-cell lines 
Epstein−Barr virus (EBV) transformed B-cell lines were created from PBMCs of each 
donor through incubation with supernatant of the virus-producing cell line B95-8 in 
order to initiate a transformation process. These lines were kept in culture for 
approximately 3 weeks in APC medium. Cyclosporin A was added for the first 10 
days of culture to prevent EBV-induced T-cell growth. The transformed B-cell line 
was used as a source of autologous APC. 
  
- 2.2.6 Abacavir T-cell cloning 
PBMCs (1x10
6
; 0.5 ml) were exposed to abacavir (50 μM; 0.5 ml) and cultured for 
two weeks in T-cell medium. Cultures were supplemented with IL-2 on day 6 and day 
9. After two weeks, CD8
+
 T-cells were separated using a CD8 MultiSort kit. Cells 
were harvested and re-suspended in phosphate buffered saline (PBS) solution 
containing 2mM ethylene diamine tetra-acetic acid (EDTA) and 0.5% bovine serum 
albumin (BSA). Magnetic CD8 microbeads were added to the cells and incubated for 
15 minutes at 4˚C. The cells were then washed twice and added to an MS column held 
in a magnet.  Unlabelled cells pass through the column and were collected as the CD8
+
 
negative T-cell population. The column was then removed from the magnet and CD8
+
 
T-cells were flushed out and collected as the target population of interest. CD8
+
 T-
cells were then cloned by serial dilution using a previously established procedure (Wu 
et al, 2006). Cells were seeded in 96-well plates at densities of 0.3, 1 and 3 cells/well 
and re-stimulated with cocktail media comprising of allogenic irradiated PBMCs (5 x 
10
4
 cells/well), IL-2 (60 U/ml) and PHA (1 µg/ml). Well-growing clones were 
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transferred to new 96-well plates and split as required. 1304 clones were expanded to 
approximately 1x10
6 
cells and tested for abacavir reactivity (Figure 2.1-2.3). 
 
- 2.2.7 Antigen-specificity of T-cell clones  
Four weeks after starting the serial dilution, abacavir-specificity was evaluated by 
adding irradiated autologous APCs (1 x 10
4
/well) and abacavir (50 µM) to T-cell 
clones (5 x 10
4
/well; 200 μl). [3H] thymidine (0.5 µCi) was added after 48 hr and T-
cell proliferation was measured 16 hr later by scintillation counting. Using the same 
experimental protocol, T-cell responses were also quantified via interferon gamma 
ELISpot. The proliferative response of T-cell clones is expressed as counts per minute. 
T-cell clones with a proliferation stimulation index greater than 1.5 were expanded and 
re-stimulated with a cocktail media comprising of allogenic irradiated PBMCs (5 x 10
4
 
cells/well), IL-2 (60 U/ml) and PHA (1 µg/ml) for further analysis. 
 
- 2.2.8 Proliferation assay 
Abacavir-specific T-cell clones (5 × 10
4
 cells, 50 μl) generated from naïve  individuals 
were co-cultured with irradiated autologous APCs (1 × 10
4
 cells, 50 μl) in the presence 
and absence of single or multiple abacavir concentrations (1-250 μM, 100 μl). The 
proliferation assay was set up in duplicate in a 96-well U-bottom plate. Plates were 
incubated with the drug for 48 hr, after which [
3
H] thymidine (0.5 µCi) was added for 
16 hr. T-cell proliferation was evaluated using a scintillation counter and the results 
are expressed as mean of duplicate wells. 
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- 2.2.9 ELISpot (enzyme linked immune spot) assay  
ELISpot plates were first coated with 100 μl/well interferon gamma capture antibody 
(15 μg/ml) and incubated overnight at 4˚C. Tested wells were then washed five times 
with sterile PBS. T-cell culture medium was added to tested wells for 30 minutes at 
room temperature. Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured 
with autologous irradiated APCs (1×10
4
, 50 μl) in the presence and absence of single 
or multiple abacavir concentrations (1-250 μM, 100 μl). The plates were incubated in 
an atmosphere of 37˚C and 95% O2/5% CO2 for 48 hr. T and B lymphocytes were 
discarded and tested wells washed five times with 200 μl PBS. Detection antibody was 
diluted to 1 μg/ml in PBS containing 0.5% FBS and 100 μl added to the wells. The 
plates were incubated for 2 hr at room temperature and washed five times with PBS. 
Streptavidin antibody was diluted to 1 μg/ml in PBS containing 0.5% FBS and 100 μl 
added to wells. The plates were incubated for 1 hr at room temperature and washed 
five times with PBS. BCIP/NBT substrate solution was filtered before 100 μl was 
added to wells. The plates were kept at room temperature in the dark for 15-25 
minutes to allow spots to emerge. Wells were then washed under slow running tap 
water and left over bench to dry. The forming spots were visualised and counted using 
an AID ELISpot reader (Cadama Medical, Stourbridge, UK). 
 
- 2.2.10 Flow cytometry and cell phenotyping 
T-cell clones were stained using fluorescent antibodies and phenotyped for CD 
molecules using a FACS Canto II flow cytometer, BD Biosciences. Data was analyzed 
using Cyflogic software downloaded from (http://www.cyflogic.com/). A minimum of 
50,000 lymphocytes were acquired using forward scatter and side scatter 
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characteristics. T-cell clones were examined for cell surface expression of CD3, CD4 
and CD8 molecules by staining a T-cell suspension (100 μl) with fluorescent 
antibodies (CD3-APC (3 μl), CD4-FITC (3 μl), CD8-PE (3 μl). Tubes were then 
incubated in the dark for 20 minutes at 4°C. Finally, cells were washed and 
resuspended in 200 μl fluorescence activated cell sorting (FACS) buffer before 
analysis. 
 
- 2.2.11 MHC restriction assay 
  
An anti-human MHC class I antibody (HLA-A, -B, -C) was used to determine whether 
abacavir presentation to drug-specific T-cell clones was MHC Class I restricted or not. 
ELISpot plates were coated with human interferon gamma antibody and incubated 
overnight at 4˚C.  Autologous APCs (1×104, 50 μl) were irradiated and incubated with 
anti-MHC class I antibody (5 μg/ml) for 90 minutes in an atmosphere of 37°C and 
95% O2/5% CO2. The APCs were then co-cultured with abacavir specific CD8
+
 T-cell 
clones (5×10
4
 cells, 50 μL) in presence or absence of abacavir (100 μM, 100 μl) for 48 
hr. ELISpot was developed as previously described in the ELISpot assay method. 
 
- 2.2.12 Drug pulsing assay 
APCs were incubated (pulsed) overnight with abacavir (100 μM) in an atmosphere of 
37˚C and 95% O2/5% CO2. The next day they were washed three times in T-cell 
medium, counted (1×10
4, 50 μl) and irradiated before co-culturing with T-cell clones 
(5×10
4
 cells, 50 μl). No further drug was added and the T-cell response was quantified 
by interferon gamma ELISpot. Soluble drug was used as a positive control.  
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- 2.2.13 APC mismatch assay 
 
ELISpot plates were coated with human interferon gamma antibody and incubated 
overnight at 4˚C. Abacavir-specific CD8+ T-cell clones (5×104 cells) were co-cultured 
with irradiated autologous and heterologous APCs (1×10
4
 cells) in presence and 
absence of abacavir (100 μM, 100 μl) for 48 hr. ELISpot was developed as previously 
described in ELISpot assay. Table 2.1 describes the distribution of HLA-B* alleles 
among APCs of 19 healthy volunteers. Volunteer selection was random to investigate 
a large panel of possible HLA-B* alleles. The study aimed to identify any allo- HLA 
molecules that could impact in abacavir-specific T-cell responses. 
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Table 2.1 distribution of HLA-B* alleles among 19 healthy volunteers 
ID HLA-B alleles 
HLA-074 
 
44:03 
 
44:03 
HLA-202* 
 
08:01 
 
01:57 
241*-HLA  
 
01:57 
HLA0320 07:02 44:03 
HLA-176 07:02 35:01 
HLA0283 15:01 44:02 
HLA-386 15:01 27:05 
HLA0400 15:16 44:02 
HLA0282 37:01 51:01 
*179-HLA 07:02 57:01 
KA** 13:02 44:03 
HLA-005** 15:01 51:01 
SL 15:01 18:01 
DHS 18:01 40:01 
HM 35:01 40:02 
HLA-178* 44:02 57:01 
HLA-245** 18:01 27:05 
HLA-097 35:01 44:03 
HLA-364* 40:01 01:57 
 
* Yellow shading highlights the 5 positive B*57:01 donors. 
** Green shading highlights the 3 allo-donors whose APC presented abacavir to 
specific clones. 
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2.3 Results 
- 2.3.1 Generation of abacavir-specific CD8+ T-cell clones 
Our cell archive of 1000 HLA-typed healthy volunteers was used to source samples to 
generate abacavir specific T-cell clones for the screening of drug-specific T-cell 
responses. PBMCs (1x10
6
; 0.5 ml, 48 well tissue culture plate) from three HLA-
B*57:01
+
 donors were firstly incubated with abacavir (50 μM; 0.5 ml) for 14 days to 
enrich the number of drug-responsive T-cells prior to cloning by serial dilution. 
Abacavir-specific responses were then assessed by culturing the clones with abacavir 
and autologous APC, then measuring [
3
H] thymidine incorporation. 110 out of 1304 
clones were found to proliferate in the presence of abacavir with stimulation index 
greater than 1.5. Figures 2.1-2.3 show the proliferative response of all clones from 3 
donors when cultured with abacavir for 48 hr.  
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Figure 2.1 Antigen specificity of T-cell clones (Donor 1, HVN-KL HLA-B*57:01).  
T-cell clones (5×10
4
 cells/50 μl) were co-cultured with irradiated autologous APCs 
(1x10
4
 cells/50 μl) in +/- abacavir (50 μM) using a 96-well U-bottom microplates. 
The plates were then incubated for 48 hr in an atmosphere of 37°C and 95% O2/5% 
CO2. [
3
H] thymidine (0.5 μCi) was added for 16 hr incubation time and T-cell 
proliferation was measured using scintillation counting. Clones with a stimulation 
index greater than 1.5 (indicated as cut-off value) were considered positive and 
expanded for further experiments. 
 
A. 
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B. 
 
 
Figure 2.2 (A. and B.) Antigen specificity of T-cell clones (Donor 2, HVN-364 
HLA-B*57:01).  T-cell clones (5×10
4
 cells/50 μl) were co-cultured with irradiated 
autologous APCs (1x10
4
 cells/50 μl) in +/- abacavir (50 μM) using a 96-well U-
bottom microplates. The plates were then incubated for 48 hr in an atmosphere of 
37°C and 95% O2/5% CO2. [
3
H] thymidine (0.5 μCi) was added for 16 hr incubation 
time and T-cell proliferation was measured using scintillation counting. Clones with a 
stimulation index greater than 1.5 (indicated as cut-off value) were considered 
positive and expanded for further experiments. 
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Patch 1 
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Patch 2 
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Patch 3 
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Figure 2.3 Antigen specificity of T-cell clones (Donor 3, HVN-202 HLA-B*57:01, 
Patch 1-3).  T-cell clones (5×10
4
 cells/50 μl) were co-cultured with irradiated 
autologous APCs (1x10
4
 cells/50 μl) in +/- abacavir (50 μM) using a 96-well U-
bottom microplates. The plates were then incubated for 48 hr in an atmosphere of 
37°C and 95% O2/5% CO2. [
3
H] thymidine (0.5 μCi) was added for 16 hr incubation 
time and T-cell proliferation was measured using scintillation counting. Clones with a 
stimulation index greater than 1.5 (indicated as cut-off value) were considered 
positive and expanded for further experiments. Patch 1-3 was generated at different 
time points. 
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- 2.3.2 Dose dependency of abacavir-specific CD8+ T-cell clones 
The dose response behaviour of abacavir-specific CD8
+
 T-cell clones was determined 
using two functional readouts; T-cell proliferation and cytokine secretion. Abacavir-
specific responses were assessed by culturing the T-cell clones (5×10
4
 cells/50 μl) 
with irradiated autologous APCs (1x10
4
 cells/50 μl) +/- graded abacavir 
concentrations (1-250 µM). T-cell proliferation was evaluated using a scintillation 
counter in which the results are expressed as mean of duplicate wells. Thirty six clones 
were found to proliferate in dose-dependent manner (see Figures 2.4 and 2.5). Nine 
clones were tested using the interferon gamma ELISpot and similar dose dependent 
response to abacavir was observed (see Figure 2.6). 
 
Figure 2.4 Abacavir activates T-cell clones in a drug concentration dependent 
manner. (Donor 1, HVN-KL HLA-B*57:01) T-cell clones (5×10
4
 cells/50 μl) were 
co-cultured with irradiated autologous APCs (1x10
4
 cells/50 μl) +/- graded abacavir 
concentrations using a 96-well U-bottom microplate. The plates were then incubated 
for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. [
3
H] thymidine (0.5 μCi) 
was added for 16 hr and T-cell proliferation was measured using scintillation 
counting. 
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Figure 2.5 Abacavir activates T-cell clones in a drug concentration dependent 
manner. (Donor 3, HVN-202 HLA-B*57:01) T-cell clones (5×10
4
 cells/50 μl) were 
co-cultured with irradiated autologous APCs (1x10
4
 cells/50 μl) +/- graded abacavir 
concentrations using 96-well U-bottom microplates. The plates were then incubated 
for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. [
3
H] thymidine (0.5 μCi) 
was added for 16 hr and T-cell proliferation was measured using scintillation 
counting. 
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Figure 2.6A & B: Abacavir concentration 
dependent cytokine secretion from drug-
specific T-cell clones (Donor 1-3 HLA-
B*57:01). ELISpot plates were coated with a 
human interferon gamma antibody and 
incubated overnight at 4°C. T-cell clones 
(5×10
4
 cells/50 μl) were co-cultured with 
irradiated autologous APCs (1x10
4
 cells/50 
μl) +/- graded abacavir concentrations for 48 
hr in an atmosphere of 37°C and 95% O2/5% 
CO2. ELISpot plates were then developed 
according to manufacturer’s protocol. T-cell 
activity was measured by counting emerging 
spots using an AID ELISpot reader. 
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- 2.3.3 T-cell receptor phenotyping 
Abacavir-responsive T-cell clones were examined for cell surface receptor expression 
(CD3, CD4 and CD8). T-cell suspensions (50 μl) were incubated with CD3-APC, 
CD4-FITC and CD8-PE antibodies and flow cytometry was used to measure the 
fluorescence intensity of such molecules. Acquired data in Figures 2.7 A and B 
showed a CD8
+
 cell phenotype for all of the abacavir-responsive T-cell clones. 
A. 
HVN-364 HLA-B*57:01     HVN-202 HLA-B*57:01 
ID CD8
+
 CD3
+
 CD8
+
 CD4
- 
ID CD8
+
 CD3
+
 CD8
+
 CD4
- 
TCC 
219  
  
TCC 
15 
  
TCC 
249  
  
TCC 
36 
  
TCC 
261  
  
TCC 
149 
  
TCC 
274  
  
TCC 
173 
 
 
  
TCC 
299  
  
TCC 
191 
  
Figure 2.7 A. Cell phenotyping for CD3, CD4, and CD8 protein expression on surface of 
abacavir-specific clones (HVN-364 HLA-B*57:01) and (HVN-202 HLA-B*57:01). T-cell clone 
suspension (50 μl) were incubated with CD3-APC, CD4-FITC and CD8-PE antibodies for 20 
minutes at 4°C. Cells were then washed and flow cytometry was used to acquire data. Signals are 
highlighting exclusive CD8
+
 cell phenotype in all generated abacavir-specific clones. Red population 
shows the live cells of a gated population from a randomized unstained abacavir T-cell clone. 
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- 2.3.4 APC dependent and independent activation of abacavir-specific 
CD8
+
 T-cell clones 
Activation of abacavir specific CD8
+
 T-cell clones was determined in presence and 
absence of APCs using the two functional readouts; T-cell proliferation and cytokine 
secretion. Five clones out of 11 were found to secrete interferon gamma in dose-
dependent manner only in presence of APCs (Figure 2.8; APC dependent activation). 
Figure 2.10 shows data from the other 6 clones. Concentration-dependent secretion of 
interferon gamma was observed in presence and absence of APCs (APC independent 
activation). The T-cell proliferative response with abacavir was evaluated using 
scintillation counting with 4 clones +/- APC. Two clones were found to proliferate 
with APC (see Figure 2.9). Abacavir-specific proliferative responses with the other 2 
clones were observed in the presence and absence of APCs (Figure 2.11). 
 
 
 
Figure 2.7 B. Live cells of a 
gated population (red colour) 
from a randomized unstained 
abacavir T-cell clone used to 
calibrate all above clones 
signals. 
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- 2.3.4.1 APC dependent abacavir-specific activation of T-cell clones 
 
 
 
 
Figure 2.8 Activation of certain T-cell clones with 
abacavir was dependent on the presence of APC. 
(Donor 3, HVN-202 HLA-B*57:01). ELISpot 
plates were coated with a human IFN-ϒ antibody 
and incubated overnight at 4°C. T-cell clones (5×10
4
 
cells/50 μL) were co-cultured with irradiated 
autologous APCs (1x104 cells/50 μL) +/- graded 
abacavir concentrations for 48 hr in an atmosphere 
of 37°C and 95% O2/5% CO2. ELISpot plates were 
then developed according to manufacturer’s protocol 
and T-cell activity measured by counting emerging 
spots using an AID ELISpot reader. 
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Figure 2.9 Activation of certain T-cell clones with abacavir is dependent on the presence 
of APC. A. (Donor 3, HVN-202 HLA-B*57:01) B. (Donor 2, HVN-364 HLA-B*57:01) T-
cell clones (5×10
4
 cells/50 μl) were co-cultured with irradiated autologous APCs (1x104 
cells/50 μl) +/- abacavir (50 μM) using  96-well U-bottom microplates. The plates were then 
incubated for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. [
3
H] thymidine (0.5 μCi) 
was added for 16 hr and T-cell proliferation was measured using scintillation counting. Each 
bar in every graph represents a T-cell proliferation mean of two measurements to one tested 
T-cell clone sample. 
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- 2.3.4.2 APC independent activation of abacavir-specific T-cell clones 
  
 
 
Figure 2.10 Activation of T-cell clone with 
abacavir does not always require 
professional APC (Donor 3, HVN-202 
HLA-B*57:01). ELISpot plates were coated 
with a human IFN-ϒ antibody and incubated 
overnight at 4°C. T-cell clones (5×10
4
 cells/50 
μL) were co-cultured with irradiated 
autologous APCs (1x104 cells/50 μL) +/- 
graded abacavir concentrations for 48 hr in an 
atmosphere of 37°C and 95% O2/5% CO2. 
ELISpot plates were then developed according 
to manufacturer’s protocol and T-cell activity 
was measured by counting emerging spots 
using an AID ELISpot reader. 
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Figure 2.11 Activation of T-cell clones with abacavir does not always require APC 
(Donor 3, HVN-202 HLA-B*57:01) T-cell clones (5×10
4
 cells/50 μl) were co-cultured with 
irradiated autologous APCs (1x10
4
 cells/50 μl) +/- abacavir (50 μM) using 96-well U-bottom 
microplates. The plates were then incubated for 48 hr in an atmosphere of 37°C and 95% 
O2/5% CO2. [
3
H] thymidine (0.5 μCi) was added for 16 hr and T-cell proliferation was 
measured using scintillation counting. Each bar in every graph represents a T-cell 
proliferation mean of two measurements to one tested T-cell clone sample. 
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- 2.3.5 Abacavir-HLA-B*57:01 binding is important for activation of 
abacavir-specific T-cells 
 
o 2.3.5.1 MHC-blocking 
An anti-human MHC class I antibody was used to explore whether abacavir-specific 
activation of clones was MHC-restricted. Autologous APCs (1×10
4
 cells/50 μl) were 
irradiated and incubated with the anti-MHC class I antibody for 90 min. APCs were 
then co-cultured with abacavir-specific CD8
+
 T-cell clones (5×10
4
 cells/50 μl) +/- 
abacavir. T-cell activity was measured using interferon gamma ELISpot. MHC class I 
blockade was found to diminish abacavir induced CD8
+
 T-cell activity. Results from 
3 representative clones are shown in Figure 2.12. 
 
o 2.3.5.2 APC-pulsing 
Six representative abacavir-specific T-cell clones (APC dependent) were used to 
investigate whether abacavir pulsed APCs transfer the drug-specific signal to the T-
cell receptors. Autologous APCs were incubated (pulsed) overnight with abacavir. 
The next day, they were washed three times in T-cell medium, counted (1×10
4
 
cells/50 μl) and irradiated before co-culturing with T-cell clones (5×104 cells/50 μl). 
No further drug was added and the T-cell response was quantified by interferon 
gamma ELISpot. Four clones were activated with soluble abacavir and abacavir 
pulsed APC. In contrast, 2 clones were only activated with soluble abacavir co-
cultured with APC and T-cells for the duration of the assay (Figure 2.13). 
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Figure 2.12 MHC class I restricted activation of abacavir-specific T-cell clones. 3 
representative abacavir-specific CD8
+
 T-cell clones from 2 positive HLA-B*57:01 
volunteers are shown. Autologous APCs (1×10
4
 cells/50 μl) were irradiated and 
incubated with anti-MHC class I antibody for 90 min in an atmosphere of 37°C and 
95% O2/5% CO2. APCs were then co-cultured with abacavir-specific CD8
+
 T-cell 
clones (5×10
4
 cells/50 μl) +/- abacavir (100 μM/100 μl) for 48 hr. The ELISpot plates 
were coated with a human interferon gamma antibody and incubated overnight at 4°C. 
The ELISpot plates were then developed according to manufacturer’s protocol and T-
cell activity was measured by counting emerging spots using an AID ELISpot reader. 
Bars represent spot counts in ELISpot image from singlet well. 
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Figure 2.13 Activation of abacavir-specific T-cell clones with drug-pulsed APC. A. Four representative 
abacavir CD8
+
 T-cell clones from 1 donor (HVN-202 HLA-B*57:01) were used. Autologous APCs were 
incubated (pulsed) overnight with abacavir (100 µM) in an atmosphere of 37°C and 95% O2/5% CO2. The 
next day, they were washed three times in T-cell medium, counted (1×10
4
 cells/50 μl) and irradiated before 
co-culturing with T-cell clones (5×10
4
 cells/50 μl). No further drug was added and the T-cell response was 
quantified by interferon gamma ELISpot. P < 0.05 * states statistical analysis of Chi-square test to results 
from singlet well. B. Similarly, two additional abacavir-specific T-cell clones from the other 2 HLA-
B*57:01 positive volunteers were used. Soluble drug was used as a positive control. 
+  
Autologous 
B*57:01 B-cells 
 
 
φ 
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- 2.3.6 Activation of Abacavir-specific T-cell clones using APC expressing 
different HLA-B* alleles 
Heterologous APCs derived from PBMCs of healthy volunteers were utilised to 
conduct APC mismatch experiments and verify the role of specific HLA alleles in T-
cell activation. Autologous and heterologous (n=18) APCs (1×10
4
 cells/50 μl) were 
irradiated and co-cultured with abacavir-specific (APC dependent) CD8
+
 T-cell 
clones (5×10
4
 cells/50 μl) +/- abacavir (100 μM/100 μl). T-cell responses (n=6) were 
quantified by interferon gamma ELISpot. All heterologous APCs expressing HLA-
B*57:01 (n=4) triggered a significant T-cell response similar to autologous HLA-
B*57:01
+
 APC (Figures 2.14 and 2.15). However, 3 heterologous APCs (KA, 005 
and 245 volunteers) expressing other HLA-B* alleles were also found to interact 
strongly with abacavir and activate T-cells (Figures 2.14-2.16). 
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Figure 2.14 Cytokine secretion from abacavir-specific CD8
+
 T-cell clone 393 as 
determined by ELISpot. (A) ELISpot plates were coated with a human IFN-ϒ 
antibody and incubated overnight at 4°C. Autologous and heterologous (n=18) EBV-
transformed B-cell lines were used as APCs. All APCs (1×10
4
 cells/50 μl) were 
irradiated and co-cultured with abacavir-specific CD8
+
 T-cells (5×10
4
 cells/50 μl) +/- 
abacavir (100 μM/100 μl) for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. 
The ELISpot plate was then developed according to manufacturer’s protocol and T-
cell activity was measured by counting emerging spots using an AID ELISpot reader. 
Bars represent spot counts in ELISpot image. Responses were considered positive if 
spot counts exceeded three fifths of the maximum response. Statistical analysis of 
Mann Whitney test showed a significance of p < 0.0001 ***. (B) Bland Altman chart 
used to further discriminate between negative and positive responses using the 
average T-cell activity of treated and control versus the difference between them. (C) 
ELISpot was used to quantify the emerging spots. SFU=Spots forming units. 
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Figure 2.15 Cytokine secretion from abacavir-specific CD8
+
 T-cell clone 414 as 
determined by ELISpot. (A) ELISpot plate was coated with human IFN-ϒ antibody 
and incubated overnight at 4°C. Autologous and heterologous (n=18) EBV-
transformed B-cell lines were used as APCs. All APCs (1×10
4
 cells/50 μl) were 
irradiated and co-cultured with abacavir-specific CD8
+
 T-cells (5×10
4
 cells/50 μl) +/- 
Abacavir (100 μM/100 μl) for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. 
The ELISpot plate was then developed according to manufacturer’s protocol and T-
cell activity was measured by counting emerging spots using an AID ELISpot reader. 
Bars represent spot counts in ELISpot image. Responses were considered positive if 
spot counts exceeded three fifths of the maximum response. Statistical analysis of 
Mann Whitney test showed a significance of p < 0.0001 ***. (B) Bland Altman chart 
used to further discriminate between negative and positive responses using the 
average T-cell activity of treated and control versus the difference between them. (C) 
ELISpot was used to quantify the emerging spots. SFU=Spots forming units. 
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Figure 2.16 Cytokine secretion from abacavir-specific CD8
+
 T-cell clones 162, 219, 424 
and 446 as determined by ELISpot. (A) ELISpot plate was coated with human IFN-ϒ 
antibody and incubated overnight at 4°C. Autologous and heterologous (n=5) EBV-transformed 
B-cell lines were used as APCs. All APCs (1×10
4
 cells/50 μl) were irradiated and co-cultured 
with abacavir-specific CD8
+
 T-cell clones 162, 219, 424 and 446  (5×10
4
 cells/50 μl) +/- 
abacavir (100 μM/100 μl) for  48 hr in an atmosphere of 37°C and 95% O2/5% CO2. The 
ELISpot plates were then developed according to manufacturer’s protocol and T-cell activity 
was measured by counting emerging spots using an AID ELISpot reader. Bars represent mean 
spot counts in ELISpot images. P < 0.05 * states statistical analysis used here. (B) ELISpot was 
used to quantify the emerging spots. SFU=Spots forming units. 
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2.4 Discussion 
Abacavir has been used as a paradigm to elucidate mechanisms of drug-specific T-cell 
activation for 2 main reasons: (1) reactions are exclusively seen in human patients 
expressing the HLA allele B*57:01 (Mallal et al, 2008; Mallal et al 2002) and (2) it is 
(relatively) simple to detect abacavir-specific CD8+ T-cell responses in vitro using 
lymphocytes from healthy human donors who carry the HLA risk allele (Chessman et 
al, 2008). Through the cloning of T-cells from abacavir-treated PBMC it was possible 
to show that only CD8+ T-cells are activated by the drug and that the response is 
HLA-B*57:01 restricted (Bell et al, 2013 ; Adam et al, 2012). Recent studies from 
independent research groups have shown that abacavir HLA-B*57:01 binding alters 
the repertoire of peptides displays on the surface of APC (Illing et al, 2012; Ostrov et 
al, 2012, Norcross et al 2012). In the presence of abacavir, approximately 20% of the 
peptides displayed by HLA-B*57:01 are altered. From these findings, the “altered 
peptide repertoire” hypothesis evolved. This hypothesis states that abacavir-specific 
T-cells are not actually activated through drug T-cell receptor binding, but rather the 
T-cell response is triggered through the display of these “altered-self” peptides, which 
would not normally be displayed in the context of HLA-B*57:01 in the absence of 
abacavir. It must however be noted that the nature of the peptide(s) that activate T-
cells is yet to be defined (see chapter 4). Importantly, the way in which individual T-
cells are activated with abacavir is yet to be fully understood. Thus, the aim of this 
first experimental chapter was to generate a panel of T-cell clones that could be used 
for mechanistic studies to evaluate mechanisms of drug antigen presentation and also 
biobanked for future experiment to evaluate whether (1) specific HLA B*57:01 
binding peptides activate abacavir-specific T-cells (see chapter 4) and (2) whether it 
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is possible to change the structure of abacavir to prevent HLA-B*57:01 binding whilst 
retaining pharmacological activity (see chapter 3). 
          
One hundred and ten CD8
+
 T-cell clones out of 1304 clones generated  from 3 HLA-
B*57:01 healthy volunteers displayed proliferative responses and/or secreted 
interferon gamma in the presence of abacavir. Fourty five clones were analysed in 
detail. In each case abacavir-specific T-cell responses were found to be drug 
concentration-dependent. Approximately half of the clones were activated with 
abacavir in the absence of antigen presenting cells; presumably through an interaction 
with the low levels of HLA class I molecules expressed on T-cells (results not 
shown). These clones were excluded from the analyses discussed below.  
 
The abacavir-specific clones that required APC for stimulation of proliferation and 
cytokine release were then used in pulsing experiments to determine the pathway of 
drug antigen presentation. Previous studies have shown that it is possible to activate 
abacavir-specific T-cell lines with abacavir pulsed APCs; a 16 hr APC incubation was 
optimal for activation of the clones. This is thought to be the time required for 
abacavir to bind to endogenous HLA-B*57:01, protein processing, the loading of 
MHC binding peptides and their subsequent transport to the cell surface. Importantly, 
detection of a response with abacavir-pulsed APC indicates that the drug does not 
bind directly to surface MHC molecules, as weakly associated drug is removed 
through the repeated washing steps. Approximately half of the clones were activated 
with abacavir pulsed APC and half were not. The APC pulse negative clones are 
likely activated via a PI mechanism involving the direct binding of abacavir to surface 
HLA-B*57:01. In contrast, the pulse positive clones seem to be activated via the 
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altered peptide repertoire mechanism involving abacavir binding to endogenous HLA-
B*57:01. These divergent pathways of drug-specific T-cell activation add to the 
growing body of evidence showing that MHC-restricted T-cell responses occur via a 
variety of pathways. Of note, almost all studies investigating immune mechanisms of 
abacavir hypersensitivity have utilized cells from healthy donors never exposed to the 
drug. As such future analyses exploring the dominant pathways of abacavir-specific 
T-cell activation should focus on abacavir hypersensitive patients with HIV. 
 
Adam et al in 2014 found that HLA-B*57:01-restricted abacavir-specific CD8+ T-cell 
clones are also activated in the presence of APC expressing the structurally-related 
HLA-B*58:01. The two different MHC molecules differ by only one amino acid 
residue at position 97 of the determining F pocket (see Table 2.3), 2 residues of those 
determining B pocket (see Table 2.2), and 5 residues not in direct contact with B or F 
pockets (see Table 1 in appendix). The detection of HLA cross-reactivity/allo-
reactivity with this one HLA molecule prompted us to investigate whether additional 
allo-HLA reactivity might be observed with less closely-related HLA subtypes. In our 
study, we utilized our HLA-typed cell bank (Alfirevic et al, 2012) to generate a broad 
panel of APC expressing different alleles (n=18). Somewhat surprisingly, APC-
dependent, abacavir-specific clones were activated with the drug in the presence of 
APC expressing from at least 3 allo-donors (KA, 005 and 245 donors). As each 
volunteer expressed 2 different HLA-B alleles, there were six possible allo-HLA 
molecules that abacavir could interact with to activate the clones. Analysis of the 
primary amino acid sequence of the different HLA molecules revealed that each 
molecule had a similar structure (see Table 1 in appendix). Position 97 of HLA-
B*57:01, which is a determining F pocket residue (March et al, 2000) was substituted 
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with R, T or N amino acids in all 6 allo-HLA molecules (see Table 2.3). The amino 
acid residue at position 97 is located in MHC peptide binding groove; thus, we 
speculate that is the critical anchor position for (1) the abacavir-MHC-T-cell receptor 
interaction and (2) allogenicity activation. Among all positions determining B and F 
pocket of HLA-B* alleles, only position 97 was substituted in all allo-HLA 
molecules. This raises the possibility that allogenic abacavir-specific T-cell activation 
may relate to the substitution of amino acid V within HLA-B*57:01 binding groove. 
Importantly, this allo-reactivity was detected with all 6 clones generated from 
different HLA-B*57:01 positive blood donors. In on-going experiments, we are 
attempting to generate abacavir-responsive CD8+ T-cell clones from blood donors 
carrying these HLA-B alleles. If successful, the objective will be to conduct HLA-
mismatching experiments similar to those described above. 
  
HLA Residue at position 
* 
 9 24 45 46 63 66 67 99 
-B*57:01 Y A M A E N M Y 
-B*58:01 - - T E - - - - 
-B*13:02 - T - - - I S - 
-B*44:03 - T K E - I S - 
-B*15:01 - - - - - I S - 
-B*51:01 - - T E N I F - 
-B*18:01 H S T E N I S - 
-B*27:05 H T E E - I C - 
* Based on (March et al, 2000) 
 
Table 2.2 amino acid residues determining B pocket
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Table 2.3 amino acid residues determining F pocket 
 
HLA Residue at position 
*
 
 77 80 81 94 95 97 114 116 
-B*57:01 N I A I I V D S 
-B*58:01 - - - - - R - - 
-B*13:02 - T - T W T N L 
-B*44:03 - T - - - R - D 
-B*15:01 S N L T L R - - 
-B*51:01 - - - T W T N Y 
-B*18:01 S N L T L R - - 
-B*27:05 D T L T L N H D 
* Based on (March et al, 2000) 
 
In conclusion, the data presented in this chapter shows that it is possible to generate 
abacavir-responsive CD8+ clones from PBMC of HLA-B*57:01 positive healthy 
human donors. The clones are activated in an HLA-class I restricted fashion through 
the binding of abacavir to both endogenous and cell surface HLA-B*57:01. The data 
adds to the growing body of evidence which indicate that it is possible to activate T-
cells with abacavir in all individuals expressing the risk allele. Thus, the ability to 
induce a T-cell response seems to be not the major determinant of whether a HLA-
B*57:01 positive patient will develop hypersensitivity following abacavir exposure, 
as only half of patients expressing B*57:01 develop abacavir hypersensitivity. An 
additional as yet undefined factor must determine whether T-cell activation will result 
in a hypersensitive or tolerant outcome. The clones were also activated with APC 
from certain allogeneic donors expressing different HLA-B alleles, which suggest that 
abacavir binds to multiple HLA alleles. These data have important implications for 
future research strategies attempting to develop HLA binding screens that evaluate at 
the drug development stage the likelihood that a new chemical entity might cause 
hypersensitivity. Much more detailed analysis is needed to determine whether there is 
an HLA binding threshold that is relevant for the activation of T-cells. 
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Chapter 3: Towards Depersonalised Abacavir Therapy: 
Chemical Modification Eliminates HLA-B*57:01-
Restricted CD8+ T-Cell Activation Whilst Maintaining 
Antiretroviral Activity 
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3.1 Introduction 
Pharmacogenomic studies have revealed that several drug hypersensitivity reactions 
are strongly associated with specific human leucocyte antigen HLA alleles (Daly, 
2012; Philips et al, 2011). For a limited number of reactions [e.g. abacavir 
hypersensitivity, (Hetherington et al, 2002; Mallal et al 2002; Mallal et al 2008) 
flucloxacillin-induced liver injury, (Monshi et al, 2013) carbamazepine-induced 
Stevens Johnson syndrome (Wei et al, 2012)], an HLA-allele-restricted drug-specific 
T-cell response has been described, (Chessman et al, 2008; Monshi et al, 2013; Wei et 
al, 2012; Ko et al, 2011) which has gone some way to explain the genetic association. 
Abacavir’s (1) (Figure 3.1) hypersensitivity is unique in that skin test-confirmed 
reactions are only seen in individuals carrying the risk allele HLA-B*57:01; 
(Hetherington et al, 2002; Mallal et al, 2002; Mallal et al, 2008; Martin et al, 2004; 
Hetherington et al, 2001)
 
 furthermore, the drug interacts selectively with the B*57:01 
peptide binding pocket to activate CD8+ T-cells (Chessman et al, 2008; Illing et al, 
2012; Ostrov et al, 2012; Norcross et al, 2012). These clinical data and experimental 
findings support widespread genetic screening in the clinic to prevent abacavir 
hypersensitivity.  
 
Figure 3.1 Structures of abacavir and carbovir. 
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Binding of abacavir to endogenous HLA-B*57:01 has been shown to change the 
conformation of the peptide binding cleft and alter the repertoire of peptides displayed 
on the cell surface (Illing et al, 2012; Ostrov et al, 2012; Norcross et al, 2012). These 
data suggest that abacavir might indirectly activate pre-existing peptide-specific T-
cells through the display of cross-reacting “altered-self” peptides. Abacavir-
responsive CD8+ T-cells have been cloned from drug-naïve donors carrying HLA-
B*57:01 to elucidate mechanisms of drug antigen presentation (Adam et al, 2012; 
Bell et al, 2013; Adam et al, 2014; see chapter 2). 
   
Consistent with the altered-self peptide concept, activation of certain clones is time-
dependent and requires protein processing within the antigen presenting cell. 
However, other clones are activated through the direct binding of abacavir to surface 
HLA-B*57:01. Thus, studies attempting to unravel the molecular mechanism of 
abacavir hypersensitivity should encompass both pathways.        
 
In the investigations described here, we have developed an experimental approach 
towards overcoming hypersensitivity of abacavir: firstly by firstly recognizing the 
molecular initiating event in the case of abacavir activation of HLA-B*57:01-
restricted CD8+ T-cells; secondly, conducting formal structure activity analysis of the 
molecular initiating event; and thirdly, designing and synthesizing abacavir analogues 
which are devoid of the unwanted immunological activity but which retain the 
pharmacological properties of this otherwise highly effective antiviral agent (Figure 
3.2).  
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Figure 3.2 Screening cascade developed for the discovery of safer analogues of 
abacavir. 
 
 
Given that the 6-amino cyclopropyl group of abacavir plays a key role in the binding 
interaction with HLA-B*57:01, resulting in T-cell activation [carbovir (2) is inactive, 
Figure 3.1], (Chessman et al, 2008) a wide range of 6-substituted analogues were 
designed (Figure 3.3) to probe the steric constraints of the F-pocket within the drug 
HLA complex. We report that replacement of the 6-cyclopropylamino group in 
abacavir with an isopropylamino or isopropyl(methyl)amino group prevents T-cell 
activation by impeding HLA-B*57:01 binding, while maintaining antiviral activity.   
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Figure 3.3 Synthesis of 6-substituted abacavir analogues. 
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3.2 Methodology 
- 3.2.1 Materials 
Abacavir was received as a gift from GlaxoSmithKline pharmaceutical company. 
Human AB serum and fetal bovine serum (FBS) were obtained from Innovative 
Research Class A (Michigan-USA) and Invitrogen (Paisley-UK), respectively. 
Recombinant human protein interleukin-2 (IL-2) was supplied by Peprotech (London-
UK). Multisort bead separation kits were purchased from Miltenyi Biotec (Surrey-
UK). Antibodies for staining co-stimulatory molecules (CD3-APC, CD4-FITC and 
CD8-PE) were purchased from BD Biosciences (Oxford-UK). [
3
H] thymidine was 
supplied by Moravek (California-USA). Interferon gamma ELISpot kits including 
coating, detection and streptavidin antibodies and substrate solution were obtained 
from Mabtech (Stockholm-Sweden). Other reagents were purchased from Sigma-
Aldrich (Dorset-UK) unless otherwise mentioned. 
 
- 3.2.2 Synthesis of abacavir analogues 
Synthesis of probe molecules is depicted in Figure 3.3; key intermediate ((1S,4R)-4-
(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl) methanol 3 was produced via 
an established route that involved reaction of the aminoalcohol 4 with 2,5-diamino-
4,6-dichloropyrimide 5 to provide 6 followed by ring closure with 
triethylorthoformate and catalytic sulfuric acid (Lawrence, 2009). From this 
intermediate, 15 analogues (7-21) were synthesized. A detailed description of the 
synthetic procedures is provided in the appendix. All synthetic chemistry was 
conducted by Miss Emma Yang (Department of Chemistry, University of Liverpool). 
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1
H and 
13
C NMR were run on a Bruker ARX 400 (400 MHz) nuclear magnetic 
resonance spectrometer and all deuterated solvents used are as stated within the 
appendix. Tetramethylsilane was used as the internal reference. Multiplicities are 
recorded as singlet (s); doublet (d); triplet (t); multiplet (m) and broad (br). All J 
couplings are recorded in Hertz. Mass spectra were recorded on a Micromass LCT 
Mass Spectrometer. Accurate mass values are stated within ± 5 ppm. Infrared 
spectrometry was measured using a Jasco FT/IR-4200 spectrometer and samples were 
run neat. Melting points were determined on a Gallenkamp melting point apparatus. 
   
- 3.2.3 Cell culture media 
- 3.2.3.1 T-cell medium contained RPMI 1640 supplemented with 10% human 
AB serum, 25 mM HEPES, 2 mM L-glutamine, 1000 U/ml penicillin, 0.1 mg/ml 
streptomycin, and 25 µg/ml transferrin. 
- 3.2.3.2 Antigen-presenting cell (APC) medium contained RPMI 1640 
supplemented with 10% FBS, 25 mM HEPES, 2 mM L-glutamine, 1000 U/ml 
penicillin, 0.1 mg/ml streptomycin. 
 
- 3.2.4 Donors characteristics, T-cell culture and cloning 
Three HLA-B*57:01 positive individuals were selected from our cell bank containing 
peripheral blood mononuclear cells (PBMC; 70-150 × 10
6
; stored in vials of 10 × 10
6 
cells) from 1000 HLA-typed healthy volunteers. Ethical approval for the study was 
obtained from the local research ethics committee and all volunteers were consented 
prior to blood donation. Before cloning, PBMC (1 × 10
6
; 0.5 ml) were cultured with 
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abacavir (50 μM) in complete medium (RPMI 1640 supplemented with 10% human 
AB serum [Innovative Research, Class A], 25 mM HEPES, 1000 U/ml penicillin, 0.1 
mg/ml streptomycin, 2 mM L-glutamine and 25 μg/ml transferrin). Cultures were 
supplemented with IL-2 (Peprotech, UK) on days 6 and 9 to maintain abacavir-driven 
T-cell expansion.  On day 14, CD8+ cells were positively selected using MultiSort 
kits (Miltenyi Biotec, Surrey, UK) and clones were generated by serial dilution using 
established methods (Wu et al, 2007).
 
Briefly, T-cells (0.3, 1 and 3 cell per well; 96 
well U-bottomed tissue culture plates) were seeded, stimulated with allogeneic PBMC 
and the mitogen phytohaemagglutinin (PHA; 5 μg/ml) and expanded in IL-2 
containing medium.  On day 14, clones were re-stimulated and expanded for a further 
28 days. 1304 clones were expanded to approximately 1 × 10
6 
cells and tested for 
abacavir reactivity (Figure 2.1-2.3 in chapter 2).       
   
- 3.2.5 Drug-specific T-cell responses 
Abacavir-specific proliferative responses were assessed by culturing clones (5 × 10
4 
/ 
well; 200 μl) with irradiated autologous APCs (1 × 104 / well) and abacavir (50 μM).  
[
3
H] Thymidine (0.5 μCi) was added after 48 hr and proliferation measured by 
scintillation counting. Clones with a stimulation index of greater than 1.5 were 
expanded by repetitive mitogen stimulation in IL-2 containing medium for further 
analysis. Phenotyping was performed using a BD FACSCanto II flow cytometer. 
Interferon gamma secretion after abacavir stimulation was measured using ELISpot in 
accordance with the manufacturer’s instructions (Mabtech AB, Sweden; Chapter 2). 
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To discriminate between clones activated via abacavir binding to surface and 
endogenous HLA-B*57:01 assays were conducted with APCs pulsed with abacavir 
for 16 h. The APCs were subjected to repeated washing steps to remove unbound 
drug before addition to the T-cells. Sixteen hours is the time required for the display 
of abacavir-dependent altered MHC binding peptides on the surface of APCs 
(Chessman et al, 2008; Adam et al, 2012; Bell et al, 2013). 
 
The effect of chemical modification of the 6-amino cyclopropyl group of abacavir on 
the T-cell response was measured by incubating clones and irradiated autologous 
APCs with the compounds (10, 25, 50, 100 and 250 μM) and measuring interferon 
gamma secretion. Cytokine secretion was selected as a T-cell readout as it provided 
the greatest discrimination between abacavir-treated and control cells. HLA-B*57:01-
restricted T-cell activity of the abacavir analogues was tested using 6 clones selected 
from all 3 donors. When possible, equal numbers of APC pulse positive and negative 
clones were analyzed. Abacavir was used as a positive control.  
 
- 3.2.6 Inhibition of lymphocyte proliferative responses 
To determine the direct inhibitory effect of chemicals on cell proliferation, abacavir 
and the analogues (1-300 μM) were cultured with autologous APCs (1 × 104 / well, 
200 μl; 96 well culture plates) or PBMC. In the B-cell assays, [3H] thymidine was 
added directly and plates were harvested after 8 hr to count incorporated radioactivity.  
In the experiments with PBMC, PHA was added for 36 hr to promote the proliferation 
of viable cells before the addition of [
3
H] thymidine.  Experiments were conducted in 
triplicate using cells from three donors. IC50 values were calculated using Sigmaplot 
12.5 (Systat Software Inc, London, UK). 
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- 3.2.7 HLA-B*57:01 modelling 
Ligands were prepared for docking in Spartan ‘08 (Wavefunction INC., Irvine 1991-
2009).  Native SMA ligand exported from PDB 3UPR (Ostrov et al, 2012). For each 
required analogue the cyclopropyl ring of abacavir was replaced. Molecular 
mechanics and MMFF energy minimisation calculations were performed with all 
atoms frozen except the newly added substitution. Structures were saved using SD file 
format ready for docking. 
 
For docking studies, GOLD 5.1 (CCDC Software Limited, Cambridge, UK) was used 
to find potential binding poses of abacavir analouges in the F-pocket of HLA-B*57:01 
(PDB code 3UPR) (Ostrov et al, 2012). Hydrogen molecules were added to the 
protein and the native ligand abacavir was used to define the binding site as residues 
within 6 Å of the ligand. Rigid docking was performed (‘Fix Ligand Rotatable 
Bonds’). Ligands were loaded and docked using the rescore option and the GoldScore 
fitness function, with the ‘Perform local optimisation’ option unchecked. All other 
settings were left at default. All docking studies were performed in the laboratory of 
Dr. Neil Berry (Department of Chemistry, University of Liverpool). 
 
- 3.2.8 Antiviral activity and cytotoxicity 
Antiviral activity was tested in HIVIIIB-infected MT4 cells incubated with abacavir 
and the analogues, was performed by researchers in the laboratory of Prof. Andrew 
Owen (Department of Pharmacology, The University of Liverpool) (Owen et al, 
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2004; Owen et al, 2005). HIV kills MT4 cells and the reciprocal therefore represents a 
measure of antiviral activity. Results are given as the mean of at least 4 independent 
experiments. EC50 (antiviral activity) and IC50 (cytotoxicity) data were generated using 
non-linear regression in GraphPad Prism 3.0 statistical analysis software and used to 
calculate selectivity index (SI; IC50 / EC50).  
 
- 3.2.9 Statistical analysis 
The Mann–Whitney test was used for comparison of control and test values. 
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3.3 Results 
- 3.3.1 Synthesis of abacavir analogues 
The 16 abacavir analogues were synthesized in good yields and high analytical purity 
for pharmacological and immunological testing. NMR, LC-MS, infrared 
spectrometry, melting points and accurate mass values are recorded in the appendix. 
The analogues were separated into 2 groups: Series 1 (analogues 7-14), compounds 
containing O- or N-linked rings of 3-6 carbon atoms; series 2 (analogues 15-22), 
compounds containing O- or N-linked straight or branched carbon chains (Figure 
3.4). 
 
Figure 3.4 Synthesis of 6-substituted abacavir analogues. 
 
- 3.3.2 Generation of abacavir-responsive CD8+ clones 
110 out of 1304 clones were found to proliferate in the presence of abacavir with 
stimulation index greater than 1.5. Figures 2.1-2.3 in chapter 2 show the 
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proliferative response of all clones from 3 donors when cultures with abacavir for 48 
hr. All of the abacavir-responsive clones were CD8
+
 and secreted interferon gamma, 
in a drug-concentration-dependent fashion (EC50 [50% of maximal interferon gamma 
spot forming units detected by ELISpot] < 20 μM for all clones). Since the interferon 
gamma ELISpot was superior to [
3
H] Thymidine at distinguishing abacavir-specific 
and non-specific clones from one another, interferon gamma release was used as a 
primary readout for all subsequent experiments (Figure 3.5A and B). 
 
Figure 3.5 Activation of CD8+ T-cell clones with abacavir. (A) Proliferative 
response (*10
3
) of abacavir treated cells (black bars) and untreated cells (white bars) 
and (B) interferon gamma release from 6 abacavir-responsive CD8
+
 T-cell clones 
incubated with abacavir and autologous APCs measured using [
3
H] Thymidine and 
ELISpot, respectively. 
 
Activation of the clones by abacavir was inhibited with an anti-MHC class I blocking 
antibody (Figure 2.12 in chapter 2). In agreement with previous studies, (Adam et al, 
2012; Bell et al, 2013) approximately half of the clones displayed (1) abacavir 
reactivity in the presence and absence of APCs (Figure 2.8 and 2.10 in chapter 2). 
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Similarly, around half of the clones were activated with abacavir-pulsed APCs 
(Figure 2.13 chapter 2). Clones displaying reactivity against abacavir-pulsed APCs 
are thought to respond via an “altered peptide” mechanism (Illing et al, 2012). In 
contrast, the pulse negative clones are activated via the direct binding of abacavir to 
surface class I molecules expressed on APCs and/or T-cells. Clones activated with 
abacavir via both pathways were included in our analysis.          
 
- 3.3.3 CD8+ T-cell activity with 6-substituted abacavir analogues  
Most of the compounds in analogue series 1 (7-14) did not activate the clones. With 
the exception of analogue 11, clones from all 3 blood donors were not stimulated to 
secrete interferon gamma. Figure 3.6A & B shows results from 5 clones tested 
against titrated concentrations of each analogue, with mean abacavir data as a 
comparator. Figure 3.6C & D shows representative ELISpot images from wells 
containing compounds 7-17 and abacavir used as a comparator. Analogue 11 of series 
1 was less potent than abacavir; however, concentration-dependent interferon gamma 
secretion was detected with all of the clones.  
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Figure 3.6A: Activation of CD8+ T-cell clones with abacavir and abacavir analogues 7-10, 12 and 14-
16. Activation of clones (n=5) with abacavir analogues. Each analogue was tested against a minimum of 5 
abacavir-responsive CD8
+
 T-cell clones isolated from the 3 patients. Abacavir was used as a positive 
control in each experiment. Mean abacavir-mediated interferon gamma release is shown in bold. 
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Figure 3.6B: Activation of CD8+ T-cell clones with abacavir and abacavir analogues 11, 13 and 17-21. 
Activation of clones (n=5) with abacavir analogues. Each analogue was tested against a minimum of 5 abacavir-
responsive CD8
+
 T-cell clones isolated from the 3 patients. Abacavir was used as a positive control in each 
experiment. Mean abacavir-mediated interferon gamma release is shown in bold. 
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Drug Conc. (µM) Ø 10 25 50 100 250Donor HLA-202  TCC # 36
274 282 265 269 329
23 28 25 41 52
27 19 13 19 13
20 28 37 49 66
22 33 34 58 72
33 142 223 274 267
31
32
Ø + DMSO
C 8
C 7
C 9
C 10
C 11
 
 
Figure 3.6C: Activation of CD8+ T-cell clone with abacavir and abacavir 
analogues 7-11. Representative ELISpot images from wells containing compounds 7-
11 and abacavir are shown from a single experiment. Abacavir was used as a positive 
control in each experiment. Chemical structures of the compounds are drawn beside 
relevant T-cell activity. 
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Drug Conc. 
(µM) 10 25 50 100 250
Ø
C 15
C 16
C 14
C 17
C 13
C 12
Donor
HLA-202  
TCC # 36 **
**
 
 
Figure 3.6D: Activation of CD8+ T-cell clone with abacavir and abacavir 
analogues 12-17. Representative ELISpot images from wells containing compounds 
12-17 and abacavir are shown from a single experiment. Abacavir was used as a 
positive control in each experiment. Chemical structures of the compounds are drawn 
beside relevant T-cell activity. 
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Analogue Series 2 contained compounds where the 6-amino cyclopropyl group of 
abacavir was replaced with O- and N-linked straight and branched chains. Analogues 
17, 18, 20 and 21, containing straight carbon chains stimulated interferon gamma 
release from the clones are the same concentrations as abacavir. In contrast, analogues 
15 (iso-propyl), 16 methyl iso-propyl) and 19 (t-butyl), each containing branched 
chains did not activate the clones (Figure 3.6A & B). The response detected with one 
clone at the highest concentration of analogue 19 was not reproduced following repeat 
testing. Finally, we replaced the 6-amino cyclopropyl group with an oxetane, an 
increasingly used isopropyl isostere to provide 22, and similar to 15 and 16, this 
molecule was negative in terms of T-cell activation (Figure 3.7). 
 
Figure 3.7: T-cell activity of the 6-substituted analogues 15 and 22 and abacavir. 
Interferon gamma release was measured by ELISpot. Each analogue was tested against a 
minimum of 5 clones. 
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- 3.3.4 Inhibition of T-cell and B-cell proliferation by abacavir and 
abacavir analogues  
To explore whether the abacavir analogues inhibited lymphocyte proliferation through 
direct toxicity, mitogen-activated PBMC and epstein-barr virus-transformed B-cells 
were incubated with range of concentrations of the test compounds. Abacavir 
inhibited PBMC (IC50 84 μM) and B-cell (IC50 207 μM) proliferation in a 
concentration-dependent manner (Figure 3.8). Similar IC50 values were obtained with 
the abacavir analogues 7-9 and 11-17 (Table 3.1); analogue 10 was the only 
compound that suppressed proliferation of both cell types at lower concentrations than 
abacavir. 
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Figure 3.8 Inhibition of T-cell and B-cell proliferation by abacavir and abacavir 
analogues. Abacavir and the analogues (1-300 μM) were cultured with autologous 
APCs (1 × 10
4 / well, 200 μl; 96 well culture plates) or PBMC. (A) In the B-cell 
assays, [
3
H] thymidine was added directly and plates were harvested after 8 hr to count 
incorporated radioactivity. Experiments were conducted in triplicate using cells from 
three donors. (B)  In the experiments with PBMC, PHA was added for 36 hr to 
promote the proliferation of viable cells before the addition of [
3
H] thymidine. 
A. 
B. 
Chapter 3    
 
116 
Compound Inhibition of B-cell 
proliferation 
IC50 (μM)
[1] 
Inhibition of mitogen-driven 
PBMC proliferation 
IC50 (μM)
[2] 
Abacavir 207.2 84.4 
7 177.0 193.6 
8 83.4 80.4 
9 99.6 <300 
10 79.3 43.5 
11 215.8 <300 
12 Not performed <300 
13 80.0 99.7 
14 92.2 93.3 
15 85.4 <300 
16 119.4 <300 
17
3 194.0 <300 
 
Table 3.1: Inhibition of T-cell and B-cell proliferation by abacavir and abacavir analogues. 
1 
measured in EBV-transformed B-cells (antigen presenting cells in the T-cell studies) 
2 
measured in PHA-stimulated PBMC isolated from 3 donors 
3 
compounds 18-22 were not studied as most activated abacavir-specific T-cell clones
 
 
 
- 3.3.5 Docking solutions in the F-pocket of HLA-B*57:01  
A docking protocol was developed that reproduced the native crystal structure binding 
pose of abacavir in the HLA-B*57:01 F-pocket binding site (Illing et al, 2012). This 
protocol was used to predict the binding poses of compounds 7-21. These poses were 
analysed in order to rationalise the observed differences in their T-cell response. 
Abacavir and all of the analogues studied are predicted to bind in a similar fashion, 
with the guanosine portion of the molecule forming multiple hydrogen bonds with 
residues Asp114, Ser116 and Ile124 (Figure 3.9). Crucially, this conserved binding 
motif means that the modifications at the 6-position result in a range of steric 
interactions with the HLA-binding peptide. 
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Figure 3.9: Crystal structure of HLA-B*57:01 (PDB: 3UPR) represented as a cartoon coloured by loop, 
with the peptide and abacavir as red and blue sticks respectively. (A) Crystal structure binding orientation 
of abacavir. Stick representation of the peptide, pep-V (HSITYLLPV) shown in red, with the chemical 
structure of abacavir in blue. Key amino acid protein residues which bind abacavir are shown as yellow 
sticks. All non-polar hydrogen atoms removed. Key H bond interactions shown as black dashes. Spheres 
used to illustrate the atomic radii of the atoms in the cyclopropyl group of abaavir, peptide molecule, and 
Tyr123 amino acid closest to each other. Groups sufficiently spaced so there is no unfavourable steric 
clashes upon complexation of the peptide. Docking solution of (B) N-isopropyl (15), (C) N-methyl-
isopropyl (16) and (D) N-propyl (17) analogue in the f-pocket of HLA-B*57:01.  Stick representation of 
the peptide, pep-V (HSITYLLPV) shown in red. Amino acid protein residues shown as yellow sticks, 
with key H bond interactions as black dashes. All non-polar hydrogen atoms removed. Spheres used to 
illustrate the atomic radii of the atoms in the N-methyl-isopropyl group of the analogue, peptide molecule, 
and Tyr123 amino acid closest to each other. Steric clashes observed by the overlapping spheres, between 
the analogue and both the protein and the peptide. This indicates the hindered binding of the analogues 
15, 16 in the f-pocket, and the reduced potential for the complexation of the peptide. 
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Figure 3.10: Comparison of CD8+ T-cell activity and HLA-B*57:01 binding of 
abacavir and analogues 15, 16 and 17. (A.) IFN-γ release from clones (n=5) was 
measured using ELISpot. (B.) Representative ELISpot images from wells containing 
each compound are shown. 
 
 
Importantly, a definitive quantitative relationship was found between the predicted 
strength of binding (GoldScore) and T-cell responses; compounds with GoldScore 
values greater than 50.0 activated abacavir-specific clones, whilst those less than 50.0 
did not activate abacavir-specific clones (Figure 3.11). 
A. 
B. 
Chapter 3    
 
119 
 
 
Figure 3.11: Comparison of maximum abacavir analogue T-cell activity and 
GoldScore fitness function values. Maximum T-cell activity was calculated as mean 
maximal sfu in interferon gamma ELISpot following analogue treatment of clones (n=5) 
with control values subtracted. GoldScore fitness function values quantify the docking 
solutions of abacavir analogues in the antigen binding site of HLA-B*57:01. 
 
6-Aminoalkyl functionalized compounds which had a GoldScore value lower than 
50.0 displayed unfavorable steric clashes with the HLA binding peptide. For example, 
compound 12, which produced no T-cell response and had a unfavorable GoldScore 
value (-175.1) with the relatively bulky 6-ethylaminomorpholino group inducing an 
extremely unfavorable steric clash with the Tyr123 residue, and the loss of favorable 
van der Waals contacts which are ordinarily observed between the cyclopropyl group 
of abacavir and Val9 of the B*57:01 binding peptide. This trend was true across all 
compounds in Series 1, in which larger substituents failed to produce a T-cell 
response.  
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Many of the compounds in Series 2 with small 6-amino substituents resulted in T-cell 
responses similar to abacavir. The docking protocol was able to correctly identify 
molecules that produce a T-cell response. For example, compounds 17,20,21 each 
possess linear substituents (NH-propyl/butyl) and all produced T-cell responses, with 
binding similar to abacavir (Figure 3.11). Interestingly, compounds 15 (isopropyl) 
and 16 (N-methyl-isopropyl) produced no T-cell response and had low GoldScore 
values. Molecular modelling shows that for compound 15, the positioning of the 
methyl groups effects peptide binding and steric clashes occur with Tyr123. This is 
also true for compound 16, with an additional steric clash observed between the N-
methyl and Asn77. These clashes combined with the loss of the stabilizing contact of 
the cyclopropyl moiety with Val9 on the peptide, accounts for the loss of the T-cell 
response. Figures 3.10 and 3.9 compares T-cell activity of abacavir and analogues 
15,16,17 with the predicted binding to HLA-B*57:01. 
 
 
- 3.3.6 Antiviral activity of abacavir and the 6-substituted analogues 
To assess antiviral activity, the analogues were tested alongside abacavir in HIVIIIB-
infected MT4 cells. Ring expansion of cyclopropyl to cyclobutyl through to 
cyclohexyl resulted in a 10 fold reduction in antiviral activity for analogues 7-9 
(Table 3.2).  Whilst ether linked analogues retained good activity they were shown to 
be cytotoxic to MT4 cells with poor therapeutic indices. Notably, N-isopropyl 15, N-
methyl isopropyl 16 and N-propyl 17 analogues had antiviral efficacy, with similar 
levels of activity as abacavir itself (Figure 3.12). Oral dosing at the level of 10 mg/kg 
in the rat revealed a similar pharmacokinetic profile for both 15 and abacavir with oral 
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bioavailabilities of 80 and 100% respectively with good overall exposure profiles 
(data not included). 
 
Compound Antiviral 
activity EC50 
(μM)[a] 
Toxicity  
IC50 (μM)
[a] 
Selectivity 
index 
(IC50/EC50) 
Abacavir 3.8 199.2 52 
7  12.6 11.5 0.91 
8 11.6 12.2 1.0 
9 15.0 9.9 0.66 
10 17.9 11.7 0.65 
11  6.8 184.0 27.1 
12 5.9 2.4 0.40 
13 6.4 3.0 0.47 
14 8.5 2.8 0.33 
15 3.9 65.3 17 
16 4.8 77.7 16 
17 4.8 197.9 41 
[a] 
measured in MT4 cells 
 
Table 3.2: Antiviral Activity of abacavir and abacavir analogues (compounds 7-17). 
 
 
MT4 cells were supplied by the EU programme EVA Centre for AIDS Reagents, 
National Institute for Biological Standards and Control (NIBSC), UK, and maintained 
in RPMI-1640 supplemented with 10% sterile filtered foetal bovine serum (FBS; Bio-
Whittaker, Berkshire, UK), incubated at 37 C with 5% CO2 and subcultured every 4 
days. Cell viability was determined by Trypan Blue exclusion assay and typically <97 
%. Prior to experiments, MT4 cells were seeded at a density of 2.5 × 10
4
 cells / 100 
μL of RPMI-1640 and 10% sterile filtered FBS in to each well of a 96 well plate 
(Nunclon™, Denmark) and incubated for 24 hr at 37 C with 5% CO2. Media was 
then aspirated and replaced with media containing a range of concentrations (0.0026, 
0.0128, 0.064, 0.32, 1.6, 8, 40, 200, 1000 or 5000 μM) of test compound (less than 
0.1% methanol vehicle in final incubation) in culture media. The plates were then 
incubated for 5 days at 37 C with 5% CO2. Subsequently, plates were removed from 
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the incubator and 20 μL of 5 mg Thiazolyl Blue Tetrazolium (Sigma, UK) per mL of 
Hanks balanced salt solution (HBSS; Sigma, UK) was added to each well. Plates were 
further incubated for 2 hr at 37 C with 5% CO2. Finally, 100 μL of lysis buffer 
containing 50% v/v dimethylformahyde (Sigma, UK) and 20% v/v sodium dodecyl 
sulfate (SDS; Sigma, UK) was added to each well prior to further incubation for 24 hr 
at 37 C and 5% CO2. Finally, absorbance was measured at 570 nm using a Tecan 
Genosis plate reader (Tecan Magellan, Austria). 
 
For determination of the inhibition of HIVIIIB (NIBSC, UK) replication in MT4 cells 
by ABC and its analogues, MT4 cells and viral isolates (Multiplicity of infection = 
0.01) were dispensed into a 50ml Falcon tube and centrifuged for 15 minutes at 2000 
x g in a Galaxy 170R Incubator (Sanyo, Japan) at room temperature. The falcon tube 
containing the MT4/viral pellet was then incubated at 37C and 5% CO2. After 2 
hours, the supernatant was aspirated and the pellet resuspended in RPMI-1640 
supplemented with 10% FBS. MT4 cells containing virus particles were then seeded 
at a density of 1 x 10
4 
cells / 80 µl into each well of a 96 well plate also containing a 
range of concentrations (0.00013, 0.0006, 0.003, 0.016, 0.08, 0.4, 2, 10 and 50 µM) of 
either ABC or the analogues in 20 µl RPMI-1640 supplemented with 10% sterile 
filtered FBS. The plate was incubated for 5 days at 37C and 5% CO2. MTT assay 
was then conducted as described above on the basis that HIV kills MT4 cells and the 
reciprocal therefore represents a measure of antiviral activity. 
 
Antiviral activity and cytotoxicity data from MT4 cells are given as the mean of at 
least 4 independent experiments. EC50 (antiviral activity) and IC50 (cytotoxicity) data 
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were generated using non-linear regression in GraphPad Prism 3.0 statistical analysis 
software and used to calculate selectivity index (SI; IC50 / EC50). 
 
Figure 3.12: Antiviral activity and cytotoxicity of abacavir and 6-substituted 
analogues in MT4 cells. Data are given as mean relative absorbance at a 570 nm 
wavelength. Each graph shows IC50 (cytotoxicity) and EC50 (antiviral activity) and 
selectivity index (SI; IC50/EC50) for each of the test compounds calculated by non-
linear regression. 
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3.4 Discussion 
The main side effect of abacavir therapy is hypersensitivity. Pharmacogenomic 
studies identified a strong association between the presence of HLA-B*57:01 and 
abacavir hypersensitivity shortly after first reports of the clinical syndrome 
(Hetherington et al, 2002; Mallal et al, 2002, Martin et al, 2004). Subsequently, 
screening for HLA-B*57:01 and exclusion of the risk allele positive group from 
abacavir therapy was found to eliminate immunologically-confirmed (patch test 
positive) hypersensitivity reactions (Mallal et al, 2008). These data resulted in the 
widespread use of a pharmacogenetic test to prevent abacavir hypersensitivity. 
 
The HLA class I allele association suggests that abacavir hypersensitivity is mediated 
by CD8+ T-cells with the drug-derived antigen presented in the antigen binding 
groove of the protein encoded by the risk allele. In this respect, Almeida et al. found 
that PBMC from HLA-B*57:01 positive hypersensitive patients, but not tolerant 
controls, secrete interferon gamma ex vitro following drug stimulation. Around the 
same time Chessman et al. found that it was possible to expand abacavir-responsive 
CD8+ T-cells from peripheral blood of HLA-B*57:01 positive healthy donors. The T-
cell response was only observed with APCs expressing HLA-B*57:01. Furthermore, 
substitution of a single amino acid serine at position 116 in the HLA-B*57:01 antigen 
binding groove to a tyrosine residue completely abrogated abacavir-specific activation 
of T-cells. Several studies then reported that abacavir bound directly to the bottom of 
the antigen-binding groove reaching into the F-pocket, where a carboxy-terminal 
tryptophan typically anchors peptides bound to HLA-B*57:01 (Illing et al, 2012; 
Norcross et al, 2012; Ostrov et al, 2012). Abacavir binding changes to shape of the 
groove and alters to repertoire of peptides that can bind to HLA-B*57:01. It is now 
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assumed that the CD8+ T-cell response seen in hypersensitive patients is driven by 
peptides that are only displayed by HLA-B*57:01 positive APCs in the presence of 
abacavir. Importantly, these data only describe part of the story as approximately 50% 
of abacavir-responsive CD8+ clones are activated with the drug by a processing-
independent pathway presumably via a direct interaction with B*57:01 molecules 
expressed on the surface of APCs (Adam et al, 2012; Bell et al, 2013). It is relatively 
simple to differentiate between clones activated via each mechanism through APC 
pulsing experiments and/or inhibition of antigen processing.  
 
The primary objective of this study was to identify antiviral compounds with no 
immunological liability. To achieve this objective, we utilized an innovative 
biological approach allied to computational chemistry. Abacavir-responsive 
CD8+clones were generated from all three HLA-B*57:01 positive drug-naïve blood 
donors. Proliferation and interferon gamma release was MHC class I-restricted and in 
agreement with our previous studies only half of the clones were activated with 
abacavir-pulsed APCs. Thus, a minimum of 5 clones, some of which displayed 
reactivity against pulsed APCs, were used to determine which abacavir analogues 
activate T-cells. 
   
Our first approach was to introduce bulky ring structures in place of abacavirs’ 
cyclopropyl group (analogue series 1). O- and N-linked rings of 4 or more carbon 
atoms were found to have a profound effect on the drug-specific T-cell response. 
Abacavir-responsive clones were not activated with analogues 7-10 or 12-14 at 
concentrations of 10-250μM. Under these experimental conditions, the abacavir and 
abacavir analogue concentrations that inhibited mitogen-driven proliferation of 
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PBMC and the division of EBV-transformed B-cell lines ranged from 80-300μM. 
Hence, replacement of the cyclopropyl group of abacavir with larger rings did not 
increase direct toxicity at therapeutic [3.1-11.2μM; (Yuen et al, 2008) steady-state 
peak concentration reported following a 300-mg twice-daily regimen] or T-cell 
stimulatory concentrations (10μM and above). The only analogue in this series that 
activated clones was N-methylene linked cyclopropyl abacavir (11). 
        
The next strategy was to replace the 6-amino cyclopropyl group with O- and N-linked 
carbon chains. Introduction of O- and N-linked straight chains with 3-4 carbon atoms 
did not alter the T-cell activity of abacavir. Importantly, the introduction of branched 
chains of 3 carbon atoms (15, 16) completely abolished T-cell activity. Figure 3.10 
shows ELISpot images from wells containing analogues 15 and 16, with abacavir and 
analogue 17 as comparators. Analogues 15, 16 and 17 were well tolerated in the cell 
assays. Concentrations that inhibited B- and T-cell proliferative responses were 
similar to abacavir itself.   
 
These findings suggest that analogues in both series 1 and 2 bind to HLA-B*57:01 
with a much lower affinity or bind in such a way that the altered repertoire of peptides 
described by Illing et al and others (Norcross et al, 2012; Ostrov et al 2012) are no 
longer displayed on the surface of APCs. The availability of conserved abacavir-self 
peptide HLA-B*57:01 structures (Illing et al, 2012) allowed us to model the abacavir 
and abacavir analogue amino acid interactions within the peptide binding groove. A 
definitive relationship was observed between the predicted strength of binding and T-
cell responses. Abacavir analogues with GoldScore values greater than 50.0 activated 
the clones, whilst those less than 50.0 did not. For example, compounds 17,18,20,21 
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each containing linear O- and N-substituted side chains activated T-cells and bound to 
HLA-B*57:01 in a similar manner to abacavir. In contrast, compounds 15 and 16 
produced no T-cell response and had low Goldscore values. Molecular modelling 
identified steric clashes between the methyl groups of both compounds and the HLA-
B*57:01 binding peptide. This combined with loss of the stabilizing contact of the 
cyclopropyl moiety on abacavir accounts for loss of the T-cell response. This 
quantitative model provides a powerful tool for predicting HLA-B*57:01 binding and 
whether a compound will activate CD8+ T-cells.  
 
Abacavir inhibits viral reverse transcriptase through competition and chain 
termination of the growing viral RNA. It is a pro-drug requiring intracellular 
conversion into carbovir triphosphate. Thus, to assess antiviral activity, the analogues 
were tested alongside abacavir in HIVIIB-infected MT4 cells (Owen et al, 2004; 
Owen et al, 2005). Molecules in this study represent an expanded series over those 
previously reported by Daluge et al with the primary focus on the 6-position structure 
activity relationship. Significantly, substitution at the 6-position with N-isopropyl 15, 
N-methyl isopropyl 16 and N-propyl 17 provided analogues with similar levels of 
antiviral potency. We note that in the Daluge publication, analogue 15 was reported to 
be 10 fold less potent than abacavir. For this reason assays were performed in 
duplicate on two separate occasions and in all cases 15 was equipotent to abacavir. 
Compound 16, the N-methylated version of 15 was also potent in these assays as was 
the simple N-propyl derivative 17. Overall the structure activity relationship study 
indicates that secondary and tertiary acyclic amines are preferred with small N-
substituents. One of the key properties that led to the progression of abacavir is its 
stability and minor conversion to carbovir in animal models and in in vitro systems 
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with adenosine deaminase. Pharmacokinetic studies performed on analogue 15 
indicate comparable properties to abacavir with similar exposure and high oral 
bioavailability suggesting that this close analogue has similar metabolic stability 
profiles (results not shown). 
 
The significance of this study is that proof of principle has been achieved with respect 
to the identification of a safer alternative to abacavir as exemplified by N-isopropyl 15 
and N-methyl isopropyl 16 analogues. These molecules express acceptable antiviral 
activity, an acceptable in vitro therapeutic index with lack of T-cell activation and a 
pharmacokinetic profile comparable to abacavir. Our modeling and cellular screening 
approach provides a unique platform to discover and optimize a new class of abacavir 
analogue lacking the immunological liabilities associated with abacavir treatment. 
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Chapter 4: Activation of Abacavir-Specific CD8+ T-Cell 
by A Unique HLA-B*57:01 Binding Peptides  
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4.1 Introduction 
The traditional concepts to explain drug hypersensitivity namely (1) drug haptenation 
and (2) direct binding to immune receptors do not fully explain the mechanism by 
which abacavir activates T-cells. Emerging data focusing exclusively on abacavir 
(Ostrov et al, 2012; Norcross et al, 2012; Illing et al, 2012) suggest an additional 
mechanism whereby the drug binds human leukocyte antigen (HLA)-B*57:01 and 
alters the peptide repertoire in a way that skews the normal repertoire of peptides 
displayed on the surface of APCs. This may result in the non tolerated polyclonal 
activation of CD8
+
 T-cells and hypersensitivity. Data presented in chapter 2 explaining 
mechanisms of abacavir-specific T-cell activation revealed that approximately half of 
the drug responsive clones were activated rapidly, presumably by a direct interaction 
with HLA-B*57:01 proteins expressed on the surface of APCs. Activation of these 
clones with abacavir was observed even when APCs were fixed with glutaraldehyde, 
indicating that protein processing was not a prerequisite for T-cell activation. 
However, the other half of abacavir responsive clones are activated only when APCs 
have been pulsed with the drug for 4-16 hr, the time needed for protein processing. 
The activation of these clones with abacavir was blocked through fixation of APCs. 
Hence, these clones are likely activated with the so-called ''altered self repertoire'' of 
peptides displayed by HLA-B*57:01
+
 APCs in the presence of abacavir. 
 
By measuring fluorescence polarization, Norcross et al (2012) assessed peptide 
binding to HLA-B*57:01 in presence of variable drugs. These data illustrated that 
abacavir, in contrast to flucloxacillin, a drug associated with liver injury in HLA-
B*57:01
+
 donors, and didanosine, increased peptide binding in a dose-dependent 
manner. Furthermore, characterising the HLA-B*57:01 peptide repertoire in the 
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presence and absence of abacavir (Norcross et al, 2012; Illing et al, 2012) revealed  
series of unique self peptides in cells treated with abacavir that were not present in 
untreated cells. This finding of unique self peptides indicates that abacavir modifies 
the peptide repertoire within HLA pockets which may drive T-cell reactions. To 
investigate whether the discovered unique self peptides are capable of inducing T-cell 
responses, we have collaborated with Professor Anthony Purcell and Dr. Patricia Illing 
(Monash University-Australia) to import 120 unique 9mer self peptides that are only 
displayed in the context of HLA-B*57:01 upon abacavir treatment. In addition, C1R 
(HLA deficient B-cell line transfected with HLA-B*57:01 that expresses TAP; a 
carrier for loading endogenous peptide) and T2B (a B-cell line transfected with HLA-
B*57:01 but lacking TAP) cells were used to distinguish between T-cells activated via 
different pathways. Importantly, amino acid sequences of received peptides were 
blinded during experimental work and peptides were given numbers for identification 
(peptide 1-120). Peptides were delivered in a stable form of a C-terminal amidated 
isoform. In later studies, a selection of unique non-amidated peptides was purchased. 
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4.2 Methodology 
- 4.2.1 Materials 
Abacavir was received as a gift from GlaxoSmithKline pharmaceutical company. One 
hundred and twenty peptides were imported from Professor Anthony W Purcell and 
Dr. Patricia Illing (Monash University-Australia), together with C1R and T2B APCs. 
Two isoforms of peptide 15 (amidated and natural) were purchased from Synpeptide 
(Shanghai-China). Human AB serum and fetal bovine serum (FBS) were obtained 
from Innovative Research Class A (Michigan-USA) and Invitrogen (Paisley-UK), 
respectively. Recombinant human protein interleukin-2 (IL-2) was supplied by 
Peprotech (London-UK). Multisort bead separation kits were purchased from Miltenyi 
Biotec (Surrey-UK). Antibodies for staining co-stimulatory molecules (CD3-APC, 
CD4- FITC and CD8- PE) were purchased from BD Biosciences (Oxford-UK). [
3
H] 
thymidine was supplied by Moravek (California-USA). Interferon gamma ELISpot 
kits including coating, detection and streptavidin antibodies and substrate solution 
were obtained from Mabtech (Stockholm-Sweden). Other reagents were purchased 
from Sigma-Aldrich (Dorset-UK) unless otherwise mentioned. 
 
- 4.2.2 HLA-typed healthy volunteer cell bank  
Cells from three HLA-B*57:01 positive individuals were selected from our cell bank 
containing peripheral blood mononuclear cells (70-150x10
6
; stored in vials of 10x10
6 
cells) from 1000 HLA-typed donors. Approval for the study was acquired from the 
Liverpool Local Research Ethics Committee and informed written consent was 
obtained from volunteers. Confidentiality was maintained throughout the study. 
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- 4.2.3 Cell culture media 
- 4.2.3.1 T-cell medium contained RPMI 1640 supplemented with 10% human 
AB serum, 25 mM HEPES, 2 mM L-glutamine, 1000 U/ml penicillin, 0.1 mg/ml 
streptomycin, and 25 µg/ml transferrin. 
- 4.2.3.2 Antigen-presenting cell (APC) medium contained RPMI 1640 
supplemented with 10% FBS, 25 mM HEPES, 2 mM L-glutamine, 1000 U/ml 
penicillin, 0.1 mg/ml streptomycin. 
 
- 4.2.4 Isolation of peripheral blood mononuclear cells (PBMCs) 
Venous blood was collected from healthy volunteers to start either serial dilution for 
abacavir T-cell cloning or to re-stimulate existing T-cell clones. PBMCs were isolated 
by layering 25 ml blood on top of 25 ml lymphoprep. Tubes were centrifuged at 2000 
r.p.m for 25 mins (25°C) to separate plasma and immune cells. The buffy coat layer 
containing PBMCs was carefully collected using a Pasteur pipette. PBMCs were 
washed twice in Hanks balanced salt solution (HBSS) to remove any remaining 
lymphoprep. The formed pellet was resuspended in 10 ml HBSS. 10 μl suspension of 
PBMCs was then added to an equal volume of trypan blue (0.2 % w/v) and the cells 
were counted under a Leica microscope (Leica Microsystems-Milton Keynes) using a 
haemocytometer (Sigma-Aldrich). Cell viability was evaluated by trypan blue 
exclusion. 
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- 4.2.5 Generation of autologous EBV-transformed B-cell lines 
Epstein−Barr virus (EBV) transformed B-cell lines were created from PBMCs of each 
donor through incubation with supernatant of the virus-producing cell line B95-8 in 
order to initiate a transformation process. These lines were kept in culture for 
approximate 3 weeks in APC medium. Cyclosporin A was added for the first 10 days 
of culture to prevent EBV-induced T-cell growth. The transformed B-cell line was 
used as a source of autologous APC. 
 
- 4.2.6 Maintaining C1R and T2B cells 
Cells from the class-I-deficient lymphoblastoid cell line, C1R and T2B, transfected 
with the relevant HLA allele B*57:01 were used as stimulators for functional assays. 
Cells were maintained in RF-10 medium (RPMI (Gibco BRL) supplemented with 
10% fetal calf serum (Bovogen), 7.5mM HEPES (MP Biomedicals), 150 µg ml
-1
 
streptomycin (Sigma), 150 U ml
-1
  benzylpenicillin (CSL), 2mM L-glutamine (MP 
Biomedicals), 76 µM β-mercaptoethanolamine (Sigma) and 150 µM non-essential 
amino acids (Gibco BRL) (Illing et al, 2012). 
 
- 4.2.7 Abacavir T-cell cloning 
PBMCs (1x10
6
; 0.5 ml) were exposed to abacavir (50 μM; 0.5 ml) and cultured for 
two weeks in T-cell medium. Cultures were supplemented with IL-2 on day 6 and day 
9. After two weeks, CD8
+
 T-cells were separated using a CD8 MultiSort kit. Cells 
were harvested and re-suspended in phosphate buffered saline (PBS) solution 
containing 2mM ethylene diamine tetra-acetic acid (EDTA) and 0.5% bovine serum 
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albumin (BSA). Magnetic CD8 microbeads were added to the cells and incubated for 
15 minutes at 4˚C. The cells were then washed twice and added to an MS column held 
in a magnet. Unlabelled cells pass through the column and were collected as the CD8
+
 
negative T-cell population. The column was then removed from the magnet and CD8
+
 
T-cells were flushed out and collected as the target population of interest. CD8
+
 T-
cells were then cloned by serial dilution using established procedure (Wu et al, 2006). 
Cells were seeded in 96-well plates at densities of 0.3, 1 and 3 cells/well and re-
stimulated with cocktail media comprising of allogenic irradiated PBMCs (5 x 10
4
 
cells/well), IL-2 (60 U/ml) and PHA (1 µg/ml). Well-growing clones were transferred 
to new 96-well plates and split as required. 1304 clones were expanded to 
approximately 1x10
6 
cells and tested for abacavir reactivity (Figure 2.1-2.3 in chapter 
2). 
 
- 4.2.8 Antigen-specificity of T-cell clones  
Four weeks after starting the serial dilution, abacavir-specificity was evaluated by 
adding irradiated autologous APCs (1 x 10
4
/well) and abacavir (50 µM) to T-cell 
clones (5 x 10
4
/well; 200 μl). [3H] thymidine (0.5 µCi) was added after 48 hr and T-
cell proliferation was measured 16 hr later by scintillation counting. Using the same 
experimental protocol, T-cell responses were also quantified via interferon gamma 
ELISpot. The proliferative response of T-cell clones is expressed as counts per minute. 
T-cell clones with a proliferation stimulation index greater than 1.5 were expanded and 
re-stimulated with a cocktail media comprising of allogenic irradiated PBMCs (5 x 10
4
 
cells/well), IL-2 (60 U/ml) and PHA (1 µg/ml) for further analysis. 
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- 4.2.9 Proliferation assay 
Abacavir-specific T-cell clones (5 × 10
4
 cells, 50 μl) generated from naïve  individuals 
were co-cultured with irradiated autologous APCs (1 × 10
4
 cells, 50 μl) in the presence 
and absence of single or multiple abacavir concentrations (1-250 μM, 100 μl). The 
proliferation assay was set up in duplicate in a 96-well U-bottom plate. Plates were 
incubated with the drug for 48 hr, after which, [
3
H] thymidine (0.5 µCi) was added for 
16 hr. T-cell proliferation was evaluated using a scintillation counter and the results 
are expressed as the mean of duplicate wells. 
 
- 4.2.10 ELISpot (enzyme linked immune spot) assay  
ELISpot plates were, first, coated with 100 μl/well interferon gamma capture antibody 
(15 μg/ml) and incubated overnight at 4˚C. Tested wells were then washed five times 
with sterile PBS. T-cell culture medium was added to tested wells for 30 minutes at 
room temperature. Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured 
with autologous irradiated APCs (1×10
4
, 50 μl) in the presence and absence of single 
or multiple abacavir concentrations (1-250 μM, 100 μl). The plates were incubated in 
an atmosphere of 37˚C and 95% O2/5% CO2 for 48 hr. T and B lymphocytes were 
discarded and tested wells washed five times with 200 μl PBS. Detection antibody was 
diluted to 1 μg/ml in PBS containing 0.5% FBS and 100 μl added to the wells. The 
plates were incubated for 2 hr at room temperature and washed five times with PBS. 
Streptavidin antibody was diluted to 1 μg/ml in PBS containing 0.5% FBS and 100 μl 
added to wells. The plates were incubated for 1 hr at room temperature and washed 
five times with PBS. BCIP/NBT substrate solution was filtered before 100 μl was 
added to wells. The plates were kept at room temperature in the dark for 15-25 
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minutes to allow spots to emerge. Wells were then washed under slow running tap 
water and left over the bench to dry. The forming spots were visualised and counted 
using an AID ELISpot reader (Cadama Medical, Stourbridge, UK). 
 
- 4.2.11 Drug pulsing assay 
APCs (C1R, T2B and autologous) were incubated (pulsed) overnight with abacavir 
(50 μM) in an atmosphere of 37˚C and 95% O2/5% CO2. The next day, they were 
washed three times in T-cell medium, counted (1×10
4, 50 μl) and irradiated before co-
culturing with T-cell clones (5×10
4
 cells, 50 μl). No further drug was added and the T-
cell response was quantified by interferon gamma ELISpot. Soluble drug was used as 
a positive control.  
 
- 4.2.12 Drug-specific responses with abacavir and abacavir-dependent self 
peptides 
Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured with irradiated APCs 
(C1R and T2B cells) (1×10
4, 50 μl) in the presence and absence of a single abacavir 
concentration (50 μM, 100 μl). The clones were also co-cultured with irradiated T2B 
cells in the presence of abacavir + amidated peptide mix (100 μl, 50 μM and 20 μM 
respectively). T-cell response was quantified by interferon gamma ELISpot for 24 
peptide mixes of 5 peptides each (a total of 120 peptides) in the presence of abacavir 
and T2 APCs. 
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- 4.2.13 Drug-specific responses with a single 9mer peptide 
Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured with irradiated APCs 
(C1R and T2B cells) (1×10
4, 50 μl) in the presence and absence of a single abacavir 
concentration (50 μM, 100 μl). The clones were also co-cultured with irradiated T2B 
cells and stimulated with amidated peptide 11-15 (20 μM, 50 μl) in the presence and 
absence of abacavir (50 μM, 50 μl) for 48 hr. T-cell response was quantified by 
interferon gamma ELISpot. 
 
- 4.2.14 Dose response of abacavir-dependent self peptide 
Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured with irradiated T2B 
APCs (1×10
4, 50 μl) in the presence of multiple concentrations of amidated peptide 
15 (0.2-20 μM, 50 μl) +/- abacavir (50 μM, 50 μl) for 48 hr. T-cell response was 
quantified by interferon gamma ELISpot. 
 
- 4.2.15 Cross-reactivity of abacavir-dependent self peptide  
Autologous APCs (1×10
4
 cells/50 μl) were irradiated and co-cultured with drug-
specific T-cell clones (5×10
4
 cells/50 μl) +/- 4 drugs (1.5 mM flucloxacillin; 50 μM 
nitroso sulfamethoxazole; 1mM amoxicillin; 0.1 mM clavulanic acid/100 μl) and 
amidated peptide 15 (20 μM) for 48 hr. T-cell response was quantified by interferon 
gamma ELISpot or [
3
H] thymidine (0.5 μCi) was added for 16 hr and T-cell 
proliferation was measured. 
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- 4.2.16 PBMCs reactivity with abacavir-dependent self peptide 
PBMCs (5×10
4
 cells/50 μl) were irradiated and co-cultured with PBMCs of 8 HLA-
B*57:01 positive and 8 HLA-B*57:01 negative naïve donors (1×10
6
 cells/50 μL) in 
the presence of 1) abacavir + peptide 15; 2) abacavir alone; and 3) peptide 15 alone 
for 48 hr. T-cell response was quantified by interferon gamma ELISpot. Similarly, 
lymphocyte proliferation from PBMC of 8 HLA-B*57:01 positive and HLA-B*57:01 
negative naïve donors (1.5×10
5
 cells/100 μL) were treated with (100 μl) abacavir 50 
μM, peptide 15 amidated 20 μM, and abacavir + peptide 15 50 μM and 20 μM 
respectively. Plates were incubated with the drug for 48 hr, after which, [
3
H] 
thymidine (0.5 µCi) was added for 16 hr. T-cell proliferation was evaluated using a 
scintillation counter and the results are expressed as the mean of triplicate wells. 
 
- 4.2.17 T-cell lines reactivity with abacavir-dependent self peptide 
PBMCs of 8 HLA-B*57:01 positive and negative, abacavir naïve donors (1x10
6
; 0.5 
ml) were exposed to (abacavir + peptide 15; 50 μM and 20 μM respectively, in 0.5 
ml) and cultured for two weeks in T-cell medium. Cultures were supplemented with 
IL-2 on day 6 and day 9. Irradiated autologous PBMCs (5×10
4
 cells/50 μl) and C1R 
APCs (2×10
4
 cells/50 μl) were co-cultured with T-cell lines (10×104 cells/50 μl) in 
the presence of 1) abacavir + peptide 15 (50 μl ; 50 μM and 20 μM respectively; 2) 
abacavir alone (50 μl ; 50 μM); and 3) peptide 15 alone (50 μl ; 20 μM) for 48 hr. T-
cell response was quantified by interferon gamma ELISpot. 
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- 4.2.18 HPLC and LC/MS analysis to isoforms of abacavir-dependent self 
peptide 
Mass spectrometric analysis of the two isoforms of Peptide 15 was conducted to 
confirm amino acids sequence NTVELRVKI, although, slight mass differences at the 
C-terminal position was investigated with the 2 peptides. Differences between 
isoforms in relation to the retention time were investigated by HPLC. The 
comparisons were conducted by Dr. Jenkins Roz in The University of Liverpool 
(Proteomic Laboratory, Department of Pharmacology).  
 
- 4.2.19 Drug-specific responses to isoforms of abacavir-dependent self 
peptide 
Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured with irradiated T2B 
APCs (1×10
4, 50 μl) in the presence and abscence of the C-terminal amide peptide 15 
and the natural peptide 15 (20 μM, 50 μl) +/- abacavir (50 μM, 50 μl) for 48 hr. T-cell 
response was quantified by interferon gamma ELISpot. 
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4.3 Results 
- 4.3.1 Generation of abacavir-specific CD8+ T-cell clones and analysis of 
proliferative response and interferon gamma release 
110 out of 1304 clones were found to proliferate in the presence of abacavir with a 
stimulation index greater than 1.5. Figures 2.1-2.3 in chapter 2 show the proliferative 
response of all clones from 3 donors when cultured with abacavir for 48 hr. All of the 
abacavir-responsive clones secreted interferon gamma, in a drug-concentration-
dependent fashion (Figure 2.6 in chapter 2). Since the interferon gamma ELISpot 
was superior to [
3
H] Thymidine at distinguishing abacavir-specific and non-specific 
clones from one another, interferon gamma release was used as a primary readout for 
all subsequent experiments (Figure 3.5A and B in chapter 3). 
 
- 4.3.2 Abacavir- specific T-cell responses with autologous APC and C1R 
and T2B APCs 
Abacavir CD8
+
 T-cell clones were used to investigate T-cell responses with different 
APCs (C1R and T2B). These APCs were incubated (pulsed) overnight with abacavir 
before co-culturing with T-cell clones. ELISpot images were used for quantifying 
emerging spots and soluble drug was used as a positive control. These studies 
discriminated between abacavir-specific clones activated via PI and altered self-
peptide pathways providing a framework for subsequent peptide assay. Clones 
activated via the PI pathway were activated with soluble abacavir in all three forms of 
APC. This was because the drug binds directly to HLA-B*57:01 expressed on the 
APC surface to activate T-cells (Figure 4.1 A). These clones were not activated with 
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APC pulsed with abacavir for 16 hr (Figure 4.1 B). In contrast, clones activated via 
an altered self-peptide pathway were incubated with abacavir-pulsed autologous APC 
and C1R cells, but not T2B cells. These data show that transport of newly processed 
peptide in the context of HLA-B*57:01 is important for the activation of these clones 
(Figures 4.1 C). 
A. 
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Figure 4.1 (A): Abacavir-specific T-cell responses with autologous APC and C1R 
and T2B APCs. All three APCs were co-cultured with the drug abacavir (50 µM) in 
an atmosphere of 37°C and 95% O2/5% CO2. APCs were counted (1×10
4
 cells/50 μl) 
and irradiated before co-culturing with abacavir-responsive CD8
+
 T-cell clone (5×10
4
 
cells/50 μl). T-cell response was quantified by interferon gamma ELISpot. 
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(TAP deficient) 
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Figure 4.1 (B): Abacavir-specific T-cell responses with autologous APC and C1R and T2B 
APCs. APCs were pulsed overnight with abacavir (50 µM) in an atmosphere of 37°C and 95% 
O2/5% CO2. Next day, APCs were washed with T-cell medium three times, counted (1×10
4
 
cells/50 μl) and irradiated before co-culturing with abacavir-responsive CD8+ T-cell clone 
(5×10
4
 cells/50 μl). No further drug was added. T-cell response was quantified by interferon 
gamma ELISpot. 
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Figure 4.1 (C): Abacavir-specific T-cell responses with autologous APC and C1R and T2B 
APCs. Two representative abacavir-responsive CD8
+
 T-cell clones from different donors are 
shown. APCs were pulsed overnight with abacavir (50 µM) in an atmosphere of 37°C and 95% 
O2/5% CO2. Next day, APCs were washed with T-cell medium three times, counted (1×10
4
 
cells/50 μl) and irradiated before co-culturing with abacavir-responsive CD8+ T-cell clone 
(5×10
4
 cells/50 μl). No further drug was added. T-cell response was quantified by interferon 
gamma ELISpot. Soluble abacavir responses were included in above drug pulsing assay. 
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- 4.3.3 CD8+ T-cell activity with abacavir and abacavir-dependent self-
peptides 
Twenty four cultures containing mixes of 5 peptides each (a total of 120) were 
screened collectively in the presence of abacavir to identify potential self peptide/s 
that could activate abacavir-specific CD8
+
 T-cells. With the exception of peptide mix 
3 (a cocktail of Peptide11 to Peptide15), CD8
+
 clones were not stimulated to secrete 
interferon gamma. Figure 4.2 shows results from 6 clones tested against 24 peptide 
mixes in the presence of abacavir and T2 APCs. Self presentation was assessed by 
culturing abacavir with clones in the absence of APC. Importantly, only peptide mix 
3 was found to contain self-peptide/s capable of activating abacavir-responsive T-cell 
clones (Figure 4.2A).  
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Figure 4.2 (A): Activation of abacavir-specific CD8
+
 T-cell clones in the presence of abacavir and the 
abacavir-dependent self peptides. Data from clones activated with abacavir and a library of 120 self peptides 
are shown. Two abacavir-specific CD8
+
 T-cell clones where the drug-specific response was abolished using 
T2B APCs (i.e. altered peptide concept). Abacavir specific T-cell clones (5×10
4
, 50 μl) were co-cultured with 
irradiated APCs (C1R and T2B cells) (1×10
4, 50 μl) in the presence and absence of a single abacavir 
concentration (50 μM, 100 μl). The clones were also co-cultured with irradiated T2B cells in the presence of 
abacavir + amidated peptide mix (100 μl, 50 μM and 20 μM respectively). The plates were incubated in an 
atmosphere of 37˚C and 95% O2/5% CO2 for 48 hr. T-cell response was quantified by interferon gamma ELISpot. 
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Clones that were not activated with abacavir in the absence of APC, likely via binding 
to endogenous MHC molecules, are depicted in figure 4.2A. As expected these clones 
were stimulated to secrete interferon gamma with abacavir in the presence of fully 
functional C1R cells. In contrast, T-cell responses were not detected under the same 
experimental conditions using T2B cells. Hence, these clones seem to be activated via 
an ''altered-self peptide repertoire'' pathway. Protein processing and transport of the 
processed peptides onto MHC is a prerequisite for the T-cell response. This 
experimental set up with T2B APC allowed us to artificially load synthetic peptides 
onto abacavir-treated APC to assess their ability to activate CD8
+
 clones. All clones 
analysed were activated via this pathway and were stimulated to secrete interferon 
gamma in the presence of abacavir and peptide mix 3 containing peptides 11-15. 
Interferon gamma spot forming units did not exceed 2-fold control values in all other 
experimental conditions. 
 
Clones activated via direct binding to surface MHC are shown in figure 4.2B as a 
comparator. Each of these clones is stimulated to secrete interferon gamma in the 
absence of APC and in the presence of C1R and T2B APC. Thus, it is not possible to 
assess whether these clones are activated or at least receive activation signals in the 
presence of the peptide mixes. 
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Figure 4.2 (B): Activation of abacavir-specific T-cell clones in the presence of abacavir 
and the abacavir-dependent self peptides. Data from four clones activated with abacavir and 
a library of 120 self peptides are shown. Four abacavir-specific CD8+ T-cell clones showing 
a significant response upon abacavir treatment in the presence and absence of APC (i.e. 
p-i concept). Experimental conditions were identical to those described in Figure 4.2A. 
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- 4.3.4 Abacavir-specific clones are activated with a single 9mer peptide 
Peptide mix 3 was further analysed to identify which particular self peptide(s) were 
responsible for the activation of specific clones. Clones activated with abacavir via 
the “altered peptide” pathway (Illing et al, 2012; Norcross et al, 2012; Ostrov et al, 
2012) were selected for all experiments. Furthermore, peptides were included in the 
assay in the presence and absence of abacavir. Figure 4.3 shows three representative 
clones displaying reactivity against only 1 peptide from peptide mix 3, namely 
peptide 15. Furthermore, somewhat surprisingly this peptide consistently activated 
the clone in the presence and absence of abacavir. 
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Figure 4.3: Activation of an abacavir-specific clone with a single abacavir-dependent self-
peptide from peptide mix 3. Clones isolated from HLA-B*57:01 positive blood donors were 
stimulated with C1R and T2B APCs in the presence of peptide 11-peptide 15 (+/- abacavir). 
Abacavir specific T-cell clones (5×10
4, 50 μl) were co-cultured with irradiated APCs (C1R and 
T2B cells) (1×10
4, 50 μl) in the presence and absence of a single abacavir concentration (50 μM, 
100 μl). The clones were also co-cultured with irradiated T2B cells and stimulated with amidated 
peptide 11-15 (20 μM, 50 μl) in presence and absence of abacavir (50 μM, 50 μl). The plates were 
incubated in an atmosphere of 37˚C and 95% O2/5% CO2 for 48 hours. Interferon gamma release 
from a singlet well was measured by ELISpot. Data from three representative clones are shown. 
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- 4.3.5 Dose-dependent activation of abacavir-responsive clones with 
titrated concentrations of peptide 15 
Activation of abacavir-responsive clones with peptide 15 generally displayed dose-
dependent characteristics. Figure 4.4 shows representative clones to illustrate the 
different responses observed. Each concentration of peptide 15 (0.2-20 μM) 
stimulated interferon gamma release from clone 1 when the cells were cultured with 
T2B APCs and abacavir. In the absence of abacavir interferon gamma release was 
only detected with peptide concentrations of 5 μM and above. With clone 2, 
interferon gamma release was detected at peptides concentrations of 2 μM and above 
and no significant difference was observed when the experiment was performed in the 
presence and absence of abacavir. Finally, clone 3 was only activated to secrete 
interferon gamma with the highest concentration of peptide 15 (i.e. 20 μM). 
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Figure 4.4: Activation of abacavir-specific T-cell clones in the presence of 
titrated concentrations of peptide 15. Clones isolated from HLA-B*57:01 positive 
blood donors were stimulated with T2B APCs in the presence of amidated peptide 15 
(0.2-20 μM) +/- abacavir. Interferon gamma release from a singlet well was measured 
by ELISpot. Data from three representative clones are shown. 
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- 4.3.6 Activation of T-cell clones displaying reactivity against other drugs 
with   peptide 15 
Since peptide 15 activated all abacavir ''altered-self'' repertoire responsive clones in 
the presence and absence of abacavir, the next component of the project was to 
investigate the specificity of the peptide specific response. Drug-specific clones from 
patients with (a) flucloxacillin-induced liver injury [n=3 all CD8
+
], (b) co-amoxiclav-
induced liver injury [n=3; 2 amoxicillin responsive (CD4
+
, CD8
+
); 1 clavulanic acid 
responsive (CD4
+
)], and (c) sulfamethoxazole [n=2, CD4
+
] hypersensitivity (clones 
displayed reactivity against the metabolite nitroso SMX) were cultured with 
autologous antigen presenting cells in the presence of optimal concentrations of the 
culprit drug or peptide 15. Flucloxacillin was selected initially as the response of all 
clones to flucloxacillin was HLA-B*57:01 restricted. CD8
+
 T-cell clones were 
stimulated to secrete interferon gamma following exposure to flucloxacillin; 
surprisingly, peptide 15 was able to weakly activate two clones. Similar results were 
obtained with sulfamethoxazole-responsive CD4
+
 clones. Peptide 15 activated two 
sulfamethoxazole-responsive CD4
+
 clones to proliferate to approximately 30-50% of 
that seen with the drug antigen (Figure 4.5). Interestingly, CD4
+
 and CD8
+
 clones 
from patients with co-amoxiclav-induced liver injury were activated to secrete 
interferon gamma with the 2 components of co-amoxiclav (amoxicillin and clavulanic 
acid); however, peptide 15 failed to stimulate a response. 
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Figure 4.5 (A): Activation of flucloxacillin-responsive CD8
+
 T-cell clones with peptide 15. 
Autologous APCs (1×10
4
 cells/50 μl) were irradiated and co-cultured with drug-specific T-cell 
clones (5×10
4
 cells/50 μl) +/- drug (1.5 mM flucloxacillin/100 μl) and amidated peptide 15 (20 
μM) for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. The ELISpot plates were then 
developed according to manufacturer’s protocol and T-cell activity was measured from a singlet 
well by counting emerging spots using an AID ELISpot reader. SFU=Spots forming units. 
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Figure 4.5 (B): Activation of sulfamethoxazole-responsive CD4+ T-cell clones with peptide 
15. Autologous APCs (1×104 cells/50 μl) were irradiated and co-cultured with drug-specific T-
cell clones (5×104 cells/50 μl) +/- drug (50 μM nitroso sulfamethoxazole/100 μl) and amidated 
peptide 15 (20 μM) for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. The ELISpot 
plates were then developed according to manufacturer’s protocol and T-cell activity was 
measured from a singlet well by counting emerging spots using an AID ELISpot reader.  
SFU=Spots forming units. 
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Figure 4.5 (C): Activation of co-amoxiclav-responsive CD4+ and CD8
+
 T-cell clones 
with peptide 15. Autologous APCs (1×104 cells/50 μl) were irradiated and co-cultured 
with drug-specific T-cell clones (5×104 cells/50 μl) +/- drug (1mM amoxicillin; 0.1 mM 
clavulanic acid/100 μl) and amidated peptide 15 (20 μM) for 48 hr in an atmosphere of 
37°C and 95% O2/5% CO2. The ELISpot plates were then developed according to 
manufacturer’s protocol and T-cell activity was measured from a singlet well by counting 
emerging spots using an AID ELISpot reader. SFU=Spots forming units. 
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(D) 
 
Figure 4.5 (D): Activation of sulfamethoxazole nitroso-responsive T-cell clones 
with peptide 15. T-cell proliferation of nitroso sulfamethoxazole-responsive T-
cell clones was evaluated from two blood donors (RK-61 and 33). T-cell clones 
(5×10
4
 cells/50 μl) were co-cultured with irradiated autologous APCs (1x104 cells/50 
μl) +/- nitroso sulfamethoxazole (50 μM) or amidated peptide 15 (20 μM) using 96-
well U-bottom microplates. The plates were then incubated for 48 hr in an atmosphere 
of 37°C and 95% O2/5% CO2. [
3
H] thymidine (0.5 μCi) was added for 16 hr. Each bar 
represents a T-cell proliferation mean of two measurements to one tested T-cell clone 
sample. 
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- 4.3.7 PBMCs reactivity with abacavir self peptide 
Given the surprising activation of nitroso sulfamethoxazole-responsive clones with 
peptide 15, we next sought to estimate the abundance of peptide 15 responsive T-cells 
in PBMCs of HLA-B*57:01 positive and negative donors. PBMCs of 8 HLA-
B*57:01 positive and 8 HLA-B*57:01 negative naïve donors (1x10
6
; 50 µl) were 
exposed to abacavir, peptide 15, and abacavir + peptide 15 (50 μM and 20 μM 
respectively in 0.5 ml). Secretion of interferon gamma was measured after 48 hr 
(Figure 4.6A). PBMC from HLA-B*57:01 positive and negative donors were not 
stimulated to secrete interferon gamma with abacavir, peptide 15 or the drug peptide 
mix. Similarly, lymphocyte proliferation was evaluated among 8 of those positive and 
negative HLA-B*57:01 donors. PBMC from 3 donors were stimulated to proliferate 
in the presence of abacavir and peptide 15; however, the strength of the induced 
response (less than 1000 cpm) was weak. Thus, it is difficult to draw firm conclusions 
from the results (Figure 4.6B). 
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Figure 4.6: (A) Cytokine secretion from PBMC of 16 blood donors. ELISpot 
plates were coated with human interferon gamma antibody and incubated overnight at 
4°C. PBMCs (5×10
4
 cells/50 μl) were irradiated and co-cultured with PBMCs (1×106 
cells/50 μL) in the presence of 1) abacavir + peptide 15; 2) abacavir alone; and 3) 
peptide 15 alone for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. The 
ELISpot plates were then developed according to manufacturer’s protocol and T-cell 
activity was measured from a singlet well by counting emerging spots using an AID 
ELISpot reader. SFU=Spots forming units. (B) Lymphocyte proliferation from 
PBMC of 8 blood donors. PBMCs (1.5×10
5
 cells/100 μL) were treated with (100 μl) 
abacavir 50 μM, peptide 15 amidated 20 μM, and abacavir + peptide 15 50 μM and 20 
μM respectively. The average value to each condition conducted in triplicate is shown 
and standard error calculated. P < 0.05 * states statistical analysis used here. 
 
- 4.3.8 Activation of T-cell lines with abacavir-dependent self peptides 
PBMCs of 8 HLA-B*57:01 positive and negative, abacavir naïve, donors (1x10
6
; 0.5 
ml) were exposed to (abacavir + peptide 15; 50 μM and 20 μM respectively, in 0.5 
ml) and cultured for two weeks in T-cell medium. Cultures were supplemented with 
IL-2 on day 6 and day 9. T-cell lines were tested against autologous PBMCs and C1R 
as APCs in the presence of 1) abacavir + peptide 15; 2) abacavir alone; and 3) 
peptide 15 alone. A significant increase in interferon gamma release was detected in 
a positive HLA-B*57:01 donor (202) after re-exposure to abacavir and peptide 15 
(Figure 4.7). The absence of a response to abacavir in cell line is consistent with 
previous unpublished data at the University of Liverpool. The similar negative results 
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with peptide 15 (in most donors) indicate that the frequency of peptide-specific T-
cells in PBMC is low. 
 
Figure 4.7: Interferon gamma secretion from T-cell lines generated from 8 naïve 
donors by culturing PBMC with abacavir and peptide 15. ELISpot plates were 
coated with human interferon gamma antibody and incubated overnight at 4°C. 
Autologous PBMCs (5×10
4
 cells/50 μl) and C1R APCs (2×104 cells/50 μl) were 
irradiated and co-cultured with T-cell lines (10×10
4
 cells/50 μl) +/- drug and/or peptide 
15 for 48 hr in an atmosphere of 37°C and 95% O2/5% CO2. The ELISpot plates were 
then developed according to manufacturer’s protocol and T-cell activity was measured 
from a singlet well by counting emerging spots using an AID ELISpot reader. P < 0.05 
* states statistical analysis of two way ANOVA. SFU=Spots forming units. 
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- 4.3.9 Activation of abacavir-responsive clones with amidated and natural 
isoforms of peptide 15 
T-cell responses with the two isoforms of peptide 15 (i.e. C-terminal amidated 
peptide 15 and natural peptide 15) were investigated +/- abacavir to determine 
whether amidation alters the T-cell response. Figure 4.8 C shows the structure of 
peptide 15 and mass spectrometric analysis of the amidated and un-amidated forms. 
Figure 4.8 A shows all 9mer amino acids and how isoleucine mass slightly differs 
during natural and amidated state, ultimately discriminating structural identity. 
Moreover, HPLC retention time for peptide 15 was reported earlier with C-terminal 
amide isoform (Figure 4.8 B). 
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Figure 4.8: Analysis of the two isoforms of Peptide 15 (A) The spectrum of peptide 
15 illustrates similar amino acids sequence NTVELRVKI, however, slight mass 
difference at C-terminal position was noted with the 2 peptides. (B) Differences 
between isoforms were noted in retention time, with the amidated form reaching 
earlier. (C) Structural representation of peptide 15 linking the 9 amino acids 
NTVELRVKI together. 
 
As expected the amidated peptide activated abacavir-responsive clones in the 
presence of T2B APC and the strength of the response was enhanced when abacavir 
was added to the culture medium. The natural isoform of the peptide did not activate 
the clones. However, when abacavir and natural peptide 15 were cultured together 
with T2B APC significant interferon gamma release was detected. Figure 4.9 A and 
B show data from 2 clones in graphical form and raw ELISpot images, respectively. 
(A) 
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Figure 4.9: Activation of abacavir-
responsive clones with amidated and 
natural forms of peptide 15 (A) the C-
terminal amide peptide 15 which is 
considered a more stable isoform versus 
the natural peptide 15. Clones isolated 
from HLA-B*57:01 positive blood donors 
were stimulated with irradiated T2 APCs 
in the presence of self peptide 15 +/- 
abacavir. Interferon gamma release was 
measured from a singlet well by ELISpot. 
(B) Original ELISpot images. 
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4.4 Discussion 
In our previous studies (chapter 2), we successfully cloned abacavir-responsive 
CD8+ T-cells from PBMC of healthy HLA-B*57:01+ human donors. It is possible to 
isolate abacavir-responsive clones from all HLA-B*57:01+ donors, even though only 
~50% of HLA-B*57:01+ abacavir-exposed patients develop hypersensitivity. During 
the cloning process, PBMC are exposed to soluble abacavir for 14 days to enrich the 
number of drug-responsive T-cells. Thus, T-cells could theoretically be activated via a 
PI pathway involving direct abacavir binding to MHC molecules expressed on the 
surface of APCs or an “altered-self peptide repertoire” pathway which involves the 
binding of abacavir to endogenous MHC molecules for the time it takes to process 
proteins into MHC class I binding peptides. Both pathways of drug-specific activation 
should be MHC class I-restricted and indeed the addition of MHC class I blocking 
antibodies to cytokine release assays prevents the activation of abacavir-responsive 
CD8
+
 T-cells. It is relatively straight-forward to discriminate between the two 
pathways of T-cell activation using APC pulsing experiments or fixation of APCs, 
which blocks protein processing. Pulsing experiments involve the culture of APCs 
with drug for different durations, normally 1-16 hr, followed by repeated washing and 
the addition of the pulsed cells to cloned T-cells in the absence of soluble drug. Our 
early studies are in agreement with the findings of Adam and Bell (Adam et al, 2012; 
Adam et al, 2014; Bell et al, 2013), in that abacavir-responsive CD8+ clones were 
found to be activated via both pathways. Approximately 50% of the clones were 
activated with abacavir in the presence of fixed APCs and with these clones pulsing 
assays yielded completely negative results, which indicates that the drug binds 
directly to surface MHC molecules to activate the T-cells. In contrast, with the other 
clones, proliferative responses and cytokine release are blocked by fixation of APCs, 
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while APCs pulsed with abacavir for 16 hr provide an activation signal for the T-cells. 
These clones are likely activated via the “altered-self peptide repertoire” proposed by 
Illing (Illing et al, 2012) and others (Norcross et al, 2012; Ostrov et al, 2012). 
Interestingly, shorter pulses (1-2 hr) do not activate T-cells, which indicates that the 
drug must interact with HLA-B*57:01 for the duration of protein processing for the 
so-called “altered-self peptide repertoire” to be seen by T-cells. 
 
So what does this data tell us? First, as it is possible to clone abacavir-responsive T-
cells from all HLA-B*57:01+ donors, activation of the adaptive immune system 
following drug exposure is not the primary determinant of susceptibility (even though 
T-cells are the likely drivers of tissue injury). This effectively rules out infection with 
common viruses (e.g., herpes viruses) as a primary source of antigenic determinants 
for the T-cells. It is reasonable to assume that an imbalance in co-stimulatory/co-
inhibitory signaling, which might be disease related, or a deficiency in Treg activity 
are important in determining whether abacavir exposure in HLA-B*57:01+ donors 
results in an aberrant immune response and tissue injury. Second, activation of T-cells 
via a PI pathway indicates that certain clones “see” the drug molecule as a component 
of the T-cell receptor triggering interaction as originally proposed by Pichler (Pichler 
et al, 2011). This is important as it emphasizes that the altered peptide repertoire 
pathway is not the only mechanism of drug-specific T-cell activation in abacavir 
hypersensitivity. Furthermore, the broad applicability of the pathway has been 
questioned as flucloxacillin, an HLA-B*57:01 binding drug antigen (Daly et al, 2009; 
Monshi et al, 2013), does not alter the repertoire of peptides that bind to HLA-
B*57:01 (Norcross et al, 2012); carbamazepine only subtly (if at all) alters the 
repertoire of peptides that bind HLA-B*15:02 (Illing et al, 2012) and HLA-A*31:01 
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(personal communication), the HLA alleles associated with carbamazepine 
hypersensitivity; and despite intensive research, other examples of clones activated 
via an altered-self peptide repertoire of HLA binding peptides has not been 
forthcoming. Third, notwithstanding the above discussion, clones activated via the 
altered-self peptide repertoire pathway are detectable in all HLA-B*57:01+ donors. 
The concept suggests that T-cell receptors expressed on these clones are activated via 
triggering signals delivered by peptides and not the drug itself as it is buried deep in 
the MHC peptide binding cleft (Pavlos et al, 2015). This can be modeled 
experimentally, using B-cell lines C1R and T2B as APCs. These lines are so useful 
because they express a single transfected class I molecule, HLA-B*57:01, and differ 
in only one fundamental pathway. T2B cells are TAP deficient and do not transport 
and load processed peptides onto class I molecules and therefore endogenous 
antigenic peptides are not displayed on the cell surface. In contrast, C1R cells are 
fully functional APCs. All abacavir-responsive clones are activated with the drug and 
C1R cells, whereas only clones activated via a PI pathway are stimulated to 
proliferate and secrete cytokines with T2B cells and the drug (or in the absence of 
professional APC). This experimental set-up provided the opportunity to begin to 
assess whether the altered repertoire of abacavir-dependent self-peptides actually 
activate abacavir-responsive clones. One hundred and twenty 9mer peptides displayed 
within HLA-B*57:01 only after abacavir binding were synthesized. This represents 
approximately half of the altered repertoire of 9mer peptides from the unpublished list 
of Illing (Illing et al, 2012). Peptides were selected randomly with their absence from 
HLA-B*57:01 elution minus abacavir the only parameter taken into account. Peptides 
were added externally to abacavir-treated T2B cells, which on their own do not 
activate clones. The peptides replace natural B*57:01+ binding peptides embedded in 
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the binding cleft on the surface of the APC, mimicking the natural MHC-abacavir-
peptide formed endogenously in the fully functional antigen presenting cells and are 
ultimately displayed on the surface. 
  
In initial experiments, clones were cultured with T2B cells in the presence of abacavir 
and mixes of 5 peptides. All relevant controls, clones alone, clones and C1R cells and 
clones and T2B cells (+/- abacavir, but – peptide) were included in the experimental 
design. Surprisingly, clones activated via an altered self-peptide repertoire pathway 
were stimulated to secrete interferon gamma with T2B cells, abacavir and only 1 
peptide mix. Experiments focusing on the 5 peptides within this mix revealed that 
clones were activated by 1 peptide, peptide 15. The activation of clones was peptide 
concentration-dependent and was even detected in the absence of abacavir, suggesting 
that under the relatively forced in vitro conditions (i.e., microM peptide), the peptide 
binds sufficiently to abacavir-free HLA-B*57:01 and cross-links the specific T-cell 
receptors.  
 
The sequence of the peptide that activates clones is NTVELRVKI. It is from dolichyl-
diphosphooligosaccharide-protein glycosyltransferase subunit 2 
(http://www.uniprot.org/uniprot/P04844), an endoplasmic reticulum / membrane 
protein involved in protein glycosylation. It also catalyzes the transfer of high-
mannose oligosaccharides to asparagine residues on nascent polypeptides (Yamagata 
et al, 1997). The protein is a component of the putative endoplasmic reticulum 
lumenal domain expressed in all cell types. One-third of all cellular proteins are 
translocated into the endoplasmic reticulum lumenal domain where post-translational 
modification, folding, and oligomerization occur. The endoplasmic reticulum 
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provides a unique oxidizing compartment for the folding of membrane and secretory 
proteins that are destined to the cell surface, as well as for proteins destined to other 
intracellular organelles, such as lysosomes and the Golgi compartment. Whether the 
origins of the peptide are relevant to the development of abacavir hypersensitivity and 
indeed influence susceptibility are open to debate. Nevertheless, our data show that 
most abacavir-dependent “altered-self-peptide” repertoire-specific T-cells are 
activated by a very restricted number of peptides. These data provide the first 
evidence that the display of altered-self peptides by HLA-B*57:01 is relevant for the 
activation of drug-responsive T-cells. Our study utilized only around 50% of the 
observed altered repertoire of 9mer peptides displayed by antigen presenting cells in 
the presence of abacavir. Thus, it is likely that other peptides will stimulate a similar 
CD8+ T-cell response. Furthermore, it should be noted that our study focused on 
9mer peptides. It is possible that other peptides with 8-12 amino acids will activate 
the clones.  
 
The next objective was to explore the specificity of the peptide-specific T-cell 
response (i.e., does NTVELRVKI only activate abacavir-responsive CD8+ clones?). 
Searching Google (www.google.co.uk) and the PubMed (www.ncbi.nlm.nih.gov) 
databases using search terms NTVELRVKI and the name of the protein revealed no 
published literature linking the protein to the activation of antigen-specific CD8+ T-
cells. Thus, CD4+ and CD8+ clones with specificity to other drug antigens 
(flucloxacillin, amoxicillin, clavulanic acid and nitroso sulfamethoxazole) were 
acquired from other students at the MRC Centre for Drug Safety Science and cultured 
in the presence of autologous antigen presenting cells and NTVELRVKI prior to 
analysis of proliferation or cytokine release. Of particular relevance was the 
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experiments with flucloxacillin-responsive clones as the drug-derived antigen is also 
presented to T-cells in the context of HLA-B*57:01, albeit via a hapten pathway 
(Monshi et al, 2013). CD8+ clones displaying reactivity against amoxicillin and 
CD4+ clones with reactivity against amoxicillin and clavulanic acid were not 
activated with NTVELRVKI. In contrast, NTVELRVKI activated a moderate 
(compared with the drug response) proliferative response of nitroso 
sulfamethoxazole-responsive CD4+ clones. CD8+ clones displaying reactivity against 
flucloxaicillin and CD4+ clones with reactivity against nitroso sulfamethoxazole were 
stimulated to secrete interferon gamma. These data were unexpected and lead us to 
hypothesise that NTVELRVKI might act as some form of polyclonal T-cell activator. 
To address this, PMBC were cultured with NTVELRVKI and proliferative responses 
and interferon gamma release were measured. Furthermore, T-cell lines were 
generated by culturing PBMC with abacavir and NTVELRVKI for 14 days. Lines 
were then restimulated with NTVELRVKI and antigen specificity measured. Both 
experiments yielded largely negative results indicating that the frequency of 
NTVELRVKI responsive CD4+ and CD8+ T-cells in HLA-B*57:01 positive donors 
is very low. The reason why flucloxacillin-responsive CD8+ clones and nitroso 
sulfamethoxazole-responsive CD4+ clones were stimulated with NTVELRVKI 
remains unresolved. However, it is possible that drug-reactive memory T-cell cross 
react with some peptide epitopes; this phenomenon is discussed in more detail in the 
final discussion. 
 
C-terminal amidation is one of the most common post translational modifications, 
occurring naturally on a wide variety of peptides such as aureins, caerins and melittin 
(Dennison & Phoenix, 2011). Early studies by Rothbard et al. (Rothbard et al, 1989) 
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proposed that amidation of the carboxy terminus of a class II peptide derived from 
influenza haemagglutinin enhances HLA-DR binding, when compared with the 
natural structure. The amidated peptide was able to activate clones at concentrations 
approximately two orders of magnitude lower than the natural peptide. The authors 
proposed that amidation generated a peptide that can bind more effectively to HLA-
DR than the natural peptide. Others have replicated these early studies (Allen et al, 
1989; Brinckerhoff et al, 1999; La Rosa et al, 2001; Maillere et al, 1995; Rubio-
Godoy et al, 2002); Brinckeroff et al, found that terminal amidation of peptides 
inhibits (or at least delays) degradation by serum peptidases and enhances the stability 
of the peptide MHC interaction. Studies on C-terminally amidated isoforms of the 
13mer peptide indolicidin (Falla & Hancock, 1997) and 16mer peptide modelin 
(Dennison & Phoenix, 2011) showed increased potency against microorganisms 
compared to non-amidated isoforms, which was thought to be due to enhanced 
stabilization of the amidated isoform and its ability to co-ordinate with the cell 
surface. All of the peptides synthesized for use in the current study were C-terminally 
amidated. After identifying T-cells that were responsive against a single peptide, this 
peptide was also synthesized in its native form. RP-HPLC/MS confirmed the peptide 
sequence and the presence or absence of C-terminal amidation. Consistent with the 
amidated peptide, the native peptide was capable to activate abacavir-responsive 
CD8
+
 T-cell clones when cultured with T2B cells. Interferon gamma secretion was 
detected with certain clones that were incubated with T2B cells, native peptide and 
abacavir. The strength of the response was significant when compared with the 
amidated isoform. Consistent with the altered self peptide concept, we found the two 
isoforms of peptide 15 (C-terminal amidated and unmodified) with amino acid 
sequence NTVELRVKI were capable of triggering abacavir-responsive CD8
+
 T-cell 
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clones. Importantly, all other peptides were unable to trigger a T-cell response. Thus, 
providing experimental evidence that a highly restricted repertoire of the altered self 
peptides displayed by HLA-B*57:01 were able to activate abacavir specific CD8
+
 T-
cell clones. In on-going experiments, researchers in Liverpool are comparing the 
ability of native and amidated forms of NTVELRVKI to complex with HLA-B*57:01 
and their stability in serum-containing medium. 
 
Collectively, we have utilized a relatively large panel of abacavir-dependent HLA-
B*57:01 binding self peptides to understand the mechanism of T-cell activation. Our 
data provides experimental evidence that a 9mer peptide (Peptide 15; NTVELRVKI) 
is responsible for the polyclonal CD8
+
 T-cell activation seen in abacavir 
hypersensitive patients. Furthermore, the discovery that most discovered unique 
altered self peptides are unable to induce CD8
+
 T-cell activation indicated that the 
immune response is highly peptide specific. 
 
In conclusion, these studies describe the identification of a single T-cell stimulatory 
peptide within the 9mer repertoire of altered self-peptides displayed by antigen 
presenting cells in the presence of abacavir.    
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Chapter 5    Final Discussion 
I initially generated a panel of abacavir-responsive CD8+ T-cell clones from different 
HLA-B*57:01 positive donors to address 4 main research objectives: (1) confirm that 
T-cells are activated with the drug via 2 pathways; (2) characterize the exclusivity of 
the HLA-B*57:01 restricted T-cell response; (3) identify the abacavir-dependent 
altered-self peptides that activate T-cells; and (4) determine whether it was possible to 
design out abacavir-specific HLA-B*57:01-restricted T-cell responses through 
structural modification, without loss of pharmacological activity.  
 
Activation of abacavir-specific CD8+ clones was HLA class I restricted and indeed 2 
pathways of T-cell activation were observed. Certain clones were activated directly 
with the drug sometimes even in the absence of professional antigen presenting cells. 
Antigen presenting cells pulsed with abacavir overnight and presumably displaying 
altered-self peptides within surface HLA-B*57:01 molecules did not activate these 
clones and inhibition of processing did not block the response. In contrast, other 
clones were activated with abacavir pulsed antigen presenting cells and inhibition of 
antigen processing blocked the drug-specific response. These clones are thought to be 
activated with HLA-B*57:01 binding self-peptides displayed only in the presence of 
abacavir. Clones activated via both pathways were included in experiments (1) with 
abacavir analogues and (2) exploring HLA allo-reactivity, whereas experiments 
identifying abacavir-dependent peptide-specific T-cell responses only utilized clones 
activated with abacavir-pulsed antigen presenting cells.   
 
A panel of antigen presenting cells displaying different HLA-B alleles was cultured 
with abacavir and abacavir-responsive T-cell clones and T-cell activation was 
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assessed by measurement of interferon gamma secretion (chapter 2). All clones were 
activated with autologous antigen presenting cells and antigen presenting cells from 
other volunteers expressing HLA-B*57:01. Somewhat surprisingly, clones were also 
stimulated to secrete interferon gamma in the presence of antigen presenting cells 
displaying different HLA-B alleles. Adam et al. (2014) have reported that abacavir 
activates certain T-cells when bound to HLA-B*58:01, which is structurally related to 
HLA-B*57:01. However, our data are the first to show responses with structurally 
disparate HLA molecules. Although we have not assessed the pathway of T-cell 
activation with these antigen presenting cells, the data do indicate that abacavir 
interacts with a variety of HLA molecules in vitro. In on-going experiments, 
researchers at the Centre for Drug Safety Science are attempting to clone T-cells from 
donors expressing several of these HLA-B alleles. If successful similar experiments 
with antigen presenting cells expressing different HLA-B alleles will be conducted.  
 
Antigenic peptides differ in their capacity to promote T-cell responses among donors 
expressing variant HLA alleles since individual peptides bind either in an HLA allele 
selective fashion or more broadly, interacting with proteins encoded by multiple 
HLA-alleles. Influenza virus hemaglutinin HA 307–319 peptide represents an 
example of a peptide capable of binding multiple HLA-DR alleles, such as DR1, 
DR4, and DR5 (Pavlos et al, 2015). Furthermore, herpes simplex virus-specific 
CD8αα+ tissue-resident T cells were found persistent in the skin for prolonged time 
and cause rapid cytotoxicity to cells expressing low levels of herpes simplex virus 
upon re-challenge (Zhu et al, 2013). Hence, T-cells have been proposed to cross react 
with different endogenous peptides especially those from a pathogen or during organ 
transplantation that were not previously tolerized and alert the immune system. 
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Memory T-cell may cross-react with endogenous peptide presented in the presence of 
drug through the newly proposed altered self-peptide repertoire pathway. A major 
objective of my studies was to screen a library of 9mer self-peptides that are uniquely 
displayed by HLA-B*57:01 molecules expressed on antigen presenting cells treated 
with abacavir (chapter 4). Peptide 15 NTVELRVKI was shown to trigger abacavir-
responsive T-cell clones. All other peptides analyzed yielded negative results. 
Experiments using PBMC from HLA-B*57:01 found that the peptide only activated a 
small number of T-cells. These data provide the sequence of the first abacavir-
dependent altered-self peptide that activates abacavir-specific T-cells. It is possible 
that other T-cell stimulatory peptides exist as our analysis included around 50% of the 
9mer altered-self peptide repertoire. However, our data do show that the number of 
peptides able to activate abacavir-specific T-cells will be limited.  Surprisingly, the 
same peptide was able to activate certain flucloxacillin-responsive T-cell clones from 
HLA-B*57:01 positive donors. Apparently, this indicates how memory T-cells can 
cross react endogenous peptide and provide robust in vitro evidence of cross-reactive 
T-cell recognition. Future studies are needed to evaluate drug-HLA binding alongside 
T-cell responses to evaluate whether drugs other than abacavir activate T-cells via this 
mechanism.  
 
Our data discussed in detail above show that abacavir activates T-cells via 2 different 
pathways. Through the generation of T-cell clones from HLA-B*57:01 positive 
donors it is possible to discriminate between each pathway. Importantly both 
pathways involve the direct binding of abacavir to HLA-B*57:01. Thus, it should be 
possible to modify the structure of abacavir to restrict the binding interaction and 
prevent T-cell responses.  
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Previous studies investigating the immunogenicity of abacavir included compounds 
lacking the 6-cyclopropyl moiety (carbovir, didanosine and guanosine) in their 
analysis. Each of these compounds did not activate abacavir-reactive CD8
+
 T-cells 
(Chessman et al, 2008). Thus, in my studies, 2 groups of structural analogues with 
differences around the 6-cyclopropyl group were synthesized and assayed for HLA-
B*57:01 binding and T-cell and anti-viral activity. By modifying the 6-cyclopropyl 
moiety it was possible to identify analogues that did not activate T-cells, but retained 
pharmacological activity. In silico modelling was utilised to study the HLA-B*57:01 
binding interaction (e.g. hydrogen bonds and van der wall contacts). The model that 
was developed successfully predicted which of the analogues would activate T-cells 
and in on-going studies the same model is been used to design a compound that may 
be taken forward in the long-term as a replacement for abacavir. 
 
In conclusion, drug hypersensitivity is currently receiving a higher global interest 
which is reflected in an increased number of recent publications. This has been driven 
largely by the elegant work of independent researchers studying abacavir 
hypersensitivity. These studies have shown that the drug interaction with MHC is 
extremely complex and not easily explained by a single mechanism. My studies have 
contributed to this work in several ways. Of particular importance is (1) the 
identification of a single 9mer peptide that activates abacavir-specific T-cells and (2) 
development of a strategy to design-out abacavir hypersensitivity through an 
integrated approach incorporating pharmacological and immunological analyses 
alongside computer modelling. It remains uncertain whether classical antigen 
processing and presentation of hapten-modified proteins is involved in the activation 
of abacavir-specific T-cells, especially those isolated from hypersensitive patients. It 
Chapter 5    
 
181 
should be noted that most published work focused on in vitro investigations which 
might not necessarily match the in vivo situation. Thus, in vivo research would 
substantially facilitate our understanding and enable us to reach definitive 
conclusions.
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Appendix: Chapter 2 
Table 1 Amino acids sequence differences of HLA-B*57:01 and allo-HLA 
stimulatory molecules (-B*58:01, -B*13:02, -B*44:03, -B*15:01, -B*51:01, -
B*18:01, and -B*27:05). 
 
Appendix: Chapter 3 
Experimental Procedure: Chemical synthesis 
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Appendix: Chapter 2 
Table 1 Amino acids sequence differences of HLA-B*57:01 and allo-HLA 
stimulatory molecules (-B*58:01, -B*13:02, -B*44:03, -B*15:01, -B*51:01, -
B*18:01, and -B*27:05).  
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** Mismatches between sequences were determined by sequence alignment tool 
of the EMBL-European Bioinformatics Institute (www.ebi.ac.uk). Red box 
highlights position 97 which known as a determining F pocket residue (March et al, 
2000). This amino acid residue involved in MHC peptide binding groove, which we 
speculate is critical anchor position for (1) the abacavir-MHC-T-cell receptor 
interaction and (2) allogenicity activation. Among all positions determining B and F 
pocket of HLA-B* alleles, only position 97 was substituted in all allo-HLA 
stimulatory molecules with R, T and/or N residues. 
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Appendix: Chapter 3 
Experimental Procedure 
 
- Chemical synthesis 
 
 
 
((1S,4R)-4-((2,5-Diamino-6-chloropyrimidin-4-yl)amino)cyclopent-2-en-1-
yl)methanol 6:  To (1S,4R)-4-amino-2-cyclopentene-1-methanol tartrate salt 4 (1 g, 4 
mmol) in n-BuOH (10 mL) was added DADCP 5 (0.69 g, 4 mmol) and NaHCO3 (1.12 
g, 13 mmol) and the mixture was allowed to stir for 16 hr at 95 °C.  The mixture was 
cooled and filtered under vacuum. The resulting solvent from the filtrate was removed 
in vacuo.  The crude product was purified by column chromatography (1:49 to 1:24 
MeOH−DCM) to yield 6 (0.52 g, 53%) as a pale brown solid.  m.p.: 157-159 °C (lit. 
m.p. 158.5-160.5 °C). 
1
H NMR (MeOD):  5.87 (ddd, J = 5.5, 2.0, 1.9 Hz, 1H), 5.80 
(ddd, J = 5.6, 2.0, 2.0 Hz, 1H), 5.07-5.15 (m, 1H), 3.47-3.56 (m, 1H), 3.28 (dt, J = 
3.2, 1.6 Hz, 1H), 2.79-2.83 (m, 1H), 2.53 (ddd, J = 13.4, 6.4, 6.4 Hz, 1H), 1.36 (ddd, J 
= 13.4, 6.3, 5.9 Hz, 1H). 
13
C NMR (MeOD):  158.2, 157.3, 143.2, 135.8, 133.9, 
114.4, 66.4, 57.8, 57.7, 35.8.  m/z (ES+) 256.0955 calculated for C10H15N5O
35
Cl:  
[M+H]
+
 256.0965 and 258.0928 calculated for C10H15N5O
37
Cl:  [M+H]
+
 258.0936.  
IR (cm
-1):  3451 (N−H), 3324 (N−H), 3125 (br, O−H), 2931 (C−H), 1570 (C=C 
aromatic), 1430 (CH2), 690 (C−Cl). 
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((1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 2:  To 
a solution of 6 (0.5 g, 2 mmol) in n-BuOH (15 mL) was added TEOF (0.4 mL, 2.4 
mmol) and H2SO4 (0.05 μL, 0.1 mmol). The brown solution was allowed to stir for 20 
hr at 70 °C.  The solution was allowed to cool whereupon the solvent was removed in 
vacuo and the crude mixture was purified by column chromatography (1:99 to 5:95 
MeOH−DCM) to yield 2 (0.45 g, 87%) as a brown solid.  m.p.:  158-161 °C (lit. m.p. 
160-162 °C). 
1
H NMR (CDCl3):  7.95 (s, 1H), 6.18 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 
5.82 (ddd, J = 5.5, 2.2, 2.0 Hz, 1H), 5.52-5.56 (m, 1H), 3.85 (dd, J = 10.7, 4.2 Hz, 
1H), 3.76 (dd, J = 10.7, 3.9 Hz, 1H), 3.48 (MeOH), 3.09-3.13 (m, 1H), 2.81 (ddd, J = 
14.4, 6.4, 6.2 Hz, 1H), 1.98 (ddd, J = 14.4, 6.2, 5.3 Hz, 1H).  
13
C NMR (CDCl3):  
159.1, 153.5, 151.6, 142.2, 139.5, 130.0, 115.9, 65.0, 61.1, 48.1, 33.6.  m/z (ES+) 
288.0626 calculated for C11H12N5O
23
Na
35
Cl:  [M+Na]
+
 288.0628 and 290.0603 
calculated for C11H12N5O
23
Na
37
Cl:  [M+Na]
+
 290.0599.  IR (cm
-1
):  3325 (N−H), 
3205 (N−H), 1581 (C=C aromatic), 1246 (C−O), 640 (C−Cl). 
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General Procedure A:  To a solution of 2 (1 eq) in MeOH (10 mL) was added the 
primary or secondary amine (2 eq) and the solution was allowed to stir overnight at 
60-70 °C.  The mixture was allowed to cool and the MeOH was removed in vacuo.  
The crude solid was purified by column chromatography (1:49 to 1:19 MeOH−DCM) 
to yield the appropriate product. 
 
 
 
General Procedure B:  To a solution of 2 (1 eq) in the appropriate alcohol reagent (1 
mL) was added NaH (60% dispersed in mineral oil, 3 eq) and the solution was heated 
to 80 C and allowed to stir for 4 hr.  The mixture was allowed to cool, diluted with 
1:99 MeOH-DCM and purified by column chromatography (3:97 to 6:94 
MeOH−DCM) to yield the appropriate product. 
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((1S,4R)-4-(2-Amino-6-(cyclobutylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 7:  
General Procedure A was followed to yield 7 (71 mg, 62%) as a cream coloured solid.  
m.p.:  180-183 °C (lit. m.p. 181-183 °C). 
1
H NMR (CDCl3):  7.46 (s, 1H), 6.08 (ddd, 
J = 5.2, 2.1, 2.0 Hz, 1H), 6.01 (br s, 1H), 5.73 (ddd, J = 5.2, 2.0, 1.9 Hz, 1H), 5.37-
5.41 (m, 1H), 4.66 (br s, 1H), 3.85 (dd, J = 10.3, 4.0 Hz, 1H), 3.75 (dt, J = 10.8, 3.2 
Hz, 1H), 3.48 (MeOH), 3.07-3.08 (m, 1H), 2.75 (ddd, J = 14.5, 6.1, 6.0 Hz, 1H), 2.38-
2.39 (m, 2H), 2.09 (ddd, J = 14.5, 6.0, 5.6 Hz, 1H), 1.89-1.94 (m, 2H), 1.70-1.73 (m, 
2H).  
13
C NMR (CDCl3):  159.6, 154.7, 138.5, 137.1, 130.8, 115.4, 65.5, 61.8, 48.2, 
32.9, 32.1, 15.4.  m/z (ES+) 301.1783 calculated for C15H21N6O:  [M+H]
+
 301.1777.  
IR (cm
-1):  3313 (N−H), 3213 (N−H), 2938 (C−H), 1589 (C=C aromatic), 1477 
(CH2), 1392 (CH3), 1257 (C−N), 1033 (C−O). 
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((1S,4R)-4-(2-Amino-6-(cyclopentylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 8:  
General Procedure A was followed to yield 8 (0.10 g, 85%) as a pale brown solid.  
m.p.:  142-145 °C (lit. m.p. 143-146 °C). 
1
H NMR (CDCl3):  7.47 (s, 1H), 6.10 (ddd, 
J = 5.5, 2.1, 2.1 Hz, 1H), 6.02 (br s, 1H), 5.76 (ddd, J = 5.4, 2.2, 2.1 Hz, 1H), 5.41-
5.42 (m, 1H), 4.84-4.86 (m, 1H), 4.48 (br s, 1H), 3.86 (dd, J = 10.8, 4.1 Hz, 1H), 3.76 
(dd, J = 10.8, 3.4 Hz, 1H), 3.48 (MeOH), 3.09-3.11 (m, 1H), 2.77 (ddd, J = 14.5, 6.0, 
5.9 Hz, 1H), 2.05-2.12 (m, 3H), 1.72-1.75 (m, 1H), 1.62-1.65 (m, 4H), 1.49-1.54 (m, 
2H).  
13
C NMR (CDCl3):  159.4, 155.0, 138.2, 136.5, 130.5, 115.1, 65.2, 61.4, 47.8, 
33.4, 32.6, 23.8 (2C).  m/z (ES+) [M+H]
+
 315.1492 calculated for C16H23N6O found  
[M+H]
+
 315.1933.  IR (cm
-1):  3324 (N−H), 3205 (br, O−H), 2931 (C−H), 1581 (C=C 
aromatic), 1477 (CH2), 1392 (CH3), 1249 (C−O). 
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((1S,4R)-4-(2-Amino-6-(cyclohexylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 9: General Procedure A was followed to yield 9 (87 mg, 71%) as a 
cream coloured solid.  m.p.:  191-194 °C.  
1
H NMR (CDCl3):  7.53 (s, 1H), 6.13 
(ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.79 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.43-5.44 (m, 
1H), 4.03 (br s, 1H), 3.81 (dd, J = 10.8, 4.4 Hz, 1H), 3.71 (dd, J = 10.8, 3.9 Hz, 1H), 
3.48 (MeOH), 3.38-3.42 (m, 1H), 3.05-3.11 (m, 1H), 2.79 (ddd, J = 14.4, 6.2, 6.0 Hz, 
1H), 1.94-2.04 (m, 3H), 1.75-1.80 (m, 2H), 1.62-1.66 (m, 1H), 1.37-1.48 (m, 2H), 
1.18-1.33 (m, 3H).  
13
C NMR (CDCl3):  159.6, 154.1, 138.2, 135.8, 129.7, 113.8, 
64.7, 59.9, 47.5, 33.8, 32.9, 29.5 (2C), 25.4 (2C), 24.6.  m/z (ES+) 329.2095 
calculated for C17H25N6O:  [M+H]
+
 329.2090.  IR (cm
-1):  3317 (N−H), 3209 (O−H), 
1597 (C=C aromatic), 1481 (CH2). 
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((1S,4R)-4-(2-Amino-6-(benzylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 10: 
General Procedure A was followed to yield 10 (90 mg, 81%) as an orange solid.  m.p.:  
174-176 °C (lit. m.p. 174-176 °C). 
1
H NMR (MeOD):  7.74 (s, 1H), 7.30-7.47 (m, 
5H), 6.24 (ddd, J = 5.3, 2.1, 2.0 Hz, 1H), 5.93 (ddd, J = 5.3, 2.1, 2.1 Hz, 1H), 5.55-
5.59 (m, 1H), 4.80 (s, 2H), 3.73 (dd, J = 10.8, 5.2 Hz, 1H), 3.66 (dd, J = 10.8, 5.2 Hz, 
1H), 3.39-3.40 (m, 1H), 2.85 (ddd, J = 14.0, 6.4, 6.2 Hz, 1H), 1.79 (ddd, J = 13.9, 6.3, 
5.8 Hz, 1H). 
13
C NMR (MeOD):  159.9, 154.6, 138.3, 137.9, 129.2, 128.2, 127.8, 
127.8, 127.3, 127.2, 126.8, 126.5, 113.2, 64.0, 59.0, 44.2, 43.5, 33.8.  m/z (ES+) 
337.1781 calculated for C18H21N6O:  [M+H]
+
 337.1777.  IR (cm
-1):  3298 (br, O−H), 
3248 (=C−H), 2935 (C−H), 1585 (C=C), 752 (C−H aromatic). 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix    
 
193 
 
 
((1S,4R)-4-(2-Amino-6-((cyclopropylmethyl)amino)-9H-purin-9-yl)cyclopent-2-
en-1-yl)methanol 11:  General Procedure A was followed to yield 11 (57 mg, 73%) 
as an off-white solid.  m.p.:  180-182 °C (lit. m.p. 182-183 °C). 
1
H NMR (CDCl3):  
7.49 (s, 1H), 6.05 (ddd, J = 5.5, 2.1, 2.0 Hz, 1H), 5.72 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 
5.45-5.32 (m, 1H), 3.71 (dd, J = 10.8, 4.5 Hz, 1H), 3.61 (dd, J = 10.8, 4.1 Hz, 3H), 
3.37-3.19 (m, 2H), 3.48 (MeOH), 3.00 (td, J = 7.8, 2.1 Hz, 1H), 2.71 (ddd, J = 14.3, 
6.3, 6.2 Hz, 1H), 1.85 (ddd, J = 14.3, 6.4, 5.7 Hz, 1H), 1.11-0.97 (m, 1H), 0.53-0.44 
(m, 2H), 0.26-0.17 (m, 2H).  
13
C NMR (CDCl3):  159.6, 155.0, 138.3, 136.2, 130.1, 
114.3, 64.9, 60.6, 47.6, 33.2, 10.6, 3.3 (2C).  m/z (ES+) 301.1780 calculated for 
C15H21N6O:  [M+H]
+
 301.1777.  IR (cm
-1):  3340 (N−H), 3.89 (N−H), 1593 (C=C 
aromatic), 1377 (CH2), 1261 (C−O). 
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((1S,4R)-4-(2-Amino-6-cyclobutoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
12: General Procedure B was followed to yield 12 (80 mg, 70%) as an off-white solid.  
m.p.:  150-152 °C.  
1
H NMR (CDCl3):  7.65 (s, 1H), 6.12 (ddd, J = 5.5, 2.1, 2.0 Hz, 
1H), 5.77 (ddd, J = 5.5, 2.2, 2.0 Hz, 1H), 5.44-5.49 (m, 1H), 5.34-5.42 (m, 1H), 3.90 
(dd, J = 10.8, 3.9 Hz, 1H), 3.80 (dd, J = 10.8, 3.2 Hz, 1H), 3.48 (MeOH), 2.94-2.98 
(m, 1H), 2.79 (ddd, J =14.6, 9.6, 6.4 Hz, 1H), 2.42-2.50 (m, 2H), 2.23-2.33 (m, 2H), 
2.13 (ddd, J = 14.6, 6.3, 5.8 Hz, 1H), 1.81-1.89 (m, 1H), 1.60-1.72 (m, 1H).  
13
C 
NMR (CDCl3):  161.1, 159.1, 153.2, 139.2, 138.7, 130.7, 116.7, 77.6, 71.4, 65.5, 
61.9, 48.1, 32.8, 31.0, 13.9.  m/z (ES+) 316.1775 calculated for C16H22N5O2:  [M+H]
+
 
316.1774.  IR (cm
-1):  3303 (N−H), 3184 (=C−H), 2942 (C−H), 1627 (C=N), 1581 
(C=C aromatic), 1461 (CH2), 1250 (C−N), 1076 (C−O). 
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((1S,4R)-4-(2-Amino-6-(cyclopentyloxy)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 13:   
General Procedure B was followed to yield 13 (43 mg, 73%) as an off-white solid.  
m.p.:  187-189 °C (lit. m.p. 188-190 °C). 
1
H NMR (CDCl3):  7.63 (s, 1H), 6.12 (ddd, 
J = 5.5, 2.1, 2.1 Hz, 1H), 5.77 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.62-5.66 (m, 1H), 
5.44-5.49 (m, 1H), 3.90 (dd, J = 10.8, 3.9 Hz, 1H), 3.80 (dd, J = 10.8, 3.2 Hz, 1H), 
3.48 (MeOH), 3.10-3.15 (m, 1H), 2.79 (ddd, J = 14.6, 6.3, 6.0 Hz, 1H), 2.14 (ddd, J = 
14.6, 6.4, 5.6 Hz, 1H), 1.81-2.01 (m, 5H), 1.62 (m, 2H), 1.28-1.35 (m, 1H).  
13
C NMR 
(CDCl3):  161.7, 159.1, 153.2, 139.1, 138.6, 130.7, 117.0, 79.8, 77.6, 65.5, 61.9, 
48.1, 33.3, 32.7, 30.1, 24.3.  m/z (ES+) 302.1614 calculated for C15H20N5O2:  [M+H]
+
 
302.1617.  IR (cm
-1):  3325 (N−H), 3197 (=C−H), 2954 (C−H), 1581 (C=C aromatic), 
1446 (CH2), 1246 (C−O). 
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((1S,4R)-4-(2-Amino-6-((2-morpholinoethyl)amino)-9H-purin-9-yl)cyclopent-2-
en-1-yl)methanol 14:  General Procedure A was followed to yield 14 (61 mg, 70%) 
as a white crystalline solid.  m.p.:  148-151 °C. 
1
H NMR (CDCl3):  7.53 (s, 1H), 6.45 
(br s, 1H), 6.11 (ddd, J = 5.4, 2.1, 2.1 Hz, 1H), 5.77 (ddd, J = 5.4, 2.2, 2.1 Hz, 1H), 
5.41-5.45 (m, 1H), 3.81 (dd, J = 10.8, 4.1 Hz, 1H), 3.72-3.77 (m, 5H), 3.64 (br s, 1H), 
3.48 (MeOH), 3.09-3.10 (m, 2H), 2.78 (ddd, J = 14.5, 6.2, 5.6 Hz, 2H), 2.62 (t, J = 
6.2 Hz, 2H), 2.51 (s, 4H), 2.07 (ddd, J = 14.5, 6.3, 5.6 Hz, 1H). 
13
C NMR (CDCl3):  
159.4, 155.2, 138.1, 136.7, 130.3, 115.0, 66.8 (2C), 65.0, 61.2, 57.4, 53.4 (2C), 47.6, 
36.8, 32.6. m/z (ES+) 360.2150 calculated for C17H26N7O2:  [M+H]
+
 360.2148.  IR 
(cm
-1):  3340 (N−H), 3201 (O−H), 2947 (C−H), 1643 (C=N), 1597 (C=C), 1462 
(CH2), 1257 (C−N), 1107 (C−O). 
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((1S,4R)-4-(2-Amino-6-(isopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 15:   
General Procedure A was followed to yield 15 (40 mg, 71%) as a white crystalline 
solid.  m.p.:  152-153 °C (lit. m.p. 153-155 °C). 
1
H NMR (CDCl3):  7.68 (s, 1H), 
6.12-6.14 (m, 1H), 5.86-5.87 (m, 1H), 5.45-5.48 (m, 1H), 3.61 (dd, J = 10.9, 5.3 Hz, 
1H), 3.55 (dd, J = 10.9, 5.2 Hz, 1H), 3.48 (MeOH), 3.30-3.32 (m, 1H), 2.96-2.97 (m, 
1H), 2.73 (ddd, J = 13.9, 6.4, 6.1 Hz, 1H), 1.65 (ddd, J = 13.8, 6.5, 5.8 Hz, 1H), 1.23 
(d, J = 6.5 Hz, 6H). 
13
C NMR (CDCl3):  161.8, 155.7, 151.3, 139.4, 136.8, 130.8, 
114.5, 65.4, 60.5, 49.0, 47.2, 35.3, 22.9 (2C). m/z (ES+) 289.1778 calculated for 
C14H21N6O:  [M+H]
+
 289.1777. IR (cm
-1):  3313 (N−H), 3012 (=C−H), 2927 (C−H), 
1592 (C=C aromatic), 1481 (CH2), 1388 (CH3). 
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((1S,4R)-4-(2-Amino-6-(isopropyl(methyl)amino)-9H-purin-9-yl)cyclopent-2-en-
1-yl)methanol 16:  General Procedure A was followed to yield 16 (79 mg, 74%) as 
an off-white solid. m.p.:  135-139 °C. 
1
H NMR (CDCl3):  7.49 (s, 1H), 6.10 (ddd, J 
= 5.5, 2.2, 2.0 Hz, 1H), 5.75 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.40-5.43 (m, 1H), 3.91 
(dd, J = 10.8, 3.8 Hz, 1H), 3.79 (dd, J = 10.8, 3.0 Hz, 1H), 3.48 (MeOH), 3.24 (s, 3H), 
3.11-3.13 (m, 1H), 2.77 (ddd, J = 14.6, 6.4, 6.3 Hz, 1H), 2.20 (ddd, J = 14.6, 6.4, 5.6 
Hz, 1H), 1.23 (d, J = 6.7 Hz, 6H). 
13
C NMR (CDCl3):  158.7, 155.3, 151.8, 138.3, 
135.9, 131.0, 116.3, 65.7, 62.1, 53.8, 48.1, 32.3, 20.2. m/z (ES+) 303.1932 calculated 
for C15H23N6O:  [M+H]
+
 303.1933.  IR (cm
-1):  3320 (N−H), 2966 (C−H), 1562 (C=C 
aromatic), 1454 (CH2). 
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((1S,4R)-4-(2-Amino-6-(propylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 17:  General Procedure A was followed to yield 17 as a white solid (70 
mg, 68%).  m.p.:  140-141 °C (lit. m.p. 144-146 °C). 
1
H NMR (CDCl3):  7.46 (s, 
1H), 6.12 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.85 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.30-
5.34 (m, 1H), 4.06 (s, 2H), 3.60 (dd, J = 10.8, 4.7 Hz, 1H), 3.50 (dd, J = 10.8, 3.9 Hz, 
1H), 3.48 (MeOH), 2.89-2.93 (m, 1H), 2.65 (ddd, J = 14.2, 6.4, 6.0 Hz, 1H), 1.69 
(ddd, J = 14.2, 6.4, 5.7 Hz, 1H), 1.46-1.60 (m, 2H), 0.87 (t, J = 7.4 Hz, 3H). 
13
C NMR 
(CDCl2):  159.8, 155.0, 149.5, 138.2, 135.5, 129.5, 113.6, 64.4, 59.4, 47.5, 41.9, 
33.9, 22.4, 10.8. m/z (ES+) 289.1777 calculated for C14H21N6O: [M+H]
+
 289.1773.  
IR (cm
-1): 3340 (N−H), 3259 (br, O−H), 2854 (C−H), 1597 (C=N), 1470 (C=C), 1396 
(C=C aromatic), 1389 (C−O), 1254 (C−N). 
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((1S,4R)-4-(2-Amino-6-(butylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
18:  General Procedure A was followed to yield 18 (0.14 g, 81%) as a cream coloured 
solid.  m.p.:  113-115 °C (lit. m.p. 116-118 °C). 
1
H NMR (CDCl3):  7.66 (s, 1H), 
6.12 (ddd, J = 5.0, 2.0, 2.0 Hz, 1H), 5.84 (ddd, J = 5.1, 2.1, 2.0 Hz, 1H), 5.43-5.47 (m, 
1H), 3.59 (dd, J = 12.0, 4.0 Hz, 1H), 3.53 (dt, J = 12.0, 4.0 Hz, 1H), 3.48 (MeOH), 
3.45 (br s, 1H), 3.25-3.27 (m, 1H), 2.92-2.97 (m, 1H), 2.77-2.81 (m, 1H), 2.72 (ddd, J 
= 12.0, 6.4, 5.8 Hz, 1H), 1.54-1.66 (m, 3H), 1.34-1.43 (m, 2H), 0.91 (t, J = 8.0 Hz, 
3H). 
13
C NMR (CDCl3):  161.3, 156.1, 150.7, 139.1, 136.5, 130.4, 114.2, 65.1, 60.2, 
50.4, 40.7, 35.1, 20.6, 18.1, 13.8. m/z (ES+) 303.1930 calculated for C15H23N6O:  
[M+H]
+
 303.1933. IR (cm
-1):  3329 (N−H), 3194 (br, O−H), 3163 (=C−H), 2927 
(C−H), 1647 (C=C), 1503 (C=C aromatic), 1466 (CH2), 1385 (CH3), 1246 (C−N), 
1199 (C−O). 
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((1S,4R)-4-(2-Amino-6-(tert-butylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 19: General Procedure A was followed using t-butylamine (10 eq) to 
yield 19 (0.23 g, 57%) as a cream coloured solid.  m.p.:  159-161 °C (lit m.p. 161-163 
°C). 
1
H NMR (CDCl3):  7.43 (s, 1H), 6.10-6.11 (m, 1H), 5.73-5.75 (m, 1H), 5.65 (br 
s, 1H), 5.37-5.40 (m, 1H), 4.72 (br s, 2H), 3.92 (dd, J = 10.9, 3.5 Hz, 1H), 3.80 (dd, J 
= 10.8, 2.2 Hz, 1H), 3.48 (MeOH), 2.78 (ddd, J = 14.7, 6.5, 6.3 Hz, 1H), 2.22 (ddd, J 
= 14.5, 6.3, 5.5 Hz, 1H), 1.50 (s, 9H). 
13
C NMR (CDCl3):  159.0, 155.0, 154.9, 
149.0, 138.1, 135.7, 130.1, 115.0, 64.9, 60.7, 51.8, 47.6, 35.0, 28.9 (3C). m/z (ES+) 
303.1928 calculated for C15H22N6O: [M+H]
+
 303.1926.  IR (cm
-1
): 3336 (N−H), 3313 
(N−H), 2962 (C−H), 1593 (C=C), 1458 (CH2), 1203 (C−O). 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix    
 
212 
 
 
((1S,4R)-4-(2-Amino-6-propoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 20:  
General Procedure B was followed to yield 20 (40 mg, 85%) as a yellow solid.  m.p.:  
128-130 °C. 
1
H NMR (CDCl3): δ 7.60 (s, 1H, 5.55-6.21 (m, 2H), 5.40 (ddd, J = 9.4, 
5.2, 1.9 Hz, 1H), 4.34 (t, J = 6.8 Hz, 2H), 3.79 (dd, J = 10.8, 3.7 Hz, 1H), 3.69 (dd, J 
= 10.8, 3.1 Hz, 1H), 3.48 (MeOH), 2.94-3.15 (m, 1H), 1.90-2.82 (m, 2H), 1.62-1.84 
(m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13
C NMR (CDCl3): δ 162.0, 159.2, 153.2, 139.2, 
138.8, 130.6, 116.6, 68.8, 65.3, 61.6, 48.2, 33.0, 22.6, 10.8. m/z (ES+) 312.1436 
calculated for C14H20N5O2:  [M+H]
+
 312.1436. IR (cm
-1): 3321 (N−H), 3201 (O−H), 
2967 (C−H), 1578 (C=N), 1450 (C=C), 1404 (C=C aromatic), 1238 (C−O), 1061 
(C−N). 
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((1S,4R)-4-(2-Amino-6-butoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 21:  
General Procedure B was followed to yield 21 as a pale yellow solid (50 mg, 63%). 
m.p.:  121-122 ºC (lit. m.p. 122-123 °C). 
1
H NMR (CDCl3): δ 7.61 (s, 1H), 6.12 (ddd, 
J = 5.5, 2.1, 2.1 Hz, 1H), 5.70 (ddd, J = 5.5, 2.1, 2.0 Hz, 1H), 5.39-5.42 (m, 1H), 4.37 
(t, J = 6.6 Hz, 1H), 3.84 (dd, J = 10.8, 3.8 Hz, 1H), 3.68 (dd, J = 10.8, 3.1 Hz, 1H), 
3.48 (MeOH), 2.98-3.02 (m, 1H), 2.70 (ddd, J = 14.3, 6.4, 6.1 Hz, 1H), 1.81-2.07 (m, 
1H), 1.54-1.80 (m, 2H), 1.27-1.54 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). 
13
C NMR 
(CDCl3): δ 161.9, 159.2, 153.2, 139.0, 138.8, 130.5, 116.4, 67.0, 65.2, 61.4, 48.1, 
33.2, 31.3, 19.5, 14.2. m/z (ES+) 304.1774 calculated for C15H22N5O2: [M+H]
+
 
304.1778.  IR (cm
-1
): 3313 (N−H), 3201 (br, O−H), 2951 (C−H), 1581 (C=N), 1508 
(C=C), 1462 (C=C aromatic), 1400 (C−O), 1245 (C−N). 
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((1S,4R)-4-(2-Amino-6-(oxetan-3-ylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 22:  To a solution of 2 (0.11 g, 0.4 mmol) in ethanol (3 mL) was added 
3-amino oxetane (0.15 mL, 2 mmol) and the resulting mixture was stirred in a sealed 
tube at 85 °C for 48 hr. The mixture was allowed to cool and the solvent removed in 
vacuo.  The crude product was purified by column chromatography (1:19 to 1:4 
MeOH−DCM) to yield 22 (90 mg, 80%) as an orange solid. m.p.: Decomposed at 215 
°C. 
1
H NMR (MeOD):  7.97 (s, 1H), 6.16-6.18 (m, 1H), 5.86-5.88 (m, 1H), 5.50-
5.55 (m, 1H), 4.51-4.57 (m, 2H), 4.20-4.26 (m, 1H), 3.78 (dd, J = 11.9, 3.2 Hz, 1H), 
3.70 (dd, J = 11.8, 3.8 Hz, 1H), 3.60-3.64 (m, 1H), 3.53-3.57 (m, 1H), 2.70 (ddd, J = 
14.0, 6.4, 6.3 Hz, 1H), 1.64-1.71 (m, 1H), 1.24-1.36 (m, 1H). 
13
C NMR (MeOD):  
154.9, 152.3, 142.2, 140.3, 130.3, 110.4, 78.2 (2C), 65.2, 63.6, 59.7, 48.6, 35.3. m/z 
(ES+) 303.1573 calculated for C14H19N6O2:  [M+H]
+
 303.1569. IR (cm
-1
): 3317 
(N−H), 3155 (=C−H), 1689 (C=C), 1295 (C−N), 1092 (C−O). 
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